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Continuous renal replacement therapy (CRRT) is an established treatment option 
in Australia for critically ill patients with acute renal failure (ARF). Critical care nurses 
play a primary role in the set-up of equipment, monitoring and care of patients receiving 
CRRT. Although described as a continuous therapy, delays or interruptions in CRRT 
can interfere with treatment efficiency. A review of the literature identified how optimal 
circuit function is an important factor in determining the effectiveness of treatment and 
patient outcomes. 
The aim of this research was to evaluate treatment efficiency in terms of circuit 
life between two widely used forms of CRRT, continuous veno-venous haemofiltration 
(CVVH) versus continuous veno-venous haemodiafiltration (CVVHDf). The 
investigation focused attention on the influence higher pre-dilution volumes and 
convective clearance of CVVH may have on circuit life when compared to the lower 
pre-dilution volumes and diffusive clearance required for CVVHDf. 
This thesis describes how the impact of CVVH versus CVVHDf on circuit life 
was investigated using a randomised comparative crossover study design. Once 
institutional ethics committee approval had been received, 45 patients were recruited to 
the study who were 18 years or older and required the commencement of CRRT as part 
of their Intensive Care treatment. Of the 45 patients who were randomised to receive 
CVVH or CVVHDf, 31 patients achieved a successful crossover to the alternative 
technique. Failure to achieve a „natural‟ circuit life – that is one which terminated due to 
clotting, in a CVVH and CVVHDf circuit accounted for the large drop out rate. Blood 
flow rate, vascular access device and insertion site, haemofilter, anticoagulation and 
machine hardware were standardised. An ultrafiltrate dose 35 millilitres (ml) per 
kilogram (kg) per hour (hr) delivered pre-filter was used for CVVH and a fixed pre-
dilution volume of 600ml per hr with a dialysate dose of 1litre (L) was used for 
CVVHDf. Patients were excluded if coagulopathic, thrombocytopenic or unable to 
receive heparin.  
Of the 31 paired comparisons there was a significant difference in circuit life 
measurements between CVVH and CVVHDf after a paired-sample t-test was performed 
following natural logarithm base-e (ln) dataset transformation (CVVH 6.101 versus 
CVVHDf 6.779, P-value = 0.001). A Wilcoxon signed ranks test used raw dataset 
 VIII 
values of circuit life measurements as an alternative non-parametric comparison (Z = -
4.076, P-value < 0.001). The probability of circuit survival for each treatment mode was 
estimated using the Kaplan-Meir method from the 93 circuits which had survived to 
clotting (50 CVVH circuits and 43 CVVHDf circuits). Using the truncation point of 16 
hr as a measure of expected minimum survival, 50 percent (%) of CVVHDf circuits 
remained in operation when compared with only a 5% for CVVH circuits. The same 93 
circuits were also used in a linear multiple regression analysis. None of the independent 
variables (activated prothrombin time, platelet count, heparin dose, patient haematocrit, 
urea) had a coefficient partial correlation > 0.09 (coefficient of determination = 0.117) 
or a linear relationship which could be associated with circuit life (P-value = 0.228). 
The evaluation of treatment efficiency in terms of circuit life between the 
different techniques of CVVH and CVVHDF is of clinical importance, since each 
treatment mode depends upon a measure of circuit longevity to achieve adequate 
replacement of renal function. Numerous factors have been described which influence 
circuit life in the delivery of CRRT including circuit and filter design, anticoagulation 
and staff training and expertise. In this study a longer circuit life was reported using 
CVVHDf which incorporated lower pre-dilution volumes when compared with the 
higher pre-dilution volumes associated with CVVH. This could possibly be explained 
by the physical processes involved in fluid and solute transport across the filter 
membrane. The choice of CRRT mode is a factor which may be an important 
independent determinant of circuit life using the techniques of CVVH and CVVHDf. 
This information may influence intensive care nursing practice in respect of mode 
selection for CRRT in collaboration with medical colleagues. 
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GLOSSARY OF TERMS 
Solute: 
A substance dissolved in plasma water (for example, sodium chloride). 
 
Semi-permeable membrane: 
A barrier made from synthetic material which allows the movement of solutes and 
plasma water to pass through, but prevents the cellular components of plasma and other 
larger molecles from leaving the blood compartment.  
 
Diffusion: 
The movement of solutes through a semi-permeable membrane governed by a 
concentration gradient between blood and dialyate.  
 
Convection: 
The movement of solutes through a semi-permeable membrane governed by a pressure 
gradient between the fluid and blood compartments on either side of the membrane. 
 
Ultrafiltration: 
The removal of plasma water from blood across a semi-permeable membrane. 
 
Veno-venous: 
The outflow of blood from a vein and the inflow of blood to a vein. 
 
Continuous Veno-venous Haemofiltration (CVVH): 
A technique used for the removal of solutes and plasma water in support of renal 
function. Solute removal is achieved by convection.  
 
Continuous Veno-venous Haemodiafiltration (CVVHDf): 
A technique used for the removal of solutes and plasma water in support of renal 
function. Solute removal is achieved by diffusion and convection. 
 
Extracorporeal Circuit: 
A hollow tube made from non-bilogical materials for the circulation of blood outside of 
the body. 
 
Artificial Kidney (blood filtration device): 
A device connected to the extracorporeal circuit for the channelling of blood through 
bundles of hollow fibres to facilitate the movement of solutes by diffusion and 
convection and plasma water by ultrafiltration. 
 
Dialysate: 
A solution containing a lower concentration of solutes when compared with the 
patient‟s blood to facilitate solute removal by diffusion.   
 
Replacement Fluid: 
A solution composed of electrolytes and other important substances used for the 













The volume of fluid discarded from the patient as blood is circulated through the 




The ability of the extracorporeal circuit and blood filtration device to operate without 
decreasing the capacity of the circuit to achieve solute clearance and fluid removal.  
 
‘Natural’ Circuit Life: 
The spontaneous appearance of circuit failure caused by the accumulation of blood clots 
along different sections of the extracorporeal circuit.  
 
Circuit Failure: 






Acute renal failure (ARF) is a condition which can complicate the recovery of 
critically ill patients, lengthen the number of days spent in hospital and ultimately 
contribute to patient mortality (Abernethy & Lieberthal, 2002). The condition is defined 
as a sudden loss of renal function causing the retention of excess fluid, the development 
of biochemical imbalances and/or the accumulation of metabolic waste products. The 
causes of ARF in the critically ill patient are primarily due to inflammatory, ischaemic 
or toxic events, either having occurred in isolation or in association with the failure of 
several organs. The condition is potentially recoverable provided the affected kidneys 
are treated and complications of renal insufficiency avoided. The temporary loss of 
renal function can be overcome by technology replacing many important functions of 
the kidney, either short or long-term. In the event of severe damage to the kidneys and 
irreversible loss of adequate renal function, the option of kidney transplantation is 
considered once a suitable donor is found. 
 The development of hospital-acquired ARF has been observed to occur in 
hospitalised patients including those who require intensive care admission. Over the 
duration of a prospective European epidemiologic study the yearly incidence of ARF for 
intensive care patients was reported to be 95 cases per million of population (Liano, 
Junco, Pascual, Madero, & Verde, 1998). During a three month survey of intensive care 
patients in Australia it was estimated each year 2% of the adult population (80 per 
million of population) had severe ARF which required the instigation of Renal 
Replacement Therapy (RRT) (Silvester, Bellomo, & Cole, 2001).  
In situations of severe ARF some form of RRT is required until adequate renal 
function returns or if there is permanent loss of kidney function requiring long term 
management. Renal replacement therapy is defined by the Australia and New Zealand 
Dialysis and Transplant Registry (The 30th ANZDATA Registry Report, 2007) as a 
collection of treatments which include kidney transplantation, but is more commonly 
used to describe treatments which „artificially‟ take over the biochemical and fluid 
regulatory functions of the kidney (Foot & Fraser, 2005). The removal of metabolic 
waste products and the maintenance of water and electrolyte balance can either be 
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achieved using peritoneal dialysis or by the circulation of blood outside of the body 
through a semi-permeable membrane.  
The requirement for RRT in the critically ill patient was the subject of 
investigation reported by the Beginning and Ending Supportive Therapy (BEST) 
prospective multinational, multi-centre observational kidney study (Uchino et al., 2005). 
Although the use of RRT ranged between 4.0 and 4.4 percent (%) from the total number 
of patients admitted to the Intensive Care Unit (ICU), the commencement of RRT was 
associated with a decline in both patient survival and recovery of renal function. The 
hospital mortality rate of patients admitted over the duration of the BEST study that 
required RRT as part of their treatment in ICU was around 60%. In the case of 
Australia, a hospital mortality of 53.4% was reported from the six participating centres. 
Of those who had survived in different regions of the developed world, 11.2 to 16.3% of 
patients at the time of discharge from hospital were dependent on some form of RRT 
using peritoneal dialysis or haemodialysis.  
The high mortality associated with severe ARF can be misleading, since the 
condition usually occurs in conjunction with other failing organs. The inability of other 
organs to function normally can have a greater influence on patient survival than the 
development of renal insufficiency alone.  With the advent of modern-day RRT 
techniques the management of ARF is now rarely the single cause of death, but is 
instead the consequence of systemic illness and the kidneys‟ repeated exposure to 
injury. How best to treat the critically ill patient with severe ARF and the impact of 
choice of RRT may have on patient outcome, is the subject of controversy and on-going 
investigation (Tonelli, Manns, & Feller-Kopman, 2002). The approach can either be 
intermittent haemodialaysis (IHD) or continuous renal replacement therapy (CRRT). In 
the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network 
(ATN) study (2008) CRRT was the preferred technique used in patients who were 
haemodynamically unstable. Several operational features of CRRT allow this technique 
to be tolerated more easily in the critically ill patient.   
Continuous renal replacement therapy is widely used in different regions of the 
world for the management of critically ill patients with severe ARF (Uchino et al., 
2007). The techniques of continuous veno-venous haemofiltration (CVVH) and 
continuous veno-venous haemodiafiltration (CVVHDf) are two different forms of 
CRRT which effectively manage the removal of unwanted solutes and excessive fluid to 
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achieve metabolic and fluid volume control (Hall & Fox, 2006). The treatment mode of 
CVVH is a convective-based technique (removal of plasma water and dissolved wastes) 
in comparison to the diffusive-based technique of CVVHDf (removal of wastes across a 
concentration gradient). In order to manage ARF in the critically ill patient the 
effectiveness of both techniques is dependent on maintaining continuity of treatment.  
The majority of incidents which interrupt the continuous nature of CRRT are 
caused by the development of blood clots in the extracorporeal circuit as a consequence 
of blood exposure to non-biological surfaces (Davenport, 1997). A number of 
interventions have been identified as strategies which can delay clotting and improve 
the duration of circuit life. These include ensuring the reliability of blood flow from the 
vascular access device (Baldwin, Bellomo, & Koch, 2004), the use of anticoagulant 
agents (Davies & Leslie, 2007), and the addition of replacement fluid before the 
haemofilter; pre-dilution mode (Uchino, Fealy, Baldwin, Morimatsu, & Bellomo, 
2003b; van der Voort et al., 2005). Several authors suggest the choice of CRRT mode 
can affect circuit life, given the different life spans of circuits between convection-based 
and diffusion-based techniques (Davenport, 1998; Joannidis & Oudemans-Van Straaten, 
2007). If this is so, then selection of treatment mode may be an important consideration 
in an overall management strategy aimed at extending circuit life and continuity of 
treatment. 
In this thesis the impact of treatment choice on circuit life was evaluated using 
the techniques of CVVH and CVVHDf. The evaluation of both approaches occurred in 
the context of the critically ill patient who as part of their treatment in ICU required 
CRRT. Observations of potential differences in circuit life between CVVH and 
CVVHDf provide the opportunity to improve treatment delivery in the support of renal 
function. The thesis describes how the measurement of circuit life was achieved using a 
rigorous approach in the methodology adopted for the investigation. To reach a clearer 
understanding of how best to carry out the investigation it was necessary to obtain 
background information on the subject of severe ARF, undertake a review of the 
reasons behind why in some cases there is preference for CRRT when compared with 
other approaches, investigate specific aspects regarding application of the technique in 
clinical practice, and develop a conceptual framework based on factors which are 
known to influence circuit life.   
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Research Aim 
The primary aim of this research project was to evaluate two related treatment 
modes of CRRT in order to better inform decision making around treatment modes in 
relation to circuit longevity. More specifically, the effect of a higher pre-dilution 
volume associated with CVVH on circuit life was compared to a lower pre-dilution 
volume associated with CVVHDf.  
Significance of Study 
The management of ARF using CRRT is affected when the duration of treatment 
able to be delivered to the patient is decreased. Investigation of the duration in treatment 
down-time was shown to adversely influence azotemic control when the continuous 
nature of CRRT was interrupted and the setup of a new circuit delayed the 
recommencement of treatment (Uchino, Fealy, Baldwin, Morimatsu, & Bellomo, 
2003a). A prolonged period of treatment down-time causes the temporary suspension of 
the technique which can adversely impact the clinical course of patients when as a result 
of the delay azotemic control is reduced. The degree of dose intensity of ultrafiltrate 
able to be applied using CVVH has been shown to influence the outcome of critically ill 
patients (Ronco et al., 2000).  
The extension of circuit life is an important factor to consider when attempts are 
made to improve the effectiveness of CRRT and maximise the treatment dose the 
patient is able to receive. A decision on what is an adequate circuit life when 
anticoagulation of the circuit is able to be used safely has not been validated by formal 
investigation. Experience using CVVH suggests treatment within a 24 hour (hr) cycle 
which is less than 16hr reduces the ability of the technique to achieve azotemic stability 
(Uchino, et al., 2003a). The ability of CRRT to operate „continuously‟ for a length of 
time ensures the quality of renal support delivered to the patient is maintained. It will 
also reduce the workload of nursing activity required in the setup of a new circuit, allow 
for the containment of costs associated with single-use items, and reduce the amount of 
blood which is lost due to circuit failure (Joannidis & Oudemans-Van Straaten, 2007). 
The overall impact of a shortened circuit lifespan represents a threat in the successful 
application of CRRT for those patients admitted to the ICU with complex medical 
problems. Not only impacting on the prospect of patient recovery from renal 
insufficiency but also affecting the ability of the nurse to respond to other patients care 
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needs and in the management of hospital resources constrained by concerns over 
budgetry expenditure.    
Background 
A discussion on why critically ill patients may require CRRT is provided here 
before the literature surrounding the use of the technique is reviewed in the next 
chapter. In looking at the vulnerability of patients in ICU who develop renal 
insufficiency background information is given on the major functions of the kidney. 
This is followed by commentary on how injury to the kidney is defined with the causes 
and prevalence of the disease a main feature of critical illness. Once injury to the organ 
has been sustained recovery of the critically ill patient is threatened by a decline in 
kidney function. A number of interventions are discussed which seek to protect or 
prevent further injury to the kidneys before the commencement of CRRT becomes 
necessary. 
  Acute Kidney Injury 
Acute kidney injury (AKI) refers to the entire spectrum of renal insufficiency 
and describes a pathological event which causes functional or structural changes to the 
kidneys (Kellum, Bellomo, & Ronco, 2007). The term has recently been adopted in an 
attempt to reach a consensus on a common quantitative definition and classification of 
ARF. The change of emphasis away from the terminology of describing only the 
presence of organ failure is also in recognition of observations which have shown small 
decreases in kidney function are predictive of a worse outcome when compared with 
patients who sustain no injury (Levy, Viscoli, & Horwitz, 1996).  
In Australia between 1996-2005 there has been an estimated 2.8 percent (%) 
annual increase in the reporting of AKI 24hr after admission to the ICU (Bagshaw, 
George, & Bellomo, 2007). This rise of ICU related AKI has also occurred in other 
regions of the world following the expanded use of diagnostic intravenous radio contrast 
agents and the admission of patients who have pre-existing chronic diseases which 
increase the prevalence of risk factors associated with the condition (Nash, Hafeez, & 
Hou, 2002). The development of AKI is a major complication of critical illness where 
single or multiple episodes cause an abrupt decline in kidney function. The loss of 
kidney function can be detrimental to the management and outcome of critically ill 
patients which affects the ability of the body to maintain normal physiological processes 
and interrupts the activity of other organ systems of the body. The use of technology to 
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avoid the effects of severe ARF as a consequence of AKI requires the major functions 
of the kidney concerned with the regulation of fluid and electrolytes, the maintenance of 
acid-base balance and removal of metabolic waste products to be artificially replaced.  
Major Functions of the Kidney  
The major functions of the kidney are concerned with maintaining the body‟s 
internal environment vital for cellular activity and normal operation of other organs. 
The functional unit of the kidney is the nephron which uses glomerular filtration and 
tubular reabsorption and secretion to produce urine as a way to balance fluid volume, 
conserve important nutrients and remove substances and fluid not required out of the 
body. The kidneys receive external signals from other body systems which activate 
changes in the regulation of water and electrolytes and in the maintenance of acid-base 
balance. An understanding of how these physiological processes work is important and 
necessary to appreciate the limitations as well as the benefits of instigating RRT in the 
critically ill patient.  
Glomerular Filtration 
The nephron contains two capillary beds separated by a pressure gradient 
(Chmielewski, 2003). Blood from the branches of the renal artery and ending as afferent 
arterioles enter into a network of capillaries looped together referred to as the 
glomerulus. After blood has circulated through the first bed of capillaries it leaves the 
glomerulus via the efferent arteriole. Vaso-constriction of the efferent arteriole creates 
hydrostatic pressure within the network of capillaries which favours filtration through 
the Bowman‟s capsule. The Bowman‟s capsule is a hollow tube which encircles the 
bundle of glomerular capillaries. The filtrate produced from the network of capillaries 
drains into the Bowman‟s space and passes through into the tubular system. The efferent 
arterioles then continue on to surround the tubular system as the peritubular network 
(Chmielewski, 2003). The glomerular filtrate is almost entirely returned to the 
bloodstream through the network of peritubular capillaries which operate at 
comparatively low pressures to facilitate the reabsorption of fluid and solutes. The 
driving force of filtration through the glomerular network of capillaries is maintained by 
the capacity to sustain hydrostatic pressure. The glomerular filtration rate (GFR) is 
influenced by the degree of hydrostatic pressure derived from renal blood flow and the 
subsequent movement of fluid through the capillaries. In response to a change in arterial 
blood pressure a process called autoregulation maintains renal blood flow and GFR at 
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relatively constant levels by the constriction or dilation of the afferent and efferent 
arterioles (Holechek, 2003b). 
The walls of glomerular capillaries are highly porous with the membrane 
comprising of several layers which allow only specific substances to pass through the 
filtration barrier (Holechek, 2003a). Substances which are filtered out of the blood 
depend on the size, electrical charges, protein binding, configuration and rigidity of the 
molecule. Small molecules with a molecular weight less than 7,000 Daltons (Da) are 
filtered through the membrane without restriction. These molecules include water and 
all ions such as sodium, potassium, chloride, phosphate, magnesium and calcium. Ions 
and other substances which are bound to proteins are not able to pass through the 
membrane. The passage of elliptical as opposed to round molecules easily pass through 
the filtration barrier, as will molecules which are less rigid but sufficiently flexible to 
negotiate through the membrane openings. Middle-sized molecules with a molecular 
weight of around 17,000Da, such as myoglobin released from the breakdown of red 
blood cells, do not easily filter through the membrane. Molecules which are much larger 
such as plasma proteins have molecular weights close to 70,000Da and under normal 
conditions are unable to pass through the filtration barrier. The electrical negative 
charge present in the filtration barrier restrict the movement of large molecules which 
have the same electrical charge, in comparison to the unrestricted passage of molecules 
with a positive or neutral charge. Since most proteins are positively charged the 
electrical repulsion which occurs also reinforces the restriction on the movement of 
plasma proteins through the filtration barrier. By allowing plasma proteins to be 
retained in the glomerular blood ensures osmotic pressure opposing hydrostatic pressure 
prevents the complete removal of plasma water in the capillary network (Marieb & 
Hoehn, 2007).  
The mechanism of glomerular filtration is fundamental to preserving the body‟s 
internal environment and in the fulfilment of the major functions of the kidney. It forms 
the initial step necessary for the production of urine but relies on a constant GFR to 
ensure there is adequate solute and water removal. The GFR is approximately 
125millilitre (ml) per minute (min) and close to 180  litres (L) of filtrate is produced 
over the duration of 24hr from an average total blood volume of 5L (Marieb & Hoehn, 
2007).The large volume of filtrate which is generated ensures that the efficient filtration 
of plasma occurs so long as the permeability of the glomerular membrane remains intact 
and the volume of filtration is maintained at a constant rate. Only one to two L of urine 
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is produced per day leaving about 99% of filtrate to be reabsorbed back into the 
bloodstream. The final composition of glomerular filtrate has the same concentration of 
sodium, chloride, creatinine, urea, uric acid and phosphate as found in plasma, but on 
leaving the  Bowman‟s capsule the solution is normally protein-free (Holechek, 2003a). 
Tubular Reabsorption and Secretion 
The nephron consists of specific tubular segments that extend from the 
Bowman‟s capsule which reabsorb or secrete substances as the glomerular filtrate 
passes along the tubular system (Chmielewski, 2003). The composition of the filtrate on 
leaving the glomerulus closely resembles plasma except for the almost complete 
absence of proteins in the solution. Due to the large volume of plasma which is initially 
filtered through the glomerulus there is rapid clearance of metabolic waste products, but 
in order to maintain a normal internal environment the majority of filtrate is required to 
be recycled back into the bloodstream. The composition and volume of filtrate 
undergoes considerable changes by the reabsorption and secretion at different segments 
of the tubular system.    
The requirement of the nephron to return the majority of plasma filtered through 
the glomerulus is accomplished within the tubular system according to the specific 
properties of individual tubular segments (Chmielewski, 2003). The tubular system as 
shown in Figure 1.1 is divided into four segments with each tubule division consisting 
of a single cell wall. Individual divisions of the tubular wall incorporate semi-permeable 










On first reaching the tubular system the proximal tubule is responsible for 65% 
reabsorption of water and sodium initially present in the glomerular filtrate 
(Chmielewski, 2003). Most substances are reabsorbed at this segment including 100% 
of glucose and amino acids, 90% of filtered bicarbonate, 75% of filtered phosphate, 
60% of filtered calcium, 50% of filtered chloride and potassium, 50% of filtered urea, 
and approximately 30% of filtered magnesium. Secretion of endogenous and exogenous 
substances into the tubular fluid also occurs in the proximal tubule. The osmolarity of 
the tubular fluid virtually remains unchanged from plasma (iso-osmotic) due to the large 
reabsorption capacity of the proximal tubule matched by the secretion of metabolic 
waste products (Marieb & Hoehn, 2007).  
Loop of Henle. 
The descending limb of the loop of Henle is highly permeable to water but 
impermeable to the majority of solutes contained in the segment thereby causing the 
tubular fluid to become hyper-osmotic (Chmielewski, 2003). On reaching the thin 
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section of the ascending limb the action is reversed with the tubule cell wall being 
virtually impermeable to water present in the tubular fluid whilst permeable to the 
passage of sodium, chloride and urea. The thick portion of the ascending limb forms the 
remaining part of the loop of Henle. Water is again unable to pass through the tubule 
wall and due to the reabsorption of other substances such as potassium, bicarbonate, 
magnesium and calcium the tubular fluid at this point becomes hypo-osmotic 
(Chmielewski, 2003).   
Distal tubule. 
The early distal tubule continues the reabsorption of solutes such as sodium, 
chloride, bicarbonate, potassium, calcium and magnesium. Since the tubule wall 
remains impermeable to water the hypo-osmotic nature of the tubular fluid is unchanged 
(Chmielewski, 2003). In the late distal tubule the reabsorption of water is variable with 
the degree of water permeability of the tubule cell wall influenced by the presence or 
absence of antidiuretic hormone (ADH). The hypo-osmotic nature of the tubular fluid 
will change according to levels of ADH and the volume of water which is reabsorbed 
back into the bloodstream.  
Collecting tubule. 
The „fine-tuning‟ of tubular fluid is repeated in the collecting tubule with ADH 
continuing to be instrumental in determining the final volume of water which is retained 
in the body.  Large quantities of water are able to be reabsorbed under the influence of 
sodium reabsorption and concentrate the tubular fluid to resemble the composition of 
urine. Substances which are excreted in the urine include creatinine, urea, uric acid and 
unwanted electrolytes such as sodium, potassium and phosphate (Guthrie & Yucha, 
2004). 
  The movement of water and solutes involves various transport mechanisms at 
different segments of the tubular system. Solute movement may occur by diffusion 
according to chemical and/or electrical gradients until a concentration equilibrium is 
reached on either side of the tubule wall (Ludlow, 2003). The opportunity also exists for 
some movement of solutes by co-transport and counter-transport mechanisms (Candela 
& Yucha, 2004). In other examples of solute movement active transport which requires 
the expenditure of energy may be involved. Using energy sourced from adenosine 
triphosphate (ATP) active transport allows the movement of solutes against a 
concentration gradient (Yucha & Guthrie, 2003). The movement of water is a passive 
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process influenced by the osmotic gradient established on either side of the tubule wall 
and in the degree of permeability which allows the passage of fluid across the semi-
permeable membrane (Candela & Yucha, 2004). Opposite to the process of reabsorption 
the secretion of substances out of the blood flowing through the peritubular capillaries 
also permits the movement of solutes in both the proximal and distal segments of the 
tubular system using both passive and active transport mechanisms (Chmielewski, 
2003). Substances released as end products of metabolism such as creatinine and urea 
are secreted into the tubular fluid increasing the total amount already removed from the 
blood by glomerular filtration. Other substances secreted include hydrogen ions which 
are important for acid-base control (Yucha, 2004) and potassium in exchange for 
sodium (Ludlow, 2003). The process of secretion also allows exposure of unwanted 
substances such as foreign chemicals to be removed from the blood and excreted out of 
the body (Chmielewski, 2003). 
Regulation of Water and Electrolytes 
The regulation of water and electrolytes is necessary to maintain the 
extracellular environment within a narrow range of values the body requires in order for 
cells to function normally (Candela & Yucha, 2004). The kidneys engage a number of 
mechanisms which integrate signals from other body systems, primarily the 
cardiovascular, nervous and endocrine systems, to control extracellular fluid volume 
and osmolality. The regulation of total body sodium through reabsorption or excretion 
by the tubules simultaneously regulates extracellular fluid volume. Sodium is 
predominately an extracellular solute and when alterations occur in the total body 
concentration of sodium this is accompanied by a change in the osmolality of the 
extracellular fluid (Candela & Yucha, 2004). Consequently, the concentration of sodium 
in the extracellular fluid is the major determinant of extracellular fluid volume which 
causes a similar change to occur in the volume of plasma.  
The ADH mechanism regulates the concentration of sodium and extracellular 
fluid volume by controlling the osmolality and amount of urine produced. Aldosterone 
is the major regulator of sodium excretion and according to the amount of sodium 
reabsorbed by the tubules influences the amount of water retained and the loss of other 
ions including potassium, phosphate and hydrogen (Candela & Yucha, 2004). 
According to the level of potassium present and the availability of angiotensin II in the 
body, aldosterone is secreted by the adrenal cortex in response to the release of ADH 
from the anterior pituitary gland. Angiotensin II is the primary stimulator in the release 
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of ADH and is produced as part of the sodium-regulating reflex mechanism referred to 
as the renin-angiotensin system. The presence of low sodium levels due to a decrease in 
plasma volume stimulates the release of renin from the intrarenal baroreceptors, the 
macula densa and the renal sympathetic nerves. Once discharged the release of renin 
causes the separation of angiotensin I from angiotensinogen. The actions of angiotensin 
I lie dormant in the lungs until activated into angiotensin II by the angiotensin 
converting enzyme. The presence of angiotensin II causes vasoconstriction and 
stimulates the release of aldosterone from the adrenal cortex. Aldosterone is circulated 
through the bloodstream to the distal and collecting tubules which stimulates increased 
reabsorption of sodium and water. The opposite effect occurs in the reflex mechanism 
when an increase in plasma volume is detected due to an increase in sodium levels. A 
fall in the amount of renin secreted moderate the production of aldosterone. The 
decrease in the conversion of angiotensin I to angiotensin II causes less aldosterone to 
be released in the circulation and stimulates increased secretion into the urine of sodium 
and water (Candela & Yucha, 2004).   
Maintenance of Acid-Base Balance 
The hydrogen ion concentration of a solution is represented by the pH value. 
The pH scale refers to the „potential or power of hydrogen‟ as a method of describing 
the concentration of hydrogen ions (Cree & Rischmiller, 2001). Higher concentrations 
of hydrogen ions make a solution more acidic, whilst lower concentrations of hydrogen 
ions make the solution more alkaline. Only free hydrogen ions contribute to the 
measured pH influenced by other ions such as phosphate or bicarbonate referred to as 
bases which donate or release hydrogen ions (Yucha, 2004). The kidneys play an 
important role in the regulation of acids and bases to maintain plasma pH levels 
between 7.35 and 7.45. When plasma pH levels are outside the normal range of values 
the efficiency of physiological processes in the body begins to deteriorate and the 
kidneys work in partnership with the respiratory system to avoid the adverse 
consequences of acid-base disturbances. As blood passes through the lungs and gaseous 
exchange takes place, the level of carbon dioxide retained determines the amount of 
carbonic acid present in the plasma and influences the quantity of hydrogen ions 
produced. Alterations in the rate and depth of breathing can lower or increase pH levels 
but only deals with changes by maintaining the hydrogen carbonate equilibrium (Cree & 
Rischmiller, 2001). The kidneys on the other hand have the ability to selectively remove 
or return ions and substances regardless of the hydrogen carbonate equilibrium 
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exercising greater control than the respiratory system over the concentration of various 
acids and bases in the pH level of plasma. The mechanisms employed by the kidneys to 
maintain acid-base balance involve the excretion of hydrogen ions and adjustment in the 
amount of bicarbonate reabsorbed by the tubular system or the quantity of bicarbonate 
generated by non-bicarbonate buffers (Yucha, 2004). 
As explained the kidney has an intrinsic role in the regulation of fluids and 
electrolytes, the maintenance of acid-base balance and the removal of metabolic waste 
products. In order to successfully replace or support renal function in the critically ill 
patient in response to AKI and the development of ARF any intervention must be able 
to effectively correct and stabilise the body‟s internal environment.  
Definition and Classification of Acute Kidney Injury 
Acute kidney injury is characterised by a sudden loss of renal function whereby 
the organ is unable to adequately excrete metabolic waste products, maintain fluid and 
electrolyte homeostasis and regulate acid-base balance (Hilton, 2006; Lameire, Biesen, 
& Vanholder, 2005; Singri, Ahya, & Levin, 2003). Although there is consensus 
regarding the qualitative definition of AKI no consensus has so far been reached 
regarding the biochemical quantification of a decline in renal function. Quantitative 
definitions of AKI are based on verifiable clinical measurements routinely undertaken 
which reflect some of the physiological functions of the kidney in the production of 
urine and in the clearance of urea and creatinine from nitrogen metabolism. The 
development of oliguria or anuria despite adequate intravascular volume has been used 
by investigators along with an increase in the concentration of serum creatinine (SCr) in 
a number of clinical trials (Bellomo, Champman, Finfer, Hickling, & Myburgh, 2000; 
Bernard et al., 2001; Jochimsen, Schafer, Maurer, & Distler, 1990; B. Manns et al., 
2003; Rangel-Frausto et al., 1995). Although the various quantitative definitions in 
published studies differ in their interpretation as to when organ dysfunction has 
occurred most identify a decline in urine output < 0.5ml per kilogram (kg) and specify a 
range of SCr laboratory increases > 150 micromoles (mol) per L over several days or 
sudden rises >80mol per L within 24hr as criterion of AKI. 
The clearance of creatinine over 24hr to estimate GFR is a common laboratory 
measurement used to define AKI, but is associated with several limitations when used to 
determine the degree of renal damage sustained (Lameire, et al., 2005). Alteration in 
SCr concentration is not only influenced by the GFR but will also depend on the 
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production of creatinine, the volume of creatinine distributed throughout the body, and 
how creatinine is measured. The reporting of creatinine clearance is also problematic as 
measurements are insensitive to small changes in GFR either as an indicator of a decline 
or as a marker of recovery in renal function. Despite the limitations as a marker of renal 
function creatinine clearance in the definition of AKI remains a useful measurement.  
According to the quantitative definition used to define AKI differences in the 
concentration of SCr add to the difficulties associated with the measurement of 
creatinine clearance. As a result of variations in the concentration of SCr used to 
determine loss of renal function inconsistencies can occur when the incidence and 
impact on patient outcomes of AKI are compared in the literature. The absence of an 
agreed-upon quantitative definition and the lack of a uniform classification system in 
the degree of injury sustained, influence when patients are enrolled and the endpoints 
used in studies designed to evaluate practices adopted in the management of AKI. So far 
the use of different quantitative definitions in published studies have made it difficult to 
undertake large prospective multi-centre investigations which are required to effectively 
identify patients at risk of AKI, develop strategies for prevention and treatment or, 
monitor expenditure of health resources (Uchino, 2006). 
As shown in Figure 1.2 the risk injury failure loss end-stage (RIFLE) kidney 
disease classification system has been developed by the Acute Dialysis Quality 
Initiative (ADQI) group in an effort to reach a consensus on a quantitative definition of 
AKI according to the severity of renal insufficiency (Bellomo, Ronco, Kellum, Mehta, 
& Palevsky, 2004). The condition is classified into three severity categories according 
to the degree of risk, injury and failure. Classification of the severity in each category is 
met either though changes in SCr or urine output or both. The other two clinical 
categories measure outcome according to the duration in loss of renal function and the 
development of end-stage renal disease (ESRD). The degree of sensitivity to injury 
increases with milder forms of renal failure but the detection of renal dysfunction less 
specific, whereas specificity increases with moderate to severe renal dysfunction but is 
not as sensitive in the detection of increased trauma to renal function. Although the 
measurement of urine output and the monitoring of SCr levels identify changes in 
kidney function, both markers do not accurately reflect the extent of injury which has 
occurred to the kidneys. Several urinary and serum markers have instead been identified 
and investigated as possible indicators of renal injury before the presence of a decline in 
kidney function  (Parikh & Devarajan, 2008). The use of injury rather than functional 
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markers offers the potential for the diagnosis of AKI to be identified earlier and reduce 
the delay of treatment designed to prevent the development of renal failure.    
The validity of the RIFLE classification system as a proposed standardised 
quantitative definition for AKI has been evaluated in several studies. The ability of 
RIFLE to predict the mortality of hospitalised patients was tested in a large 
retrospective single-centre study (Uchino, Bellomo, Goldsmith, Bates, & Ronco, 2006). 
The authors reported there was an almost linear increase in the predictability of hospital 
mortality when patients were retrospectively classified according to the RIFLE severity 
category. A similar relationship between the RIFLE criteria and in the prediction of 
patient outcomes has been corroborated with other examples of retrospective analyses in 
the validation of the classification system. After retrospective comparisons of survival 
were made in a large cohort of patients admitted to ICU the severity of the RIFLE 
categories was shown to correlate with an increase in mortality (Hoste et al., 2006), and 
in another study the retrospective use of the RIFLE criteria was demonstrated to 
augment the prediction of outcome in critically ill patients when applied to established 
illness severity scores such as the acute physiology and chronic health evaluation 
(APACHE) II score (Abosaif, Tolba, Heap, Russell, & Nahas, 2005). The RIFLE 
classification system has also been shown to be a reliable predictor of patient survival in 





Figure 1.2. The RIFLE classification system (Bellomo, et al., 2004) 
 
 
consistently identify increased mortality in patients who had undergone cardiac surgery 
when the procedure was associated with the incidence of postoperative renal 
dysfunction (Kuitunen, Vento, Suojaranta-Ylinen, & Pettila, 2006). The authors 
demonstrated the RIFLE classification system was an accurate predictor of 90 day 
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changes to GFR. The use of the RIFLE criteria was also shown to be a reliable 
prognostic tool in another prospective study for predicting the survival of patients who, 
based on biochemical abnormalities, were treated with CRRT (Bell et al., 2005). The 
authors observed 30 day mortality in patients with a severe RIFLE category (RIFLE-F 
and RIFLE-L) was significantly higher (> 50%) compared with those patients whose 
RIFLE category was less severe (RIFLE-R and RIFLE-I) (< 25%). 
   A number of refinements have been suggested by the Acute Kidney Injury 
Network (AKIN) in recognition of several important shortcomings of the RIFLE criteria 
(Mehta et al., 2007). One aspect not addressed by the RIFLE criteria is the lack of 
sensitivity related to SCr levels from baseline measurements. The proposed AKIN 
criteria  introduces several stages which measure changes in SCr levels over 48hr with 
the intention to reflect more accurately the degree of renal impairment sustained. 
Despite the perception of increased sensitivity by staging the measurement of SCr levels 
misclassification of AKI was observed by Joannidis and associates (Joannidis et al., 
2009) to have arisen more frequently using AKIN criteria when compared with 
assessment undertaken using RIFLE. The subsequent validation of the RIFLE criteria as 
a predictor of patient outcomes has led to wide acceptance of the definition and 
classification system for AKI. The shift of terminology away from ARF in favour of 
AKI using RIFLE to define and classify the changes in renal function has been reflected 
in the literature (Bagshaw et al., 2007). An upsurge in the use of a standard definition 
may see the RIFLE criterion adopted as a diagnostic reference point when investigations 
are undertaken to develop strategies for the prevention or management of AKI.   
Causes of Acute Kidney Injury 
The causes of AKI have traditionally been divided into three categories 
according to the location of injury sustained by the kidneys either the result of a 
reduction in glomerular perfusion (prerenal), the onset of intrinsic renal diseases 
(intrarenal), or the obstruction of the urinary tract (postrenal) (Lameire, et al., 2005). An 
important distinction can be made when comparing intrarenal failure with prerenal or 
postrenal failure. Once the causes of prerenal or postrenal failure are corrected the 
recovery from injury is usually rapid and there is often no residual loss of kidney 
function. This differs from intrarenal failure since recovery may be prolonged and 
injury to the kidney associated with permanent structural damage and the possibility of 
renal insufficiency.   
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Prerenal Injury 
Prerenal injury is caused when there is a reduction in the supply of blood leading 
to hypoperfusion of the kidneys. The arteriolar autoregulation mechanism is unable to 
compensate for changes in perfusion pressure and there is a decrease in the GFR 
(Lameire, 2005). A variety of conditions can result in prerenal failure including loss of 
intravascular volume, reduced cardiac output, obstruction of blood flow by dissected 
aortic aneurysm, or a substantial decrease in vascular resistance due to peripheral 
vasodilation. Although a certain level of interpretation is required according to the 
individual‟s age and size when determining an acceptable urinary output, the volume of 
urine normally produced by the kidneys is between 0.5 and 2ml per kg of body weight 
per hr (Perkins & Kisiel, 2005). Implementation of supportive measures such as 
intravascular fluid expansion and the use of vasopressor agents can reverse the effects 
of hypoperfusion and restore normal kidney function in the excretion of urine.  
Intrarenal Injury 
Intrarenal injury is caused when damage to the kidneys has led to structural 
changes to the nephron involving the glomeruli, renal tubules, blood vessels and 
interstitium (Lameire, 2005). This is in response to a prolonged loss of renal perfusion 
due to inadequate intravascular volume, adverse effects of nephrotoxic agents or 
mechanisms associated with the inflammatory process.  
Postrenal Injury 
Postrenal injury refers to an obstruction of the urinary tract which prevents the 
flow and emptying of urine from the kidneys (Lameire, et al., 2005). The blockage can 
be due to renal calculi within the collecting tubules, compression of the ureter by 
prostate enlargement or external masses obstructing the bladder outlet. Treatment is 
directed at removing the obstruction and once urinary flow is restored normal kidney 
function usually returns. 
The most common cause of AKI in the critically ill patient is as the result of 
intrarenal injury due to Acute Tubular Necrosis (ATN) (Lameire, 2005). The 
development of ATN can either originate as the result of an ischaemic event or after 
exposure to nephrotoxic substances. A combination of both ischaemia and 
nephrotoxicity can also lead to ATN which is of a mixed etiology.  
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Pathophysiology of Acute Tubular Necrosis 
The critically ill patient is often exposed to the effects of hypoperfusion and is 
considered a precursor to ischaemic intrarenal injury and the development of ATN. 
Controversy surrounds the use of the term ATN to describe the pathophysiology of AKI 
since the presence of necrotic tubular cells has not always been a defining feature 
observed during histological examination. Evidence from renal biopsies undertaken on 
ischaemic injury have shown the presence of only limited necrosis despite the existence 
of marked functional impairment (Lameire, 2005). The death of renal tubules is 
suspected to instead occur by apoptosis a form of cell death where the damaged cell 
undergoes a cascade of intracellular changes. Once damaged the cell is broken down 
and cellular debris removed by phagocytosis. The process is often underestimated due 
to changes which are difficult to detect in histology tissue samples (Bonventre & 
Weinberg, 2003). Consequently, the physiological derangement caused by ATN is not 
necessarily reflected by a profound alteration in renal tubule pathology.   
The development of ATN due to ischaemic intrarenal injury is associated with 
an interruption in the blood supply to the kidneys. Approximately 20 to 25% of cardiac 
output is normally distributed to the kidneys delivering a blood flow rate of 1,000-
1,200ml per min (Holechek, 2003a). The large supply of blood exceeds the metabolic 
and oxygen requirements of the kidneys in order to facilitate the efficient clearance of 
metabolic waste products and maintain internal biochemical stability. A reduction in 
blood flow can be caused by hypovolaemia, but may go unrecognised when it is not 
associated with a dramatic drop in blood pressure. The intrarenal response to 
hypotension relies on the autoregulation system to detect a reduction in perfusion 
pressure. As the result of a drop in arterial blood pressure the afferent and efferent 
arterioles which enter and leave the glomerulus vasoconstrict or vasodilate under the 
influence of the myogenic and tubuloglomerular feedback (TGF) mechanisms (Marieb 
& Hoehn, 2007). The myogenic mechanism senses changes in vascular tone and, as part 
of the juxtaglomerular apparatus the TGF mechanism recognises alterations in the 
composition of tubular fluid at the macular densa. A natural tendency for vascular 
smooth muscle to contract when stretched by increased blood flow causes the efferent 
arteriole to vasoconstrict following vasodilation of the afferent arteriole. The macula 
densa cells of the juxtaglomerular apparatus respond to the concentration of sodium 
according to the GFR and the amount of sodium reabsorption which occurs in the 
ascending limb of the loop of Henle. A decrease in the rate of filtrate reaching the distal 
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tubule exposes the macula densa cells to low levels of sodium causing juxtaglomerular 
cells in the smooth muscle walls of the afferent arteriole to vasodilate. Significant 
energy-dependent solute transport may occur in the outer medulla region of the kidney 
with the ascending portion of the loop of Henle requiring the greatest uptake of oxygen 
to release energy for the active transport of sodium. The supply of oxygen through this 
section of the loop of Henle is very sensitive to changes in perfusion pressure should a 
systolic blood pressure drop below 90 millimitres of mercury (mmHg) (Abuelo, 2007). 
A reduction in the capacity of the TGF mechanism to compensate for changes in 
perfusion pressure will stimulate activation of the renin-angiotensin mechanism (Marieb 
& Hoehn, 2007). Juxtaglomerular cells located in the efferent arteriole are stimulated to 
release renin following the detection of a drop in glomerular hydrostatic pressure. Once 
present in the circulation the enzyme converts the plasma protein angiotensinogin to 
angiotensin I. Circulation of angiotensin I to the lungs exposes the protein to the 
angiotensin converting enzyme (ACE) found in the pulmonary capillary network. 
Angiotensin I is converted into Angiotensin II which acts on the smooth muscles of 
efferent arterioles to vasoconstrict and increase vascular resistance. The decrease in 
perfusion pressure is able to be temporarily alleviated by adrenergic and angiotensin II 
activity combined with the release of aldosterone to increase tubular reabsorption of 
sodium and water. A delay in the restoration of blood flow will place extra demand for 
oxygen in the loop of Henle and provoke the development of ischaemia due to the 
effects of vasoconstriction and increased sodium and water absorption. Although the 
loss of intravascular volume has been suspended following the onset of physiological 
oliguria, the increase energy requirements for active transport in the ascending loop of 
Henle deplete tubular stores of ATP (Lameire, 2005). The severity of ATP depletion is 
halted after the increased release of adenosine causes more vasoconstriction and the 
tubular workload of the ascending loop of Henle is momentarily decreased after a 
reduction in the GFR slows down solute delivery. Eventually the normal physiological 
responses to changes in blood flow and perfusion pressure are unable to successfully 
protect the kidney from injury. Once the TGF and the renin-angiotensin mechanisms are 
exhausted ischaemia to the medullary region of the kidney will result in death of tubular 
cells and a pathophysiological decline in renal function. The development of organ 
failure is no longer considered a prerenal injury but the result of ischaemic intrarenal 
injury as a consequence of inadequate perfusion of the kidneys. 
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The other causes of ATN occur after exposure to endo- and exo toxic substances 
(Evenepoel, 2004). Endothelial cells of the renal tubules are either directly injured by 
the toxin alone, or indirectly damaged when mechanisms which normally protect renal 
blood flow such as the autoregulation system succumb to a toxic insult. Myoglobin is an 
endotoxin which can cause the development of ATN when released into the circulation 
during rhabdomyolysis (Evenepoel, 2004). The formation of casts leading to tubular 
obstruction and the death of endothelial cells is thought to occur when myoglobin is 
filtered through the glomeruli and allowed to reach the renal tubules. Haemoglobin is 
another example of an endotoxic substance which can increase the risk of ATN when 
there is intravascular haemolysis and evidence of haemoglobinuria (Evenepoel, 2004). 
Among the exotoxic substances which can cause chemical-induced ATN many are 
associated with contrast media used for diagnostic procedures and in the medications 
required to treat the critically ill patient. Aminoglycoside antibiotics are particularly 
nephrotoxic if serum levels are not carefully monitored and necessary adjustments made 
in the treatment of severe infection (R. John & Herzenberg, 2009). Similarly, 
radiographic contrast agents produce harmful effects and impair renal function when 
high doses of radio-contrast dye are delivered and the patient is not sufficiently hydrated 
(Tumlin et al., 2006).  
The development of ATN can occur as the result of sepsis representing a mixed 
injury caused by ischaemia and nephrotoxity when patients are exposed to severe 
infection. A major cause of hypoperfusion leading to tubular ischaemia during septic 
shock is the result of injury sustained by systemic arterial vasodilation following the 
release of inflammatory mediators (Wan, Bellomo, Giantomasso, & Ronco, 2003). In 
response to a decrease in systemic vascular resistance the fall in blood pressure changes 
the GFR by altering the relationship between the afferent and efferent arterioles. 
Although renal blood flow will be increased due to widespread vasodilation the pressure 
within the glomerulus can drop as the efferent arteriole dilates even more than the 
afferent arteriole. As a consequence of lost perfusion pressure the delivery of oxygen to 
the renal tubules is reduced despite an adequate supply of blood to the medullary region 
of the kidney. Activation of the coagulation pathway due to the inflammatory response 
also causes the release of microthrombi and the risk of ischaemia due to intravascular 
thrombosis occurring within the infrastructure of the nephron (Wan, et al., 2003). The 
other mechanism of injury which is caused by severe infection arises when ATN is the 
result of exposure to harmful bacteria. Once infiltration of the organism has occurred 
 22 
interaction with inflammatory mediators allow bacterial substances to enter the blood 
stream and pass through the renal vasculature leading to nephrotoxic tubular injury 
(Wan, et al., 2003).  
The pathophysiology of ischaemic or nephrotoxic ATN results in damage to the 
renal tubules and surrounding vasculature. A retrospective analysis of patients with 
ischaemic (46%) and mixed ATN (55%) observed a higher incidence of multiple organ 
dysfunction (MOD) after comparisons were made with the frequency of dysfunction 
reported when AKI was isolated to nephrotoxic ATN (7%, P-value < 0.0001) (Santos et 
al., 2006). Since the causes of ATN in the critically ill patient may have a number of 
etiologies the combined effects of ischaemia and nephrotoxity increase the risk of 
damage to the kidneys and decrease the chances of patient survival due to the adverse 
effects of renal insufficiency. The extent of injury sustained is nevertheless able to be 
offset by the capacity of the epithelial cells to repair structural and biochemical 
processes associated with restoring the integrity of the tubular system and re-
establishing renal function. Once reperfusion of the tubular system has occurred there is 
a proliferation of viable epithelial cells with the incorporation of growth factors which 
leads to the regeneration of normal tubular epithelium (Thadhani, Pascual, & Bonventre, 
1996). The prevention of repeated exposure to renal hypoperfusion will allow the 
process of regeneration to occur early, and limit the degree of permanent damage which 
is sustained by the kidney affecting the long-term viability of renal function.     
  Epidemiology of Acute Kidney Injury 
The epidemiology of AKI is not widely understood due to regional disparities in 
the definition and reporting of the condition. Studies which have investigated the 
incidence and impact of AKI on hospitalised patients have been confounded by the 
absence of standardised criteria to describe loss of renal function, the lack of adjustment 
for differences in the severity of illness, and under representation of existing co-
morbidities. Despite these shortcomings examples exist in the literature of single and 
multicentre studies which describe the epidemiology of AKI. The information gained 
from each study can provide insight on the significance of AKI as a factor influencing 
the recovery of the critically ill patient. 
Over the last decade the incidence of hospital-acquired AKI has increased. The 
results of a follow up study based on the original investigation undertaken a decade 
earlier showed a reported rise of cases from 4.9% (Hou, Bushinsky, Wish, Cohen, & 
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Harrington, 1983) to 7.2% (Nash, et al., 2002) after each single centre study used the 
same defining criteria to determine the presence of ARF. During a nine month 
multicentre epidemiology investigation of admissions to 13 tertiary hospitals the 
development of AKI was prospectively observed by the Madrid Acute Renal Failue 
Study Group (Liano & Pascural, 1996). The overall incidence of hospital-acquired AKI 
covering a population of 4.2 million people was reported to be 209 cases per million. 
Out of the 748 episodes identified by the authors 45% of cases were caused by 
intrarenal failure, 21% of cases as a result of prerenal failure, and 10% of cases due to 
postrenal failure. The mortality rate of patients with AKI was observed by Liano and 
Pascural  (1996) to be much higher (45%) when compared with other patients admitted 
to hospital who did not acquire the condition (5.4%). Attempts to investigate the 
development of AKI among the critically ill population have reported a greater 
incidence of cases when compared with those observed in other hospitalised patients 
outside of ICU. Over a period of 15 months the BEST kidney study investigated the 
incidence and causes of AKI in the critically ill patient (Uchino, et al., 2005). Across 
each of the 54 medical centres in 23 countries which participated in the study the 
prevalence of AKI in 29,269 patients ranged between 1.4% and 25.9%. Out of those 
patients diagnosed with AKI the authors observed 47.5% were associated with sepsis, 
34% after patients had undergone major surgery, 27% of cases related to cardiogenic 
shock, hypovolaemia had occurred in 26% of patients and 19% as the result of exposure 
to nephrotoxic drugs. Irrespective of the causes which had led to the development of 
AKI the authors reported over half went on to require RRT. As a consequence of AKI 
the BEST study reported a mortality rate of between 50.5% and 76.8% (Uchino, et al., 
2005). Among patients with sepsis as the cause of AKI the mortality rate was 
significantly higher when compared with nonseptic patients (70.2% versus 51.8%, P-
value < 0.001). Based on the findings of BEST the onset of sepsis was the most 
common contributing factor in the development of AKI and the condition most likely to 
decrease the chances of survival in the critically ill patient. Out of those patients who 
survived and were discharged home 13.8% were dependent on some form of RRT. 
The characteristics of hospitalised patients have changed over several years as a 
consequence of improved medical technology. Patients now admitted to the ICU who 
may not have otherwise survived are handicapped by complex medical problems with 
pre-existing chronic illnesses that weaken their chances of survival. More recent 
observational studies which have been undertaken suggest critically ill patients who 
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develop AKI occur in older patients, who have more existing co-morbidities, are more 
likely to be septic due to severe infection and have greater severity of illness and organ 
dysfunction (Bagshaw et al., 2005; de Mendonca et al., 2000; Mehta et al., 2004). The 
findings of a systematic review on the literature regarding the mortality rate of patients 
with severe ARF suggested the survival of patients had not improved and was virtually 
the same over several decades despite advances made in RRT and other forms of 
supportive interventions (Ympa, Sakr, Reinhart, & Vincent, 2005). This may not be a 
correct interpretation on the review of studies investigating the incidence of deaths 
related to the development of AKI. Caution should be exercised when undertaking 
systematic reviews on previously reported mortality of hospitalised patients when they 
are confounded by different definitions of AKI, variations in severity of illness, 
unknown number of patient co-morbidities, and various management practices over 
different time periods (Bellomo, 2006). Other attempts at investigating possible changes 
in the mortality of patients with AKI are based instead on studies using databases 
established over several years which are more representative of population sub-groups 
and use similar coding systems to determine in-hospital differences and changes to 
patient mortality. A significant fall in the mortality rate of hospitalised patients with 
AKI was observed by Bagshaw and associates (2007) between 1996 to 2005 using the 
Australian New Zealand Intensive Care Society (ANZICS) Adult Patient Database 
(annual percentage change -3.4%, 95% confidence interval [CI], -4.7 to -2.12, P-value < 
0.001). After similar adjustments were made for illness severity the stratified analysis of 
in-hospital mortality due to AKI between 1988 and 2002 was also previously reported 
to have declined in the United States (US) (40.4% versus 20.4%, P-value < 0.001) 
(Waikar, Curhan, Wald, McCarthy, & Chertow, 2006). The findings of the Australian 
study corroborates with the earlier findings of the US study where both investigations 
identified a significant decrease in mortality from AKI over the past decade. Despite the 
reported improvement in the survival of patients with AKI the mortality rate in the 
Australian study remained significantly higher when compared with the lower mortality 
observed in patients who did not sustain AKI during their stay in ICU (42.7% versus 
13.4%, P-value < 0.0001) (Bagshaw, George, et al., 2007). The additional observations 
made by the authors of the Australian study suggest although the associated mortality 
with organ dysfunction has declined in recent years the development of AKI is 
nevertheless an independent factor which increases the risk of death for the critically ill 
patient.   
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    Consequences of Acute Kidney Injury 
The physiological consequences of AKI in the critically ill patient derive from 
the important role the kidneys normally play in the maintenance of water and electrolyte 
regulation, in the excretion of metabolic waste products and in the preservation of acid-
base balance. A decline in renal function can influence the activity of other organ 
systems and jeopardise the ability to maintain normal body homeostasis which may 
culminate in the development of Multiple Organ Dysfunction (MOD). The adverse 
physiological complications of fluid volume overload, electrolyte disorders, retention of 
organic compounds and metabolic acidosis depend on the severity of renal insults which 
have occurred and the pre-existing functional status of the kidney.   
Volume overload 
The administration of intravenous fluid and liquid nutrition is often required in 
the management of the critically ill patient. This can lead to the accumulation of fluid as 
the result of AKI when there is deterioration in renal function and the development of 
oliguria. A direct correlation between fluid overload and mortality in critically ill 
patients was reported by Bouchard and associates (2009) in a prospective observational 
study. After adjustment was made by the authors regarding severity of illness a 10% rise 
in body weight above baseline measurements was associated with increased patient 
mortality due to excess fluid volume (mortality at 30 days, 37% versus 25%, P-value = 
0.02; mortality at 60 days, 46% versus 32%, P-value = 0.006; on hospital discharge, 
48% versus 35%, P-value = 0.01). Several reasons might explain why volume overload 
due to AKI can reduce survival in the critically ill patient or worsen the severity of 
injury sustained. The accumulation of fluid in lung tissue places the patient at risk of 
hypoxia when gas exchange within the alveoli is reduced and the requirement for 
mechanical ventilation increases the potential for the respiratory tract to become a 
source of infection. A positive fluid balance was shown during an observational study to 
worsen the outcome of patients diagnosed with acute lung injury (ALI) when the 
resolution of excess fluid volume was delayed (survivors of ALI total cumulative 
negative fluid balance -3.0mLs standard deviation [SD]+17.8 versus non-survivors of 
ALI total cumulative positive fluid balance 4.4mLs SD+23.6, P-value < 0.001) (Sakr et 
al., 2005). The instigation of positive-pressure ventilation increases intrathoracic 
pressure and due to a decrease in cardiac output alters renal blood flow on kidney 
function already compromised by the original injury (Pannu & Mehta, 2004). In the 
presence of existing AKI patients may also have accumulation of extracellular fluid due 
 26 
to the effects of cardiac failure or altered protein capillary permeability as the result of 
septic shock. The impact of increased transcapillary hydrostatic pressure on an 
encapsulated organ like the kidney when coupled with decreased transcapillary oncotic 
pressure, may eventually lead to the presence of fluid in the interstium causing the 
elevation of venous pressure to interrupt the distribution of renal blood flow (Prowle, 
Echeverri, Ligabo, Ronco, & Bellomo, 2010). As a result of interstitial oedema within 
the infrastructure of the kidney oxygen delivery is impaired and can prolong the 
recovery of renal function. The resolution of excess fluid volume in the management of 
AKI is now recognised as being an important pathological factor which has the potential 
to lower patient mortality and reduce the severity of organ dysfunction (Cerda, 
Sheinfeld, & Ronco, 2010).   
Electrolyte disorders 
The development of electrolyte disorders as the result of AKI can induce a wide 
range of clinical disorders by interrupting the important role electrolytes play in cellular 
metabolism and membrane potentials of muscle and nerve cells (Ahern-Gould & Stark, 
1998). Hyponatraemia is a common feature of patients with renal insufficiency when 
oliguria causes the retention of water and the dilution of sodium ions within the 
extracellular fluid compartment (Adrogue & Madias, 2000). The presence of 
hyponatremia leads to swelling of the cells due to an osmotic gradient differential 
between the intracellular and extracellular fluid compartments. Changes in the volume 
of fluid present within body cells interrupt the normal functioning of the central nervous 
system and may lead to the development of seizure activity. Hyperkalaemia is a similar 
condition which is again associated with AKI when a decrease in the renal excretion of 
potassium causes an elevation of serum potassium levels (Nyirenda, Tang, Padfield, & 
Seckl, 2009). An elevation of potassium will also occur when the transfer of potassium 
from the intracellular to the extracellular fluid compartment is increased due to 
alterations in acid-base balance caused by the retention of inorganic acids, or after 
potassium is released into the bloodstream following extensive tissue damage. The 
presence of hyperkalaemia can be a life-threatening condition as it can lead to changes 
in cardiac electroconduction and the possible development of ventricular arrhythmias 
(Mattu, Brady, & Robinson, 2000). Similar disturbances with normal physiological 
activities of the body can arise when the homeostasis of other electrolytes is affected by 
renal insufficiency. Chloride is the most abundant extracellular anion which can 
accumulate if not excreted in sufficient quantities to reduce the strong ion differential 
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necessary for maintaining acid-base balance (Thomson & Macnab, 2009). Magnesium 
is another example of an electrolyte excreted by the kidneys where failure to remove 
sufficient quantities can lead to respiratory muscle weakness and atrioventricular blocks 
due to abnormal polarisation of cardiac muscle. Calcium absorption will also be reduced 
when there is loss of renal function and may interrupt the excretion of phosphate when 
the recovery of the kidneys is delayed causing calcium and phosphate to be deposited in 
tissues leading to increased nerve stimulation and muscle spasm (Thomson & Macnab, 
2009).  
Retention of organic compounds 
Urea is an organic solute normally found in the bloodstream following the 
metabolism of protein and along with SCr levels the Blood Urea Nitrogen (BUN) level 
is used as a marker to represent the removal of nitrogenous waste products and other 
toxins which are normally excreted by the kidneys (van Holder & de Smet, 1999). In the 
presence of AKI a variety of biochemical and physiological changes occur in response 
to the retention of urea and other organic compounds including platelet dysfunction and 
neurological deterioration, particularly if urea accumulation is rapid. The adverse 
consequences of an uraemic syndrome due to renal insufficiency is well documented in 
patients who have ESRD (Alper Jr., Shenava, & Young, 2010). The syndrome can also 
occur as the result of AKI but rather than a gradual manifestation over several years the 
loss of kidney function is rapid with uraemia developing over days to weeks. 
The impact on patient outcome of urea accumulation in ARF has not been well 
defined in the critically ill population. On admission to ICU a significant difference in 
patient mortality was observed showing a worse outcome for patients who had sustained 
AKI when compared with those patients who had existing ESRD (23% versus 11%, P-
value < 0.001) (Clermont et al., 2002). The observations made by the authors suggest 
the increased mortality associated with AKI was influenced by different factors and not 
caused solely by the accumulation of urea, but the loss of kidney function was overall a 
predictor of reduced survival since patients with ESRD had a mortality rate twice that of 
patients who showed no signs of renal insufficiency (5%).  Although the impact of 
uraemia in AKI is not well understood investigations undertaken by several other 
authors have shown the survival of patients is improved when the intensity of solute 
removal reduces the concentration of urea present in the bloodstream during 
haemodialysis or haemofiltration (Ronco, et al., 2000; Saudan et al., 2006; Schiffl, 
Lang, & Fischer, 2002). 
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Metabolic acidosis 
A common manifestation of AKI in critically ill patients is the development of a 
metabolic acidosis caused by the accumulation of organic acids and the loss of alkaline 
substances (Charles & Heilman, 2005). The acid-base disorder is the result of 
deterioration in the capacity of the kidneys to excrete hydrogen ions coupled with a 
reduction in the production or reabsorption of bicarbonate. The magnitude of the 
metabolic acidosis is also influenced by non-renal sources according to the nature of 
illness sustained by the patient (Gauthier & Szerlip, 2002). Examples of non-renal 
sources include anaerobic metabolism and the build-up of lactic acid, or an elevated 
anion-gap due to diabetic ketoacidosis, or as the result of ingesting harmful substances 
causing the formation of acid metabolites. Calculation of the anion gap between 
positively charged cations and negatively charged anions is used to determine the 
severity of the metabolic acidosis. A drop in the serum concentration of bicarbonate in 
the absence of gastrointestinal losses suggests a decline in kidney function with the 
accumulation of organic acids not matched by a rise in the concentration of chloride 
(Gauthier & Szerlip, 2002). The anion gap can be used to determine the severity of the 
metabolic acidosis so long as the difference is adjusted in patients who are 
hypoalbuminaemic, otherwise the negatively charged protein can disguise the acid-base 
disorder due to the reduced concentration of albumin. The early recognition of a decline 
in kidney function is necessary to prevent a metabolic acidosis from adversely 
impacting on the function of other organs (Charles & Heilman, 2005). A decrease in 
plasma pH for example can result in pulmonary vasoconstriction and contribute to right 
ventricular failure due to higher pulmonary vascular pressures increasing the workload 
of the heart. The extra burden imposed on the lungs to increase ventilation and 
compensate for a worsening metabolic acidosis is another example of how organ 
dysfunction may be observed when a decrease in plasma pH can lead to respiratory 
muscle fatigue.      
Protective Strategies 
The instigation of therapeutic strategies in response to the physiological 
consequences of AKI is directed at the preservation of existing renal function and in the 
prevention of irreversible damage to the kidneys. A number of  interventions have been 
suggested by Ronco and Bellomo (2003) as possible strategies to protect the critically ill 
patient from AKI. The proposed strategies include interventions which benefit most 
organ systems; maximise blood flow to the kidneys by the maintenance of cardiac 
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output, the expansion of intravascular fluid volume and in the stabilisation of organ 
perfusion pressure. Based on the aforementioned interventions other examples of 
protective strategies incorporate the use of pharmacologic agents to support kidney 
function. For example some diuretic agents have been shown to be useful in maintaining 
urinary output and hence fluid balance (Bagshaw, Delaney, Haase, Ghali, & Bellomo, 
2007), whilst the use of low-dose dopamine to improve renal blood flow is not 
recommended (Friedrich, Adhikari, Herridge, & Beyene, 2005), whereas the use of 
acetylcysteine may be of benefit when combined with intravenous fluids in patients 
exposed to radiographic contrast dyes (Marthaler & Keresztes, 2004).  
Cardiac output 
The maintenance of cardiac output (CO) is important in order to sustain 
adequate blood flow and perfusion of body tissues. At what point diminished CO results 
in renal dysfunction is nevertheless unclear from the literature. A number of studies 
have investigated the use of various measures which support CO in patients at risk of 
AKI and the failure of other organs (Annane et al., 2007; Finfer et al., 2004; Waksman, 
Weiss, Gotsman, & Hasin, 1993). The array of interventions can range from the 
administration of intravenous fluids and the use of vasopressor agents to a more 
invasive approach of surgery and the insertion of mechanical assist devices. A 
prospective multi-centre study of critically ill patients found those who were 
randomised to receive goal-directed haemodynamic therapy which increased cardiac 
index to supranormal levels (> 4.5L per min), or was directed at maintaining normal 
mixed venous oxygen (SvO2) at > 70%, had no significant effect on reducing mortality 
up to the time of discharge from the ICU when comparisons were made with a normal 
cardiac index control group (supra-normal cardiac index group 48.6% versus SvO2 
group 52.1% versus normal cardiac index control group 48.4%, P-value = 0.638), and 
the absence of any difference in survival did not change when patient outcomes were 
again reviewed after six months (supra-normal cardiac index group 61.7% versus SvO2 
group 63.8% versus normal cardiac index control group 62.3%, P-value = 0.875) 
(Gattinoni et al., 1995). Out of those who had survived the authors also reported the 
prevalence of renal dysfunction did not differ significantly between the three study 
groups (urinary output mLs/hr during treatment normal cardiac index control group 110 
SD+59 versus SvO2 group 105 SD+55 versus supra-normal cardiac index group 88 
SD+55, P-value = 0.139). An important factor to note when considering the results 
observed during the study was a large proportion of patients assigned to the 
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supranormal cardiac index treatment group (44.9%) did not achieve the designated 
haemodynamic target. The extraordinary haemodynamic target may have been 
unrealistic and confounded the results obtained since compliance in reaching the 
ordinary haemodynamic target was greater in the other treatment groups (normal 
cardiac index control 94.3%, normal SvO2 values 66.7%).  
A different observation was made when goal-directed haemodynamic therapy 
was investigated during a prospective single-centre study involving patients diagnosed 
with early stages of severe sepsis before admission to ICU (Rivers et al., 2001).  
Patients who were randomised in the Emergency Department to receive standard 
haemodynamic therapy which did not specifically target SvO2 levels had a significantly 
higher mortality rate at 28 days when compared with patients who had been assigned to 
receive goal-directed haemodynamic therapy which achieved SvO2 levels > 70% 
(standard haemodynamic therapy 49.2% versus goal-directed haemodynamic therapy 
33.3%, P-value = 0.01). The goal-directed group of patients were also observed by the 
authors to experience less organ dysfunction (standard haemodynamic therapy 6.4 
SD+4.0 versus goal-directed haemodynamic therapy 5.1 SD+3.9, P-value < 0.001) and 
significantly lower APACHE II scores (standard haemodynamic therapy 15.9 SD+6.4 
versus goal-directed haemodynamic therapy 13.0 SD+6.3, P-value > 0.001) after 72-hr 
hospitalisation. Although this study was not designed to specifically investigate the 
incidence of renal insufficiency the strategy of reducing tissue hypoxia would 
nevertheless have had a possible beneficial effect on preserving kidney function.  
The maintenance of cardiac output by goal-directed haemodynamic therapy may 
avoid organ dysfunction including the preservation of renal function. This can be 
achieved by the monitoring of SvO2 levels and the instigation of measures which 
support cardiac output to meet the demand for oxygen in the supply of blood to the 
body‟s organs.  
Expansion of intravascular fluid volume  
A lack of intravascular fluid volume caused by acute haemorrhage and increased 
capillary leakage are examples of conditions commonly associated with the critically ill 
patient. The development of renal injury occurs when compensatory mechanisms such 
as the renin-angiotensin system are overwhelmed and unable to prevent a decrease in 
blood flow to the kidneys. The loss of intravascular fluid volume which is not able to be 
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replaced causes the development of hypovolaemia and a reduction in blood supply to 
the kidneys (Ragaller, Theilen, & Koch, 2001).  
The administration of fluid is used to safeguard the patient against the adverse 
effects of hypovolaemia, but there are no recommendations in regards to a specific 
intravascular fluid volume which is more protective of renal function. The restoration 
and maintenance of intravascular volume is a frequent activity undertaken by the critical 
care nurse. In many situations the administration of fluid will require the monitoring of 
Central Venous Pressure (CVP) to measure right ventricular intravascular volume. The 
task of fluid resuscitation is made more difficult to manage in patients when the risk of 
AKI is associated with other organ failures. A liberal approach to fluid administration 
(CVP 10-14mmHg) was shown in one randomised study of patients with ALI to 
increase the duration of mechanical ventilation when compared to patients who instead 
received a conservative fluid management strategy (CVP < 10mmHg) (Wiedemann et 
al., 2006). Absolute values of CVP recordings can be misleading in patients who are 
receiving positive-pressure ventilation with „artificially‟ raised intrathoracic 
measurements masking the depletion of intravascular volume. Observations made by 
the critical care nurse of marked „swings‟ in arterial pressure tracings along with 
physical inspection of the patient may instead provide a better indicator that 
intravascular fluid expansion is required (Murch, 2005). A fine balance is often required 
to achieve adequate replacement of intravascular volume sufficient to sustain renal 
function but avoid the risk of fluid overload should AKI develop.   
The choice of whether to use crystalloid or colloid solutions for the replacement 
of intravascular fluid volume has been the cause of controversy when the effect on 
patient survival was analysed differently after studies investigating fluid resuscitation 
practices in the critically ill patient were reviewed (Choi, Yip, Quinonez, & Cook, 1999; 
Cochrane Injuries Group Albumin Reviewers, 1998). This prompted the ANZICS 
Clinical Trials Group to conduct a large, multi-centred, randomised, double-blinded trial 
to evaluate the effect of crystalloid versus colloid administration on mortality in the ICU 
(Finfer, et al., 2004). The authors of the Saline versus Albumin Fluid Evaluation 
(SAFE) study reported patient survival from all-cause mortality at 28 days was no 
different using 0.9% normal saline when compared with 4% albumin. 
The practice of intravascular fluid expansion has been shown to protect the 
kidneys from possible injury caused when patients are exposed to radio-contrast agents 
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or affected by the development of rhabdomyolysis. The administration of intravenous 
fluids before and after diagnostic procedures (Bader et al., 2004) and the selection of 
isotonic rather than hypotonic hydration (Mueller et al., 2002) have demonstrated to be 
effective strategies in protecting the kidneys against the harmful effects of nephrotoxic 
substances present in radio-contrast agents. On the strength of observations made 
following the rescue of earthquake victims who had sustained crush injuries from 
collapsed masonry, early and vigorous fluid resuscitation in the management of 
traumatic rhabdomyolysis was shown to have a protective affect on maintaining kidney 
function (Gunal et al., 2004). The administration of extra volume reduces the 
development of hypovolaemia when damaged muscles become swollen and, as a 
consequence of muscular injury, expose the patient to the release of large quantities of 
myoglobin. The potentially harmful affects of myoglobin on kidney function is then 
minimized by using a mannitol-alkaline solution. Intravascular fluid expansion with a 
forced diuresis maximises renal excretion by flushing out debris following the 
breakdown of myoglobin. This reduces exposure of renal tissues to nephrotoxic 
substances and the possibility of tubular obstruction. The addition of sodium 
bicarbonate into the intravenous crystalloid infusion causes the alkalinisation of urine to 
protect the tubular system against further breakdown of myoglobin (Criddle, 2003).  
Despite the absence of a Randomised Clinical Trial (RCT) clinical experience 
suggests the depletion of intravascular volume without fluid replacement increases the 
risk of AKI. There are no recommendations in regards to a specific intravascular fluid 
volume which is more protective in safeguarding the kidney against the effects of 
hypovolaemia, what evidence is available suggests that a fluid input sufficient to 
maintain urine output at least 0.5ml per kg in an adult will sustain kidney function, fluid 
in excess of this of this may impair other organ performance without enhancing 
survival. Intravascular fluid expansion is recommended for diagnostic procedures which 
require the administration of radio-contrast agents and in the management of 
rhabdomyolysis. 
Renal perfusion pressure 
A decrease in urinary output when combined with a fall in blood pressure can 
suggest a reduction has occurred in renal perfusion pressure. In humans the lowest 
threshold of renal autoregulation is estimated to be around 80mmHg before the 
mechanism is unable to compensate for a drop in systemic blood pressure and the GFR 
can no longer be maintained at normal levels (Bersten & Holt, 1995). Once the 
 33 
autoregulatory mechanism is below this threshold any further drop in systemic blood 
pressure stimulates the release of endogenous vasoconstrictors but the affects of 
prolonged hypotension will eventually cause a reduction in renal blood flow to the 
glomeruli and in the perfusion of other tubular structures (Abuelo, 2007).  
The management of hypotension is directed at targeting a mean arterial pressure 
(MAP) which is sufficient to perfuse the kidneys and in the perfusion of blood to other 
organs. International guidelines put forward by members of the Surviving Sepsis 
Campaign recommend a MAP of greater than 65mmHg is the minimum pressure 
required to reduce the incidence of organ dysfunction as the result of tissue 
hypoperfusion (Dellinger et al., 2008). When the autoregulatory capacity of the kidneys 
is unable to compensate for a drop in blood flow to the kidneys, fluid replacement 
should be initially used to optimise intravascular volume. In patients who continue to be 
hypotensive despite adequate hydration the use of vasoactive and inotropic agents may 
be necessary in order to achieve a higher MAP. The vasoactive agent commonly used 
for the management of persistent hypotension is Noradrenaline causing widespread 
vasoconstriction by the stimulation of α - adrenergic receptors (Bellomo, Wan, & May, 
2008). In response to the vasoconstrictive effects of Noradrenaline the decline in MAP 
is interrupted and blood flow to the kidneys maintained by the restoration of the 
autoregulatory pressure threshold, but caution should be exercised in the administration 
of Noradrenaline to avoid excess vasoconstriction and organ hypoperfusion. Under 
situations of pronounced vasodilation as seen in patients with septic shock the use of 
Noradrenaline may assist in the return of normal vascular tone and as a result improve 
renal perfusion pressure. The findings of a RCT investigating the management of septic 
shock reported the use of Noradrenaline was associated with a significant improvement 
in the reversal of hypotension and restoration of urinary output when compared with 
patients who instead received high-dose Dopamine (C. Martin, Papazian, Perrin, Saux, 
& Gouin, 1993).  
A number of recommendations regarding the maintenance of renal perfusion 
pressure can be made using knowledge on the physiological regulation of blood flow 
and on the clinical experience gained at the bedside in the management of hypotension. 
Despite the limited availability of evidence from extensive investigation the 
replacement of intravascular fluid to correct hypovolaemia should be administered 
before consideration is given to the commencement of vasopressor agents. The use of 
Noradrenaline to reduce vasodilation and loss of vascular resistance in patients with 
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septic shock can restore renal perfusion pressure which may have a protective effect on 
maintaining kidney function.   
Pharmacologic Agents  
A variety of pharmacologic agents for the prevention of AKI and in the 
management of established ARF are suggested to support existing renal function, 
minimise damage to the kidneys and promote the recovery of renal activity. The 
possibility of protecting the critically ill patient against the adverse consequences of 
renal insufficiency has seen the use of pharmacologic agents undergo considerable 
investigation (Lameire, Biesen, Hoste, & van Holder, 2009). Despite the abundance of 
statistical well-powered studies investigating the use of pharmacologic agents the 
observations made have proven to be disappointing in regards to detecting a protective 
effect on kidney function. Although some of the interventions to support kidney 
function have been shown to be effective in the immediate management of the critically 
ill patient, there is the potential to cause harm when caution is not exercised in the 
application of these drugs and only limited evidence to suggest improvement in renal 
recovery. 
Diuretics. 
The development of oliguria has been identified in a number of studies as being 
a predictor of worsening renal function in patients diagnosed with AKI. Non-oliguric 
patients have instead been shown to be associated with fewer complications, reduced 
need for RRT, shorter hospital stays and a lower mortality rate (Brivet, Kleinknecht, 
Loirat, & Landais, 1996; Shilliday, Quinn, & Allison, 1997). The practice of using 
diuretic therapy to „convert‟ oliguric to non-oliguric ARF is an approach often used in 
the management of the critically ill patient to correct the accumulation of excess fluid 
and allow for the administration of blood products, vasopressor agents, antibiotic cover 
and nutritional support. During the BEST study the authors reported approximately 70% 
of critically ill patients who had sustained AKI leading to the loss of kidney function 
were administered diuretics in the management of excess fluid volume with 98.3% of 
participating organisations choosing to use the loop diuretic Furosemide (Uchino et al., 
2004). 
Furosemide is a loop-diuretic frequently used in clinical practice to induce a 
diuresis in the management of the critically ill patient who has low urinary output and 
requires the regulation of excess fluid volume (Uchino, Doig, et al., 2004). Under 
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experimental conditions Furosemide has been shown to increase medullary oxygenation 
suggesting a protective effect on kidney function due to a reduction in oxygen 
consumption required for active transport by the tubular system (Brezis & Rosen, 1995). 
Although the use of loop-diuretics may assist the management of fluid volume in the 
critically ill patient (if a diuresis is achieved) there is no evidence to suggest the 
outcome of patients with ARF is improved. Several RCTs reviewed in a meta-analysis 
on the use of loop diuretics for the management of ARF have not shown an increase in 
survival or recovery of renal function (Ho & Sheridan, 2006). Out of the nine RCTs 
reviewed a number of the investigations analysed comprised of small sample sizes of 
less than 100 patients and admission to ICU not specified. This may have affected the 
results obtained when renal function, the requirement for RRT and patient survival were 
evaluated between the experimental and control groups. As a result of low statistical 
power the appearance of marginal differences in patient outcomes are difficult to detect 
from the results reported in the meta-analysis. The ability to make inferences from the 
meta-analysis was also limited by the inclusion of a study which evaluated the 
responses to Furosemide administration both in the prevention as well as for the 
management of ARF. Despite these shortcomings in the meta-analysis by Ho and 
Sheridan (2006) the absence of a significant improvement in the outcomes of patients 
was supported when a similar meta-analysis also found no evidence of an improvement 
in patient survival or in the recovery of renal function (Bagshaw, Delaney, et al., 2007). 
Although the five RCTs selected by the authors had been reviewed previously, the 
statistical criteria applied for this meta-analysis only included investigation of patients 
once the presence of ARF had been established. The observations reported upon in both 
of the meta-analyses were nevertheless constrained by the limited number of RCTs and 
the quality of methods used. A large multi-centre RCT is required to increase statistical 
power in view of the possibility that the affect of loop diuretics on renal recovery and 
patient survival in established ARF may only be detectable when larger sample sizes are 
analysed. 
The administration of loop-diuretics which successfully converts oliguric to non-
oliguric ARF will assist in the removal of excess fluid but has not been shown to 
influence the natural progression of the original injury. The restoration of urinary output 
may instead serve to conceal the severity of renal damage, or simply indicate a milder 
form of ARF has occurred rather than providing evidence of an effective treatment 
strategy. Once a decision has been made to administer the loop-diuretic careful 
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consideration should be given in regards to the patient‟s volume status, duration in the 
exposure of the diuretic agent limited to a specific length of time and dose, and the goal 
of bringing about a diuresis not a justification for postponing RRT. The use of loop-
diuretic therapy for critically ill patients with established oliguric ARF complicated by 
the accumulation of excess fluid is an appropriate treatment strategy when an overload 
of volume has resulted in respiratory distress, or other therapeutic interventions require 
the administration of additional fluid (Bagshaw, Bellomo, & Kellum, 2008).  
Mannitol is an osmotic diuretic which has also been used for the purposes of 
renal protection in patients who are considered at risk of developing ARF (Schetz, 
2004). The action of Mannitol induces a diuresis to flush out cellular debris and casts 
which might occlude the tubular lumen, to preserve the mitochondrial function of 
cellular activity by reducing the swelling of ischaemic tissue, and to assist in the 
scavenging of free radicals. The osmotic diuresis which accompanies the administration 
of Mannitol is associated with intravascular volume depletion when not accompanied by 
hydration and can increase medullary oxygen consumption due to the upsurge of 
activity in the distal tubule (Schetz, 2004). Studies which have investigated the use of 
Mannitol have not demonstrated a reduction in the incidence of ARF. The 
administration of Mannitol was not shown to have a protective effect on kidney function 
and may have caused a delay in the recovery of renal function when comparisons were 
made with hydration alone for the prevention of radio-contrast nephropathy (Solomon, 
Werner, Mann, D'Elia, & Silva, 1994). The absence of a protective effect using 
Mannitol was again reported following a retrospective study of 24 patients at risk of 
developing ARF diagnosed with rhabdomyolysis. Observations taken during the 
management of rhabdomyolysis demonstrated the inclusion of Mannitol made no 
difference to kidney function when comparisons of SCr levels were measured against 
those taken from patients who had only hydration administered (Homsi, Barreiro, 
Orlando, & Higa, 1997). The ability of Mannitol to induce a diuresis and maintain 
urinary output has not translated into an effective pharmacologic strategy for the 
prevention of ARF. Studies which have investigated the use of Mannitol have been of 
insufficient statistical power to completely exclude the possible benefit of the diuretic 
agent in the protection of renal function. But in view of the limited evidence available to 
suggest the diuretic agent has a protective effect on kidney function and aggravation of 
renal insufficiency observed during radio-contrast administration the use of Mannitol 
for the prevention of ARF can no longer be recommended. 
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Low-dose Dopamine. 
Low-dose Dopamine (1-3 micrograms [g] per kg per min intravenously) is a 
renal vasodilator acting on dopaminergic receptors in the kidney (Hollenberg, Adams, 
Mendall, Abrams, & Merril, 1973) . At this dose Dopamine has been shown under 
experimental conditions to augment renal blood flow causing an increase in urinary 
output independent of changes in renal perfusion pressure. The use of low-dose 
Dopamine as a continuous infusion has been used with some success (Polson et al., 
1987), but over time has failed to produce convincing evidence of its protective effect 
on renal function. A meta-analysis of over 50 published studies investigating the effect 
of Dopamine showed no evidence of a reduction in the incidence of AKI, the 
requirement for RRT or an improvement in patient survival to support its continued use 
for the prevention or management of ARF (Kellum & Decker, 2001). The large multi-
centre study undertaken by the ANZICS Clinical Trials Group (Bellomo, et al., 2000) 
assessed the effectiveness of low-dose Dopamine in the management of intensive care 
renal failure. A total of 328 critically ill patients with Systemic Inflammatory Response 
Syndrome (SIRS) and renal dysfunction were randomised in a double-blind study to 
receive either low-dose Dopamine at 2g per kg per min or the placebo. The 
intervention continued until there was resolution of ARF, the requirement for RRT or 
death had occurred. There was no difference in patient demographics, severity of illness 
and duration of treatment with the peak SCr concentration used as the primary 
measurement of outcome. The study demonstrated low-dose Dopamine made no effect 
in the treatment of ARF as opposed to hydration alone. The SCr level and urine output 
at one hour, 24 hour and 48 hour and the requirement for RRT were equivalent between 
the groups whilst significantly different from baseline measurements on commencement 
of the study (P-value < 0.01). This was a well designed and rigorous study which 
demonstrated no support for the continued use of low-dose Dopamine for the prevention 
or treatment of ARF in the critically ill patient. 
N-acetylcysteine. 
N-acetylcysteine has been suggested as another pharmacologic agent which can 
be used with hydration to prevent deterioration of kidney function (Lameire, De Vriese, 
& Vanholder, 2003). The antioxidant properties of acetylcysteine scavenge oxygen-free 
radicals and reduce ischaemia by causing endothelial vasodilation (DiMari et al., 1997). 
The use of N-acetylcysteine for renal protection against radiographic contrast dyes has 
been evaluated in several RCTs but with conflicting results on the response observed 
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(Durham et al., 2002; Kay et al., 2003; Tepel et al., 2000). Many of the studies 
evaluated made omissions in regards to describing the dose of N-acetylcysteine required 
and when the agent should be administered. To clarify the degree of benefit observed 
several meta-analyses have examined theses studies collectively (Alonso, Lau, Jaber, 
Weintraub, & Sarnak, 2004; Birck et al., 2003; Isenbarger, Kent, & O'Malley, 2003). 
Although some studies had shown no benefit, the overall recommendation from each of 
the systematic reviews support the use of N-acetylcysteine as a strategy to decrease 
radiographic contrast nephropathy. The effect is more noticeable in patients who have 
chronic renal insufficiency and administration of N-acetylcysteine should be combined 
with hydration before the diagnostic procedure. The protective effect of N-
acetylcysteine on renal function has encouraged other investigators to explore whether 
the same benefit is extended to patients after major surgery. Other studies investigating 
the use of N-acetylcysteine as a renal protection strategy for none radiographic contrast 
injury has been collectively reviewed in several meta-analyses (Ho & Morgan, 2009; 
Nigwekar & Kandula, 2009). The meta-analyses of predominantly randomised 
controlled studies in the absence of radiographic contrast have not shown a beneficial 
effect of N-acetylcysteine in the prevention of renal dysfunction after major 
cardiovascular surgery. 
A number of preventative measures can be taken to protect the critically ill 
patient from AKI. The maintenance of adequate renal perfusion pressure requires 
assessment of circulatory volume and the correction of hypovolaemia. This may require 
the instigation of intravenous fluid expansion and the commencement of vassopressors. 
Once cardiac output has been stabilised only then should pharmacological interventions 
be considered. The use of N-acetylcysteine for protection against radiocontrast-induced 
nephropathy is the only drug shown to be effective in the prevention of AKI. Loop-
diuretics allow the removal of excess fluid but are not associated with increased patient 
survival or improved recovery of renal function. The use of low-dose dopamine as a 
renal vasodilator is now no longer justified with the absence of any evidence to support 
the continued use of the drug in clinical practice.     
Summary 
The vulnerability of critically ill patients to the incidence of AKI and the 
development of ARF demonstrate the important place management of renal function 
holds in the care of the critically ill patient. Aspects of normal kidney function 
summarised in the background to this thesis demonstrate the vital role the renal system 
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plays in the maintenance of water and electrolyte balance, the removal of metabolic 
waste products and in the regulation of acid-base balance. Various markers of kidney 
dysfunction described are associated with several definitions used to quantify the 
severity of AKI. The causes of AKI are divided into categories according to the location 
and related pathology with the development of ATN the most common injury observed 
in the critically ill patient. A lack of definition regarding the measurement of injury to 
the kidneys has until recently made the epidemiology of ARF unclear, but efforts to 
reach consensus on a quantitative definition of AKI has led to a greater understanding 
on the degree of organ dysfunction experienced. The consequences of ARF focus on the 
sudden loss of kidney function causing volume overload, electrolyte disorders, retention 
of organic compounds and metabolic acidosis. The implementation of measures directed 
at preventing single or multiple injuries to the kidneys include strategies which 
maximise blood flow by the maintenance of cardiac output, the expansion of 
intravascular fluid volume and the preservation of organ perfusion pressure. A variety 
of pharmacologic strategies used for the prevention of AKI and in the management of 
ARF have been discussed which may prove useful in some situations. Should both 
general preventative measures and specific renal protective strategies not prevent the 
development of AKI, then the option of techniques designed to „artificially‟ replace 
kidney function becomes inevitable. This thesis explores the current knowledge of these 
approaches for critically ill patients, and investigate how best to sustain these treatments 




Acute Renal Failure in the critically ill patient is associated with a high mortality 
rate or, following recovery from the intial illness, the possibility of permanent renal 
insufficiency. The prevention of AKI requires prospective identification of those 
patients who are at risk of developing renal insufficiency by the avoidance of nehrotoxic 
agents, the provision of adequate hydration and haemodynamic support and 
consideration given to pharmacologic strategies. Once attempts to correct or ameliorate 
the physiological consequences of AKI have failed and there is a continued decline in 
renal function some form of RRT is required (Fieghen, Wald, & Jaber, 2009).  
Various approaches to RRT include the use of extracorporeal techniques which 
support kidney function intermittently or continuously. The importance of maintaining 
continuity of treatment in the application of the „continuous‟ approach to RRT forms the 
basis of the literature review with the success of this technique being dependent on the 
ability to achieve adequate circuit life. In undertaking the literature review a systematic 
approach was used during the search strategy to source appropriate material. The search 
strategy included a PUBMED database search from 1990 to December 2010 using the 
key words: Renal Replacement Therapy; Critical Illness; Circuit Life; Patient 
Outcomes. The date of publications was widened to include material on the 
development of renal support therapies when as a result of technological improvements 
changes occurred in the management of the critically ill patient. Only articles written in 
the English language were selected. The bibliographies of selected articles were also 
examined for relevance. The results of the search strategy identified 90 review articles, 
four meta-analyses, 41 randomised controlled trials, 87 prospective and 11 retrospective 
observational studies, five surveys or quality audits, two case reports, two quality 
assurance project, and three editorial or viewpoints. A list of material sourced during the 
literature review is provided in Appendix A. The publication of research papers were 
reviewed and the findings of each study evaluated according to the levels of evidence 
proposed by the National Health and Medical Research Council (NHMRC) (2005). The 
information obtained from the literature search was sorted and placed into two broad 
categories: the management of severe ARF in the critically ill patient and the successful 
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application of CRRT. The approach used assisted in how information was processed 
during the literature review and in the way information on the topic was presented. 
The management of severe ARF which requires the instigation of RRT forms the 
first part of the chapter, and in the context of the critically ill adult patient, comprise of 
techniques which utilise extracorporeal circulation technologies. An explanation on the 
theory of solute and plasma water transport through a semi-permeable membrane 
demonstrate how the use of convection and diffusion allow extracorporeal techniques to 
mimic the actions of the kidneys in the removal of excess fluid and metabolic waste 
products and in the control of acid-base balance. The importance of solute clearance is 
discussed along with consideration given to early rather than late commencement of 
treatment. Both intermittent and continuous approaches to RRT are commonly used to 
manage severe ARF in the ICU. An historical account is provided on the development 
of CRRT and in the choice of contemporary treatment modes. The discussion is 
followed by a comparison with IHD in the effectiveness of CRRT to improve patient 
survival and promote the return of kidney function, as well as issues concerning the use 
of each approach in clinical practice.  
The second aspect of the chapter focuses on the application of CRRT and 
considers the longevity of the extracorporeal circuit as fundamental to the successful 
implementation of the technique. To achieve electrolyte balance and acid-base control 
particular attention must be given to the composition of solutions used for CRRT. The 
intensity of dose delivered to the patient will also influence the treatment‟s effectiveness 
to correct the degree of renal insufficiency present. Although not able to operate „ad 
infernitum‟ the longevity of the circuit is an important aspect of the technique. The 
circuit is exposed to a variety of factors which impact on the ability of the technique to 
deliver treatment which is effective. A review of the physiological factors associated 
with extracorporeal circulation such as exposure of the blood coagulation system to 
non-biological surfaces and the use of anticoagulation strategies to sustain circuit life, is 
followed by an examination of the mechanical factors which can also influence the 
longevity of the circuit such as operational training in the use of equipment and the 
design features of the extracorporeal circuit. The importance placed on achieving 
adequate circuit life when using the „continuous‟ approach to RRT is fundamental in 
efforts to maximise the amount of treatment time delivered to the patient. Other 
concerns regarding the duration of each circuit using the technique include the workload 
sustained by the critical care nurse in the preparation and set-up of CRRT, in the 
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containment of costs associated with the expenditure of single-use items and in the 
extent of blood loss incurred due to the repeated circuit failure. The potential for 
convective versus diffusive mechanisms to act as an independent factor in the 
maintenance of circuit life is discussed and the issue of differences in the transport of 
solutes and plasma water between alternative treatment modes identified in the literature 
review as an area of study which requires further investigation.   
Management of Severe ARF in the Critically Ill Patient 
The collection of renal protective strategies reviewed in the previous chapter 
may prove unsuccessful in preventing or correcting a sudden loss of kidney function. 
Metnitz and colleagues (2002) in a prospective multi-centre epidemiological study 
reported the requirement for RRT due to a deterioration in renal function occurred in 
4.9% of patients admitted to ICU. The methods used to replace renal function and 
control the body‟s internal environment fall into two main categories: extracorporeal 
techniques which include a blood filter (Bellomo & Ronco, 1999), or the surgical 
placement of an indwelling catheter in the peritoneal cavity which act as the filter 
membrane (Kelley, 2004). Classification of the different forms of extracorporeal RRT 
(excluding renal transplantation) are summarised in Figure 2.1. Intermittent 
Haemodialysis and CRRT incorporating CVVH are two types of extracorporeal 
therapies most commonly used in the ICU (S. John & Eckardt, 2007). Each approach 
relies on a veno-venous circuit and roller-pump technology to circulate blood outside of 
the body through a haemodialyser or haemofilter. Excess fluid and unwanted substances 
are discarded as „spent‟ dialysate or as ultrafiltrate and the „cleaned‟ blood returned 
back to the patient.  
The option of performing peritoneal dialysis (PD) is a technique not routinely 
used for the management of ARF in the critically ill adult patient (Uchino, et al., 2005). 
Only patients with an intact peritoneal cavity are suitable for the technique with the 
inherent risk of infection a potential complication along with the possibility of 
respiratory insufficiency due to the requirement for the dialysate to remain in the cavity 
during the dwelling phase of the procedure. A concern regarding the overall ability of 
the technique to remove fluid efficiently and gain metabolic control when compared 
with the alternative choice of extracorporeal therapies makes PD less attractive to use in 
the hypercatobolic patient with severe renal insufficiency. The use of PD was shown to 
take longer in the restoration of acid-base balance and to bring about a reduction in the 
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concentration of SCr, a shorter duration was also observed in patients who were 





















Figure 2.1. The Classification of Extracorporeal Renal Replacement Therapies. 
     
Mechanisms of Solute and Plasma Water Transport 
The use of extracorporeal therapy to support renal function in the removal of 
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mechanisms at work when blood is circulated through an „artificial kidney‟. An attempt 
is made using semi-permeable membrane technology and extracorporeal circulation to 
artificially replicate the actions of the nephron described in the previous chapter as the 
functional unit of the kidney. The reproduction of a concentration gradient between 
extracorporeal blood and the membrane during haemodialysis mimics the movement of 
solutes which normally occurs by diffusion along different segments of the tubular 
system (Sarkar, 2009). The   alternative process of haemofiltration instead resembles the 
operations of the glomerulus by using blood flow through the extracorporeal circuit to 
create hydrostatic pressure in forcing plasma water and solutes across the semi-
permeable membrane. In the absence of the tubular system normally associated with the 
reabsorption of plasma water and substances such as the recycling of bicarbonate, the 
manipulation of extracorporeal blood is achieved by making adjustments to the delivery 
of replacement fluid, composition of the dialysate solution and pore size of the semi-
permeable membrane. Other important functions performed by the kidney are presently 
not able to be replicated by extracorporeal membrane technology.    
Diffusion 
The predominant method of solute removal which occurs during haemodialysis 
involves the process of diffusion with the movement of dissolved substances governed 
by differences in the concentration gradient of two separate solutions (blood and 
dialysate) across a semi-permeable membrane (Misra, 2008). As a result of thermal 
kinetic energy substances within the blood and the dialysate randomly move around, 
and over time attempt to achieve an even solute distribution on either side of the 
membrane. Solute removal by diffusion occurs when the equilibration across the 
membrane shown in Figure 2.2 is prevented, and a lower solute concentration 
maintained in the dialysate continues to draw substances out of the blood. The diffusive 
flux of a particular solute (Jd) through a semi-permeable membrane depends on the 
diffusivity (D) of the solute, the surface area (A) of the membrane and the temperature 
of fluid which are inversely proportional to the concentration gradient (dc) over the 




T (dc/dx)] (Ronco & Levin, 2005). 
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Figure 2.2. An illustration of solute movement by diffusion. 
 
Convection 
The removal of solutes during haemofiltration shown in Figure 2.3 is 
predominantly by convection caused by the movement of plasma water due to the flow 
of blood and the pressure gradient across the semi-permeable membrane. The 
convective flux of a particular solute (Jc) through a semi-permeable membrane depends 
on the ultrafiltrate rate (Qf), the concentration of solute in plasma water (Cb) and the 




S] (Ronco & Levin, 2005). The sieving 
coefficient is a measure of how easily a solute can filter through the membrane by 
convection. The ideal sieving coefficient of a solute should achieve parity with the 
membrane () [S = 1 - ].  
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Figure 2.3. An illustration of solute movement by convection.  
 
Ultrafiltration 
Ultrafiltration refers to the separation and movement of water plasma from 
whole blood shown in Figure 2.4 due to a transmembrane pressure difference in favour 
of hydrostatic pressure over the oncotic pressure exerted by blood plasma (Bellomo & 
Ronco, 2002b). The rate of ultrafiltration (Qf) which occurs is dependent on the 
membrane ultrafiltration coefficient (Km) and the transmembrane pressure (TMP) 








Figure 2.4. An illustration of plasma water movement by ultrafiltration. 
Adsorption 
Once blood is exposed to an artificial membrane the non-biological material 
causes almost instantaneous adsorption of plasma proteins and as shown in Figure 2.4 
other substances onto the surface area of the membrane (Huang, Gao, Letteri, & Clark, 
2009). The construction of membranes with synthetic material have a negatively 
charged surface area which increases the adsorption of plasma proteins and in response 
contribute to activation of the coagulation pathway. The adsorption of plasma proteins 
can be considered a form of solute removal with the capacity to remove a variety of 
solutes by adsorption also dependent on the polarity of the materials used to 
manufacture the membrane. The adsorpitive capacity of the membrane decreases when 
the surface area of the membrane becomes saturated and the occlusion of pores causes 
fouling of the semi-permeable wall to adversely alter the performance of the membrane 






Figure 2.5. An illustration showing the movement of solutes and absorption along the 
semi-permeable membrane. 
 
The mechanisms of solute and plasma water transport during extracorporeal 
RRT are processes where the individual contributions of diffusion and convection are 
unable to be singled out separately producing a different response which otherwise 
would not occur when the processes are independent of each other (Ronco & Levin, 
2005). This is particularly evident in therapies like haemodiafiltration which use a 
combination of both transport mechanisms and a „struggle‟ can develop between 
diffusion and convection in the movement of solutes and plasma water. A localised 
difference in the concentration gradient across the membrane may for example interfere 
with the transfer of solutes when increased movement by diffusion causes a reduction in 
the capacity to transport solutes by convection. The opposite effect can occur when for 
example specific areas of the membrane become vulnerable to protein adsorption after 
ultrafiltration increases the movement of solutes by convection. The adsorption of 
plasma proteins is often accompanied with a thickening of the protein layer which can 
diminish solute transport by diffusion. An understanding of the exchange which occurs 
between diffusion and convection is important since the design features of the blood 
filtration device and characteristics of the artificial membrane influence the method of 
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transport which occurs in the removal of solutes and plasma water and how these may 
change as the membrane ages during use. 
 Artificial Kidney 
The functional component of all extracorporeal RRTs is the blood filtration 
device, known as the haemofilter or haemodialyser. Each device is connected to the 
extracorporeal circuit packed with a semi-permeable membrane and placed within a 
plastic outer casing to construct the artificial kidney (Sakai, 2000). Although able to 
remove excess fluid and soluble particles from the blood similar to the actions of the 
kidney, both devices do not have the capacity to mimic the important regulatory 
mechanisms of the organ. A basic feature of the blood filtration device is the inclusion 
of external ports on either end of the structure for the passage of blood and in the 
positioning of side ports to allow the entry and exit of fluid (Sakai, 2000). The inclusion 
of pathways within the haemofilter or haemodialyser channel blood and 
filtrate/dialysate for the greatest exposure to the membrane surface area of the device. 
Configuration of the haemofilter/haemodialyser originally consisted of flat membranes 
sandwiched together, but are now scarcely used in favour of contemporary membranes 
bundled together as hollow fibres. The advantages of selecting this type of membrane 
configuration included better distribution of flow into each channel which improved 
performance in the clearance of solutes and provided a more robust structure (Sakai, 
2000). The flow channels created by the bundles of hollow fibres will determine 
whether the device is a haemofilter or haemodialyser. A device designed to primarily 
remove solutes by convection is classified as a haemofilter and comprises of membranes 
which accept high sieving coefficients for the passage of plasma water due to the force 
of hydrostatic pressure (Sigler & Manns, 1996). Optimization in the degree of 
ultrafiltration provides high-flux characteristics in the clearance of large-sized 
molecules by increased hydraulic permeability through the membrane. A device which 
is instead designed to primarily remove solutes by diffusion is classified as a 
haemodialyser and incorporates membranes which have thinner walls to facilitate the 
passage of solutes by a concentration gradient (Sakai, 2000). The low-flux nature of 
membranes traditionally used for haemodialysers limit the removal of solutes by the 
passage of plasma water due to the reduced hydraulic permeability of the device. Other 
blood filtration devices referred to as haemodiafilters are designed to optimise solute 
and fluid removal by diffusion and convection (Hoenich, 2007).  
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Artificial Membranes 
 A major factor influencing solute removal is determined by the ability of the 
artificial membrane to absorb water and the porosity of the material used to allow 
solutes of a specific molecular weight to pass through to the other side of the semi-
permeable membrane (Golper, 2002). The materials which are used for the purposes of 
solute transport can directly affect the performance of the membrane. Substances which 
are dissolved in a solution normally move around at an equal rate when unrestricted. 
The insertion of a membrane can be designed to interrupt this naturally occurring 
phenomenon and restrict the passage of specific solutes by diffusion according to their 
molecular weight and the pore size of the semi-permeable membrane. Also, the force 
generated by the velocity of blood or hydrostatic pressure to create a pressure gradient 
across a membrane is influenced by the hydraulic permeability of the membrane 
(Golper, 2002), with the flux of transmembrane plasma water movement and 
subsequent solute removal by convection controlled by differences in hydraulic and 
osmotic pressures on either side of the membrane (Leypoldt, 2000). A sieving 
coefficient of 1.0 indicates complete permeability of the solute as it travels along each 
of the hollow fibres and through the membrane under pressure from the velocity of 
blood entering the haemofilter or haemodialyser. Small molecules are transported 
rapidly during diffusion but decreases when middle-sized molecules are diffused across 
the membrane with the opposite effect occuring when convective transport is increased 
for middle-sized molecules at the expense of molecules which are smaller in molecular 
size (Leypoldt, 2000). The degree of solute clearance achieved by diffusion and 
convection requires the volume of blood passing through the haemodialyser/haemofilter 
to be measured against the time a particular substance is removed from the blood 
(Golper, 2002). Urea is an example of a small solute able to be removed across the 
semi-permeable membrane and the response to solute movement monitored when the 
degree of BUN manipulation is measured. Mathematical modelling of fluid and solute 
transport can be used to calculate the clearance of substances according to the rate of 
blood flow (Qb) and the flow rate of dialysis (Qd) or ultrafiltration (Qu) delivered 
(Waniewski, 2006). 
Cellulose-based membranes such as Cuprophane were early examples of semi-
permeable membrane technology and, because of the small pore size, are considered as 
„low-flux‟ membranes with a permeability coefficient to water (Km) of 5-6ml per hr x 
mmHg x m
2
 (Ronco et al., 2003). The thin hydrophilic membrane wall (6-15m) is 
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ideal for diffusive solute transport and favours the clearance of small-sized molecules at 
the expense of other substances which have a larger molecular weight (Clark & Ronco, 
2001). In response to the limited removal of different sized molecules associated with 
cellulose membranes exploration of alternative materials led to the development of 
synthetic membranes. The manufacture of synthetic membranes has allowed the sieving 
coefficient of the semi-permeable membrane to include a wider spectrum of molecules 
and achieve a greater mass transfer through higher ultrafiltration volumes not possible 
using cellulose-based membranes (Ronco, et al., 2003). Attempts made during the late 
1970s to manufacture synthetic membranes were initially asymmetrical in design and 
constructed from hydrophic polymide polymers with a wall thickness of 40-60m. As a 
consequence of increased hydraulic permeability (30-40mL/hr x mmHg x m
2
) these 
membranes were not efficient in the removal of solutes by diffusion but were 
successfully employed in convective therapies such as haemofiltration. Modifications 
made to the original composition and structural configuration of the plastic polymers 
used to construct synthetic membranes has improved the diffusive properties of these 
membranes without affecting the convective quality of the high-flux nature of the semi-
permeable wall (Ronco, et al., 2003). 
Debate continues in the literature on whether the flux of a membrane and the 
clearance of different sized molecules is a factor which may contribute to an 
improvement in the outcome of critically ill patients with ARF. Ponikvar and colleagues 
(2001) found no significant difference in the survival (P-value = 0.784) or return of 
renal function (P-value = 0.816) in 72 patients who received IHD following a 
randomised comparison of low-flux versus high-flux synthetic membranes. The use of 
high-flux membranes is recommended for CRRT in order to improve water permability 
of the semi-permeable wall and allow the clearance of solutes by haemofiltration (C. H. 
Jones, 1998). As well as increasing the flux chatacteristics of the semi-permeable wall 
another reason for the use of synthetic materials to construct the artificial membrane has 
been associated with improvements in biocompatibility. This term is used to describe 
the tolerance and reactivity of materials used in the construction of membranes when 
they are exposed to the patient‟s immune system.  
Although the duration of blood-membrane interaction is reduced when 
compared with the increased exposure which occurs during CRRT, cellulose-based 
membranes most associated with conventional IHD are more likely to cause 
complement and coagulation cascade activation (Hakim, 1993). The use of non-
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biocompatible materials with conventional IHD stimulate monocyte activity and the 
release of cytokines, as opposed to reduced activation when bio-compatible membranes 
made from synthetic materials are used during CRRT (C. H. Jones, 1998). Several 
studies of patients with ARF requiring haemodialysis have shown survival and recovery 
of renal function is either improved with synthetic polyacrylonitrile and 
polymethylmethacrylate membranes (Hakim, Wingard, & Parker, 1994; Himmelfarb et 
al., 1998; Schiffl et al., 1994), or is no worse when compared with modified cellulose-
based membranes (Gastaldello et al., 2000; Jorres et al., 1999). A meta-analysis of 
membrane biocompatibility and the effect on patient outcomes in the treatment of ARF 
advocates the use of synthetic membranes (Subramanian, Venkataraman, & Kellum, 
2002). Despite patients with ESRD being previously managed successfully using 
cellulose-based membranes there application has declined in recent years due to 
complications associated with the effects of repeated exposure, and are not 
recommended when considered for use during the management of patients with ARF 
(Pastan & Bailey, 1998).   
   Extracorporeal Renal Replacement Therapy 
The use of extracorporeal RRT in the management of the critically ill patient 
with severe ARF continues to be dominated in North America by IHD (Hyman & 
Mendelssohn, 2002; Mehta & Letteri, 1999) whilst in Europe (Liano, et al., 1998; van 
Bommel & Ponssen, 1997; Wright, Bodenham, Short, & Turney, 2003), Australia and 
New Zealand (RENAL Replacement Therapy Study Investigators, 2008;  Silvester, et 
al., 2001) CRRT remains the most preferred technique employed. A number of recent 
international surveys have also reported the uptake of „hybrid therapies‟ as a form of 
RRT now used in some ICUs for the management of ARF (Overberger, Pesacreta, & 
Palevsky, 2007; Ricci, Ronco, D'amico, et al., 2006). The instigation of RRT is 
influenced by the magnitude of injury the kidney has sustained and the affect changes in 
renal function may have on the performance of other organs. In the critically ill patient 
the timing of when to instigate RRT can have a major influence on survival and 
restoration of renal function.    
 Early rather than late? 
The decision to commence RRT using extracorporeal technology is currently not 
based on any specific evidenced criteria as to the precise moment when to intervene in 
the management of critically ill patients with AKI. Although the indications for RRT are 
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widely accepted the precise moment to initiate correction of excess fluid, hyperkalemia, 
metabolic acidosis and uraemia is subject to differences of opinion (Overberger, et al., 
2007). In the critically ill patient the development of ARF is often associated with the 
dysfunction of other organs and the timely provision of RRT viewed as a form of renal 
support rather than the complete replacement of renal function. A number of reasons 
have been put forward why early rather than late initiation of RRT should be 
considered. The severity of physiological derangements can outweigh the potential 
harm of complications associated with commencement of RRT (the risk of injury during 
the insertion of vascular access device), or when using alternative conservative 
management strategies, there is no benefit in waiting for the possible recovery of renal 
function if failure of other organs has a greater impact on patient survival. The 
commencement of RRT for the management of excess fluid accumulation can improve 
lung function and increase the oxygenation of other organs in the absence of traditional 
indices of marked azotemia as a trigger to commence treatment (Payen et al., 2008). 
Studies investigating the ideal time to commence RRT have only recently been the 
subject of retrospective and prospective analyses. Since the recognition that ARF has 
been shown to be an independent risk factor which can increase patient mortality (Levy, 
et al., 1996), the possibility that optimisation of renal support may improve survival has 
led to several prospective evaluations of early versus late initiation of RRT. 
In a retrospective  study by Gettings and colleagues (1999) the timing of CRRT 
was shown to influence the mortality rate of patients with post-traumatic ARF. Patients 
were classified according to when they commenced CRRT based upon either a BUN < 
or > 21mmol per L. Despite receiving the same intensity of treatment the authors 
reported a significant improvement in patient survival when CRRT was initiated with a 
lower BUN level compared to the survival of patients if the BUN level was much higher 
on commencement of CRRT (patient survival 39% early initiation group versus 20% in 
the late initiation group, P-value = 0.041). Whilst the findings suggest a benefit in the 
early commencement of CRRT the observations may have been influenced by 
differences in decisions which led to when treatment was commenced. Although 
baseline demographic characteristics and severity of illness scores were similar, no 
reason was provided by the authors why some patients were selected for the early as 
opposed to the late intervention group, and the timing of treatment may have been 
confounded by decisions based according to which intensive care specialist was 
prescribing. The inconclusive results of retrospective investigations have led researchers 
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to conduct prospective comparisons of early versus late RRT prospectively. In one 
study undertaken by Bouman and colleagues (2002) randomisation of 106 patients into 
three alternative treatment groups observed the impact on patient survival using early 
high-volume Continuous Veno-Venous Haemofiltration (CVVH) (72 to 96L per 24hr), 
versus early low-volume  CVVH (24 to 36L per 24hr), versus late low-volume CVVH 
(24 to 36L per 24hr). The criteria used to determine when CVVH should be initiated 
differed among the early and late treatment groups. In the two early groups treatment 
was initiated after 12 hours (early high-volume and early low-volume CVVH). This was 
based on the development of oliguria despite efforts to maximise haemodynamic 
parameters, or after urine collection measured creatinine clearance less than 20ml per 
min. In the third group (late low-volume CVVH) treatment was not commenced until 
BUN levels were greater than 40mmol per L, potassium was greater than 6.5mmol per 
L, or there was evidence of pulmonary oedema. On completion of the study Bouman 
and colleagues (2002) found no significant difference in patient survival at 28 days 
between the three treatment groups. In the early high-volume CVVH treatment group 
74.3% of patients remained alive compared with 68.8% in the early low-volume CVVH 
treatment group and 75.0% in the late low-volume CVVH treatment group (P-value = 
0.80). Out of the total population of haemofiltered patients who survived ICU the lower 
mortality rate of 57% observed by Bouman and colleagues (2002) suggests the severity 
of illness among patients who participated in the study may not have been as severe 
when compared with the higher mortality rate of 76.8% observed in patients who had 
required RRT during the BEST study (Uchino, et al., 2005). A difference might have 
occurred in the survival of patients allocated to receive early high-volume and early 
low-volume CVVH had Bouman and colleagues (2002) included patients who may not 
have otherwise survived had they been assigned to the group of patients allocated to 
receive late low-volume CVVH.  
A review of the literature of comparisons between early and late RRT have not 
been able to demonstrate a set of criteria for the commencement of RRT which is 
associated with an improvement in patient outcomes. The criteria used during the BEST 
study, to determine the prevalence of ARF and requirement for RRT defined the trigger 
for the initiation of treatment as a urine output of less than 200ml in 12hr and/or a BUN 
level > 30mmol/L (Uchino, et al., 2005). In the opinion of the authors the criteria 
chosen included a set of values which closely resembled practice already undertaken by 
organisations who participated in the study. Using the same data from the BEST study 
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late as opposed to early commencement of RRT was associated with a decrease in 
patient survival or increased dependence for survivors of continued renal support 
(Bagshaw et al., 2009). Observations made by the authors suggest the findings were 
largely dependent on how early versus late timing of RRT was defined in the criteria 
used to initiate treatment. The suggestion of improved outcomes when RRT is initiated 
early may be a reflection of the differences in the severity of AKI which, in some 
patients if managed conservatively would be resolved regardless of whether the 
alternative approach of RRT was used in the management of the patient. The example 
of a generally agreed upon criteria for the initiation of RRT will remain as a guide until 
specific biomarkers or clinical predictors are developed indicating the degree of injury 
which has occurred to the kidneys. This will enable a randomised, controlled study to be 
undertaken which can accurately identify patients who are at risk of severe AKI, and 
avoid the inclusion and randomisation of patients with a less severe form of AKI who 
would otherwise would not normally require RRT. The commencement of RRT is 
nevertheless regarded as important should the severity of injury sustained by the patient 
require the support of kidney function. Instead of waiting for oliguria and increasing 
blood urea levels the instigation of early rather late RRT is preferable to complications 
caused by renal insufficiency and the development of MOD. Once a decision has been 
made to commence RRT management of the critically ill patient involves extracorporeal 
techniques which are prescribed intermittently (4-8hr per day) or continuously (24hr per 
day).  
Intermittent Haemodialysis 
The management of severe ARF using IHD is based on the technique originally 
developed for the management of patients with ESRD (Pendras & Erickson, 1966). 
Soon after the technique was introduced strategies employed using conventional IHD 
were found to be less than satisfactory when applied to the critically ill patient. As a 
result of refinements to the original technique changes in the way contemporary IHD is 
now performed on patients in the ICU has improved the delivery and tolerance of this 
approach to RRT (Ricci & Ronco, 2008). The technique is delivered on an alternative-
day schedule or if necessary changed to daily treatments. Each session is operated by a 
specialist dialysis nurse usually lasting for three to four hours under the supervision of a 
nephrologist. The dialysis machine manufactures dialysate when filtered tap water is 
combined with electrolytes to form a bicarbonate-based solution (Hoenich, Ronco, & 
Levin, 2006). A dialysate flow rate is set between 200ml and 300ml per min and may be 
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increased as tolerated to a maximum rate of 800ml per min. The blood flow through the 
extracorporeal circuit can start from 200ml per min and gradually increased to run at a 
rate of 300ml per min (O'Reilly & Tolwani, 2005). The use of haemodialysers promote 
the removal of solutes by diffusion with the loss of fluid and solutes by convection also 
possible following a change from cellulose-based low-flux membranes to the selection 
of high-flux synthetic membranes associated with contemporary IHD.  
Continuous Renal Replacement Therapy 
An alternative approach for the management of severe ARF in the critically ill 
patient uses CRRT to provide a more gradual approach to fluid and solute removal 
(Ronco, Bellomo, & Ricci, 2001). In contrast to IHD the technique of CRRT is able to 
be performed by the critical care nurse under the supervision of the intensive care 
specialist. A semi-automated machine operated by the critical care nurse monitors blood 
flow and the delivery of packaged dialysate solutions and/or replacement fluids. 
Haemofilters are generally used in CRRT and comprise of high-flux synthetic 
membranes which are more permeable to water. Increased hydraulic permeability of the 
membrane allows solute clearance by convection and the amount of ultrafiltrate 
produced during haemofiltration is greater in comparison to haemodialysis, since a 
larger volume of fluid is able to be filtered through the membrane. The scheduling of 
treatment using CRRT is set over 24hr with a comparatively slower blood flow rate than 
IHD of 150 to 200ml per min and a dialysate flow of 17 to 40ml per min when a 
diffusive treatment mode is used (O'Reilly & Tolwani, 2005), or an ultrafiltrate volume 
of 20 to 45ml per kg per hr for a convective treatment mode operating at a similar rate 
of blood flow (Ronco, et al., 2000). Although these settings for both treatment modes 
are described in the literature the decision on parameters has occurred by general 
agreement rather than substantial evidence of effectiveness in the management of renal 
insufficiency.      
History and Development. 
The introduction of haemodialysis as a life-saving treatment for ESRD coincided 
with the development of an alternative method of Renal Replacement Therapy (RRT) 
using ultrafiltration. Instead of diffusion as the principle mechanism of solute removal 
in the management of ESRD Henderson and associates (1967) described a RRT that 
relied on convection to remove solutes from azotemic patients. This occurred during a 
period where understanding of mechanisms in solute transport had improved along with 
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the development of synthetic polymers to produce membranes which were more 
permeable to water. The technique at the time was referred to as „diafiltration‟ a term 
used to describe when blood was forced through an extracorporeal circuit and filtered 
using a highly permeable membrane to generate large volumes of an ultrafiltrate 
solution (Henderson, Ford, Colton, Bluemle, & Bixler, 1970). The composition of the 
ultrafiltrate had the same solute concentration as „uremic‟ plasma water. At the same 
time as the plasma water was lost in the ultrafiltrate a replacement solution was added to 
the systemic blood supply which had a similar composition to normal urea-free plasma 
water. 
The original name of diafiltration to describe ultrafiltration as a RRT was later 
replaced with the term haemodiafiltration. The technique was used as an intermittent 
„pumped‟ therapy and was put forward as a possible alternative to IHD for the 
management of ARF or ESRD (Henderson, Livoti, Ford, Kelly, & Lysaght, 1973). 
Technical problems associated with accuracy in replacing large volumes of ultrafiltrate 
and the cost of sterile replacement fluid prevented the widespread use of the technique 
in preference for the cheaper alternative of IHD. 
Interest in using ultrafiltration as RRT was rekindled by Dr Peter Kramer, a 
nephrologist in Gottingen, Germany. Using a technique which placed a haemofilter 
between an arterial and venous blood line, connecting the femoral artery with the 
venous artery, the action of the heart alone rather than an external pump was shown to 
be sufficient to produce ultrafiltrate. Continuous Arterio-Venous Haemofiltration 
(CAVH) was first described by Kramer, Wigger, Rieger, Matthaei and Scheler (1977) 
for the treatment of diuretic-resistant oedema in patients with severe heart failure. The 
continuous approach to RRT was seen as being more favourable than conventional IHD 
for the management of critically ill patients with ARF due to a reduction in 
haemodynamic instability when compared with the alternative approach and the 
opportunity the technique gave in the removal and control of excess fluid volume 
(Kramer et al., 1980). To make the most of the technique‟s ability to remove solutes by 
convection as well as excess plasma water against the background of improved 
haemodynamic stability, clinical experience of CRRT in the ICU was first gained using 
the original and simplest form of the technique CAVH (Kramer et al., 1982; Lauer et 
al., 1983; Olbricht, Mueller, Schurek, & Stolte, 1982). In CAVH the femoral artery and 
vein were cannulated and blood passed „spontaneously‟ through the haemofilter under 
the influence of arterial blood pressure. Although the technique offered the critically ill 
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patient increased regulation of excess fluid volume without the problem of 
haemodynamic instability a number of weaknesses in the approach when compared with 
conventional IHD resulted in the implementation of several improvements to the 
original technique.  
The inadequacy of CAVH in achieving high and reliable solute clearance led to 
the addition of a dialytic component and the method of Continuous Arterio-Venous 
Haemodialysis (CAVHD) (Geronemus & Schneider, 1984). After this modification to 
the basic CAVH circuit solute clearance was improved and patients who were 
hypercatabolic could now be managed without resorting to IHD. Similar to the setup 
used for conventional IHD the efficiency of CAVHD to remove urea and creatinine was 
increased when the direction of dialysate through the haemodialyser was circulated in 
the opposte direction to blood flow (Davenport, Will, & Davison, 1990b).  
The next major innovation saw the incorporation of pump technology for the 
control of blood flow, with the use of double lumen central venous access and the 
techniques of continuous veno-venous haemofiltration, continuous veno-venous 
haemodialysis (CVVHD) and CVVHDf (Kirby & Davenport, 1996). These techniques 
did not require cannulation of the artery which carries the potential risk of rapid blood 
loss should accidental disconnection occur. Instead the veno-venous techniques took 
advantage of developments in the area of chronic dialysis to utilise new central venous 
catheter technology. The pump driven veno-venous system also resolved the limitation 
imposed by the original system of reliance solely on arterial blood pressure to drive 
blood flow. In the critically ill patient blood pressure is not always reliable due patient 
haemodynamic instability with the tendency of the extracorporeal circuit to clot when 
blood flow is reduced (Boyle & Baldwin, 2010).  
The introduction of veno-venous pump technology increased the efficiency of 
CRRT. As well as reducing the incidence of premature blood clotting due to the ability 
to sustain a higher rate of blood flow irrespective of the patient‟s blood pressure, larger 
volumes of ultrafiltrate could now be achieved with good solute clearance of urea and 
creatinine. The effectiveness of using both approaches have been compared in a RCT 
(Storck, Hartl, Zimmerer, & Inthorn, 1991). Patients with severe ARF following surgery 
were assigned to receive either pump-driven CVVH or spontaneous CAVH. The 
process of randomisation was restricted by the limited availability at the institution of 
veno-venous pump technology which led to all patients being assigned CVVH unless 
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the equipment was already being used in the treatment of another patient. As a 
consequence of fewer cases than expected requiring treatment simultaneously the 
distribution of patients who received CVVH as opposed to CAVH was unevenly 
distributed (68 versus 48). Despite the uneven distribution which had occurred patient 
characteristics and severity of illness were similar among the two treatment groups. The 
authors observed survival of patients to hospital discharge who had received CVVH was 
significantly higher than patients who were treated with CAVH (20[29.4%] versus 
6[12.5%]; P-value < 0.05). A correlation between patients who had survived and the 
volume of ultrafiltration produced using CVVH compared with CAVH was also shown 
to be statistically significant (15.7[13.6-17.8] versus 7.0[6.6-7.4] L per day; P-value > 
0.05).   
Contemporary Treatment Modes. 
The shortcomings of the original CAVH technique proposed by Kramer and 
associates (1977) to manage severe ARF in the critically ill patient led Bellomo (1996) 
to conclude CAVH could no longer be a treatment modality appropriate to use in 
organisations where veno-venous pump technology was available. Although 
improvements in technology have increased the effectiveness of the approach when 
compared with the original technique, the introduction of veno-venous CRRT has to 
some extent reversed the simplicity viewed at the time of its inception as an advantage, 
to the development instead of treatments which are more complex to manage. Since 
blood flow using veno-venous CRRT is determined by an external source (blood pump) 
rather than blood pressure a double lumen catheter is required to be inserted into a 
central vein (subclavian, jugular or femoral). Once placed into the correct position, 
blood is able to be drawn through the „outflow‟ lumen of the catheter. The motorised 
pump circulates the blood along the extracorporeal circuit and enters the haemofilter or 
haemodialyser before the blood is returned to the patient through the „inflow‟ lumen of 
the catheter. The technology surrounding veno-venous CRRT delivery systems initially 
used makeshift devices adapted from hardware originally developed for the delivery of 
dialysis in the management of patients with ESRD (Cruz et al., 2009). This allowed the 
technique to operate at blood flow speeds which were much higher than previously 
achieved using CAVH but required alterations to the original design of the circuit and 
the introduction of pressure monitoring to record blood flow through the circuit. Other 
changes to the original CAVH circuit included the use of a venous bubble chamber to 
allow the removal of trapped air from the veno-venous blood line.  Operational 
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differences also allowed veno-venous CRRT to achieve higher ultrafiltration volumes 
but increased the potential for fluid balance errors when this required the exchange of 
larger volumes of fluid.  
The use of makeshift devices affected the performance of the technique due to 
the lack of integration between equipment not specifically designed for the purpose of 
veno-venous CRRT. One example of how performance was influenced by the lack of 
integration with different pieces of equipment was the practice of using infusion pumps 
that were external to other parts of the device. A study investigating the use of infusion 
pumps to regulate the rate of dialysate exchanged and the volume of ultrafiltrate 
produced during CVVHD was shown to be open to potential errors in the accuracy of 
the infusion pump to maintain the correct fluid balance required (Roberts & Winney, 
1992). To overcome the problem the next generation of CRRT machines in use today 
are purpose-built appliances. These machines are designed specifically to meet the 
requirements of the technique which has semi-automated the monitoring of the 
extracorporeal circuit and the management of large volumes of fluid to provide an 
intergrated system which is easier for the critical care nurse to manage (Ricci et al., 
2004). As shown in Figure 2.1 there are four basic veno-venous options under the 
„continuous‟ classification of extracorporeal therapies. They include slow continuous 
ultrafiltration (SCUF), CVVH, CVVHD and CVVHDf. Each approach differs in 
operational complexity and in performance of solute and fluid control (Ronco, 
Brendolan, & Bellomo, 2001).  
Slow Continuous Ultrafiltration is a technique employed to achieve volume 
control in patients who have severe fluid overload (Ronco, Ricci, Bellomo, & Bedogni, 
2001). The technique takes advantage of hydrostatic pressure to remove excess fluid by 
ultrafiltration using a haemofilter which is highly permeable to water. A number of 
conditions such as heart failure reduce the capacity of the kidneys to remove the 
accumulation of excess fluid. The main difference between SCUF and other CRRTs 
which utilise ultrafiltration is the omission of replacement fluid with the removal of 
excess fluid the primary objective of SCUF rather than the clearance of solutes for the 
purposes of biochemical control. Patients diagnosed with decompensated heart failure 
are often appropriate candidates for SCUF when conservative measures to restrict fluid 
intake is unsuccessful and pharmacologic interventions such as diuretic therapy and 
vasodilating agents are ineffective. The therapeutic benefits of SCUF in these patients 
include the modulation of the renin-angiotensin-aldosterone-system with the removal of 
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sodium causing a decrease in total body fluid and a subsequent reduction in preload 
volume (Schrier, 2006). The use of SCUF in patients with heart failure who were 
hypervolaemic was shown to be more effective in the removal of excess fluid than the 
administration of intravenous diuretic therapy (Costanzo et al., 2007). Patients who 
were randomised to receive SCUF had greater fluid and weight loss at 48hr when 
compared with patients who instead were treated using a loop diuretic (fluid loss 4.6L 
SD+2.6 versus 3.3L SD+2.6, P-value = 0.001 and weight loss 5.0kg SD+3.1 versus 
3.1kg SD+3.5, P-value = 0.001). The removal of myocardial depressant factors and the 
release of other toxic substances is also suggested as a possible explanation for the 
observed improvement in cardiac function (Coraim & Wolner, 1995). An illustration of 
SCUF is shown in Figure 2.6. 
 
Figure 2.6. An illustration of slow continuous ultrafiltration. 
 
Continuous Veno-Venous Haemofiltration refers to the technique which uses the 
movement of plasma water by ultrafiltration to remove solutes by convection through a 
semi-permeable membrane (S. John & Eckardt, 2007). Depending upon the volume of 
plasma water which passes through the haemofilter and the sieving co-efficient of the 
semi-permeable membrane, biochemical control of small molecules and the modulation 
of larger septic mediator molecules is able to be achieved in conjunction with the 
removal of excess fluid. The ultrafiltrate that is produced flows from the blood 
compartment across the membrane and travels along the outer side of the fluid 
compartment before it is drained away. A replacement solution is delivered into the 
circuit to compensate for excessive removal of plasma water and to maintain the body‟s 
correct electrolyte balance. An illustration of CVVH is shown in Figure 2.7. 
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Figure 2.7. An illustration of continuous veno-venous haemofiltration. 
 
Continuous Veno-Venous Haemodialysis achieves solute clearance by diffusion 
(Dirkes & Hodge, 2007). A dialysate solution runs in the opposite direction to blood 
flow outside the blood compartment of the haemodialyser. The exchange of solutes 
across the semi-permeable membrane occurs when the concentration gradient between 
the blood and fluid compartments are different in favour of the movement of smaller 
molecules. The passive movement of solutes across the membrane is drained away from 
the dialyser as „spent‟ dialysate. Very little plasma fluid is lost during diffusion and the 
requirement for a replacement solution is generally not necessary. An illustration of 
CVVHD is shown in Figure 2.8. 
 
 
Figure 2.8. An illustration of continuous veno-venous haemodialysis. 
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The technique of CVVHDf is similar to CVVH but modified by the addition of 
dialysis to combine diffusion with convection in the removal of solutes and excess fluid 
(Dirkes & Hodge, 2007). Circulating in the opposite direction to blood flow the 
dialysate solution passes along the outer side of the semi-permeable membrane and 
merges with the ultrafiltrate produced from the movement of plasma water as blood 
passes through the haemofilter or haemodialyser. The inclusion of a dialysate solution 
facilitates the process of diffusion and the administration of a replacement solution 
exchanges the plasma fluid that is lost during convection. Small and large molecules 
concentrated in the patient‟s blood move across the membrane either due to a lower 
solute concentration found in the dialysate solution or as solvent drag; a consequence of 
plasma water removal. A schematic illustration of CVVHDf is shown in Figure 2.9. 
 
 
Figure 2.9. An illustration of continuous veno-venous haemodiafiltration. 
 
The question of whether biochemical control in the management of ARF is 
influenced by the choice of CRRT mode selected and the impact of diffusion-based 
versus convection-based techniques has on patient outcomes is the subject of discussion 
in the literature. Despite a number of studies attempting to address this issue the 
preferred method of solute removal during CRRT has yet to be established. The 
capacity of  CRRT to remove solutes of different molecular weight as a reason for 
selecting a specific treatment mode was investigated during a prospective crossover 
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study (Ricci, Ronco, Bachetoni, et al., 2006). An evaluation of small and middle-size 
solute clearance using a dose prescription of 35ml per kg per hr and polyacrylonitrile 
membranes found the capacity of both CVVHD and CVVH was the same up to 48 
hours after treatment had commenced, but a non- significant rise in middle size solute 
removal (2 microglobulin) occurred with CVVH after 72hr. Some intensive care 
specialists prefer convective treatment modalities like CVVH when there is evidence to 
suggest longer sessions of CVVHD are required to achieve equivalent clearance of 
middle-size molecules when solute removal is by diffusion. The results of a single 
centre RCT by Ronco and associates (2000) demonstrated survival in patients whose 
ARF was associated with sepsis improved when higher compared to lower ultrafiltration 
rates achieved greater convective clearance. In a retrospective controlled study the 
techniques of CVVH and CVVHDf were compared based on the ability of each mode to 
achieve azotemic stability (Morimatsu, Uchino, Bellomo, & Ronco, 2002). Despite 
attention given to ensure the treatment dose ordered was the same between both 
modalities the study found mean urea and creatinine levels were significantly lower 
during CVVH than those recorded using CVVHDf (mean urea levels 16.7mmol/L 
SD+7.8 for CVVH versus 22.3mmol/L SD+9.0 for CVVHDf [P-value < 0.0001] and 
mean creatinine levels 211mol/L SD+103 for CVVH versus 302mol/L SD+167 for 
CVVHDf [P-value < 0.0001]). The value of CVVHDf as a treatment mode uses both 
diffusion and convection to maximise the range of molecules which are cleared. Adding 
a dialysis dose to haemofiltration was shown in one RCT to increase the survival among 
critically ill patients with ARF (Saudan, et al., 2006). Although the recovery rate of 
renal function was not affected by the type of RRT, the mortality rate of patients treated 
with CVVHDf was significantly lower than patients who received CVVH. The survival 
of patients at 28 days was 59% for CVVHDf compared with 39% for CVVH (P-value = 
0.03). A difference of 20% provides strong evidence in support of change away from 
CVVH in favour of CVVHDf, but randomisation only involved 206 patients and the 
findings of the study possibly weakened by the outcome of only a few patients altering 
the estimation of significance observed.    
Intermittent versus Continuous Renal Replacement Therapy 
Over the course of three decades CRRT has been promoted by its supporters as 
superior to conventional IHD for support of ARF in the ICU (Ronco & Bellomo, 2007). 
Although the technique has received acceptance as an alternative treatment strategy and 
in some instances has superseded the use of IHD, others do not support the widespread 
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use of CRRT when there is insufficient evidence of a significant improvement in patient 
outcomes (Himmelfarb, 2007). Several important differences in the operational 
characteristics of conventional IHD and CRRT along with appropriately powered 
outcome studies continue to be the subject of comparison in the literature. In efforts to 
determine the most appropriate form of RRT to treat the critically ill patient the 
principal elements of establishing superiority over the alternative technique should 
include studies which demonstrate evidence of an improvement in patient outcomes, or 
is shown to be a more effective treatment, or the incidence of complications is reported 
to be lower.  
Effect on mortality and recovery of renal function 
The underlying cause of disease and illness severity has an overwhelming effect 
on patient survival more so than supportive measures such as RRT. When attempts are 
made to investigate differences of patient outcomes using conventional IHD versus 
CRRT, several important aspects in the design of the study need to be overcome in 
order to compare the techniques. Comparisons made from retrospective studies are 
unreliable if historical controls are used which do not take into account confounding 
variables such as outdated protocols that are no longer practiced. When prospective 
studies are undertaken and patients are unable to be treated once randomised to receive 
a specific mode, or an attempt is made to avoid adverse events from occurring, or the 
severity in one group of patients is greater in comparison to the other group, the validity 
of differences in patient outcomes is skewed in favour of the technique with the least 
number of reported complications. A number of retrospective and prospective studies 
have sought to resolve this issue with varying degrees of success (Mehta et al., 2001; 
Uehlinger et al., 2005; van Bommel et al., 1995; Vinsonneau et al., 2006). 
In a meta-analysis of mainly non-randomised studies no significant difference in 
patient survival using CRRT over IHD was observed (Kellum et al., 2002). After the 
authors made adjustments to compensate for differences in the quality of each study and 
severity of illness they did show patients treated with CRRT instead of conventional 
IHD had a lower mortality rate (relative risk [RR] 0.72, 95% CI 0.60-0.87, P-value < 
0.01). When more randomised trials were included in a second meta-analysis the 
findings were not replicated and no significant variation in mortality was observed (RR 
0.96, 95% CI 0.85-1.08, P-value = 0.50) (Tonelli, et al., 2002). A limitation of the meta-
analysis undertaken by Kellum (2002) is the systematic review only looked at patient 
mortality and did not investigate the degree of renal recovery when IHD and CRRT 
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were compared. When this was considered in the meta-analysis completed by Tonelli 
(2002) although reported as not being statistically significant, patients treated with 
CRRT compared with IHD were observed to have a reduced risk of developing ESRD 
and dialysis dependency (RR 1.19, 95% CI 0.62-2.27, P-value = 0.06). Several 
retrospective, non-randomised studies undertaken since the two meta-analyses were 
conducted have shown a benefit in patients who received CRRT as opposed to those 
patients treated with IHD in the recovery of renal function (Bell, Granath, Schon, 
Ekbom, & Claes-Roland, 2007; Jacka, Ivancinova, & Gibbney, 2005; Waldrop et al., 
2005). A meta-analysis undertaken more recently by Bagshaw and associates (2008) 
reported similar findings as in the previous meta-analysis undertaken by Tonelli (2002) 
with no significant difference observed between CRRT and IHD in mortality (odds 
ratio, 0.99; 95% CI, 0.78-1.26, P-value = 0.93; 1
2 
= 11%; nine trials, n=1,403) or return 
of renal function (odds ratio, 0.76; 95% CI, 0.28-2.07, P-value = 0.59; 1
2 
= 0%; four 
trials, n = 306). As occurred in the two previous meta-analyses the authors‟ encountered 
difficulties in undertaking the systematic review due to the limited number of studies 
which were of sufficient quality to answer the question accurately. Studies which have 
attempted to address the issue of whether differences in technique between CRRT and 
conventional IHD impact upon mortality and recovery of renal function are summarised 
in Table 2.1. 
Effectiveness of Both Approaches 
The effectiveness of CRRT or conventional IHD to manage ARF in the critically 
ill patient can be evaluated on several performance indicators. These include the ability 
of each technique to restore electrolyte and acid-base balance and to excrete metabolic 
waste products, to minimise the complexity of dose adjustment caused by excessive 
drug clearance, to remove excess fluid volume and allow adequate nutrition, to clear 
inflammatory mediators and to operate at a price which is affordable.  
 Solute control and restoration of acid-base balance. 
Solute control of small molecules which are easily diffusible can be corrected in 
a much shorter time using conventional IHD than with CRRT and pure haemofiltration. 
To treat serum potassium level of 6mmol per L, an ultrafiltration rate of 2L per hour at a 
flow rate of 200ml per min will remove 12mmol per hour. When this is compared with 
a dialysate potassium concentration of 1 mmol per L operating at 500ml per minute 
using a similar rate of blood flow, over 60mmol of potassium is removed after only an 
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hour of conventional IHD (Lameire, van Biesen, van Holder, & Colardyn, 1998). The 
development of electrolyte disturbances, acid-base imbalances or drug intoxications 
may take up to a day to resolve with CRRT whereas using IHD they can be corrected in 
a matter of hours. 
The rapid removal of solutes using conventional IHD is not always necessary in the 
management of severe ARF and the technique can be contraindicated in favour of 
CRRT. The use of this technique in patients with raised intracranial pressure (ICP) 
allows the gradual removal of solutes to avoid the development of cerebral oedema 
caused by plasma hypo-osmolality. Patients with hepatic as well as renal failure at risk 
of developing or exacerbating existing cerebral oedema, were observed to have a higher 
incidence of raised ICP when treated with intermittent haemofiltration (36 episodes ICP 
> 20mmHg) compared to those patients who received CAVH or CAVHD (16 episodes 
ICP > 20mmHg, P-value > 0.01) (Davenport, Will, & Davison, 1991). A reduction in 
cerebral oedema was also the subject of a case report when CRRT was used in the 
management of traumatic brain injury after aggressive crystalloid fluid resuscitation had 
led to the development of hypervolaemia (Fletcher, Bergman, Feucht, & Blostein, 
2009). The authors observed ICP measurements after 12 hours of treatment had 
decreased to below 20mmHg compared with an average of 35mmHg previously 
recorded before initiation of treatment.   
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Urea is a water-soluble compound which accumulates as a by-product of protein 
catabolism and is used as a marker to identify other toxic compounds when renal 
function is compromised (Dhondt, van Holder, van Biesen, & Lameire, 2000). Uremic 
toxins are removed during RRT by diffusion and/or convection and the response to 
treatment monitored by measuring the degree of BUN manipulation or azotemia control 
which is able to be achieved. A number of studies have shown the survival of patients 
with ARF is improved when the intensity of solute clearance is augmented irrespective 
of whether this has been achieved using continuous or intermittent techniques (Paganini 
et al., 1996; Ronco, et al., 2000; Schiffl, et al., 2002). Consistent azotemic control is 
able to be maintained more easily during CRRT since there is a progressive removal of 
uremic toxins which is difficult to match using IHD where solute clearance occurs at 
periodic intervals. In a retrospective study the average BUN level taken from patients 
treated with CVVH was 24mmol per L compared to the average BUN level of 36mmol 
per L taken from patients who received conventional IHD (Swartz, Messana, Orzol, & 
Port, 1999). Although azotemic control during CRRT was shown to be superior 
compared to IHD, the advantage of maintaining lower concentrations of BUN with 
CRRT was not translated into an improvement in patient survival. A weakness of this 
study may have been in the design which allowed patients who had showed signs of 
deterioration to change treatment modality and as a result, a disproportionate number of 
the severely ill patients who had initially commenced IHD were subsequently treated 
using CRRT. 
A frequent problem in the critically ill patient with ARF is the development of a 
metabolic acidosis which requires intervention to restore acid-base balance. This is able 
to be corrected quickly using IHD but sustained more effectively using CRRT due to the 
continuous supply of buffer contained within the dialysate solution and/or replacement 
fluid (Thomas & Harris, 2002). The interval between treatment schedules when patients 
are treated with IHD allows metabolic acidosis to redevelop and during the next 
treatment requires renewed correction. A significantly lower concentration of 
bicarbonate in arterial blood was observed in a retrospective report of patients treated 
with conventional IHD compared to patients who received CVVHDf (30.3% versus 
17.7%, P-value = 0.0021) (Uchino, Bellomo, & Ronco, 2001). Studies which have 
attempted to address the issue of differences in solute control and restoration of acid-
base balance between CRRT and conventional IHD are summarised in Table 2.2. 
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Drug clearance and dose adjustment. 
The use of CRRT as opposed to conventional IHD can increase the complexity 
of drug therapy in the management of the critically ill patient (Bugge, 2004). Drugs 
administered to the patient may require the dose to be adjusted according to the mode of 
RRT selected. The majority of drugs have a molecular weight equal or below 500 
Daltons with only a few greater than 1,500Da (Bugge, 2004). Conventional IHD limits 
the clearance of drugs by diffusion to substances with a low molecular weight in 
contrast to membranes used for CRRT which have a larger pore size offering no 
filtration barrier to drugs of a higher molecular weight (Bugge, 2004). The individual 
properties of drugs will also combine with the operational differences of conventional 
IHD and CRRT to influence the degree of clearance obtained. A drug that is heavily 
bound to circulating proteins is not easily cleared by diffusion and convection when 
compared with drugs which have limited protein binding. Drugs which have a large 
volume of distribution are more likely to be absorbed into body tissues and have a 
reduced concentration level in the bloodstream which can restrict the degree of 
clearance that is possible through the haemofilter or haemodialyser. The electrical 
charge of the drug will influence the ease of passage through the membrane with 
cationic drugs repelled and anionic drugs attracted when exposed to proteins retained on 
the blood side of the negatively charged membrane. Consideration should also be given 
to other properties of the drug with some clearance possible despite impaired kidney 
function or clearance achieved when metabolised by the liver. Although individual 
properties of drugs can impact on concentration levels in the body clearance of drugs is 
often greater using CRRT than conventional IHD (Bugge, 2004). Increased dose 
adjustment may be necessary to maintain adequate therapeutic levels, since the capacity 
to maintain drug concentration levels is more likely to be restored between treatment 
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Fluid regulation and nutrition. 
The regulation of fluid volume is an important consideration in critically ill 
patients who run the risk of volume overload when renal insufficiency is associated with 
poor urinary output. The capacity of CRRT to regulate fluid volume when large 
volumes of fluid for drug infusions or blood products are required is a major advantage 
over conventional IHD (van Bommel, 1995). The removal of excess fluid and the 
maintenance of a negative fluid balance during CRRT has been shown to improve 
cardiac function in patients with congestive heart failure by the reduction of pre-and 
after-load fluid volume (Coraim & Wolner, 1995), and achieve superior pulmonary gas 
exchange when compared with the respiratory function of patients treated with 
conventional IHD (Bellomo, Farmer, Wright, Parkin, & Boyce, 1995). A summary of 
this study is provided in Table 2.3. 
As nutrition is delivered in a liquid volume critically ill patients with ARF are 
exposed to the risk of relative malnutrition if fluid administration is restricted due to the 
development of oliguria (Leverve & Barnoud, 1998). During conventional IHD efforts 
to avoid overloading the patient with excess fluid volume between treatment schedules 
can result in sub-optimal nutrition. However, when using CRRT no restriction is placed 
on the delivery of high-calorie fluids. Excess fluid is able to be removed continuously 
each hour, with nutritional requirements adjusted periodically in order to match 
metabolic demands in the critically ill patient. Whilst a number of studies have shown 
patients who are catabolic are more likely to receive the required protein intake during 
CRRT (Bellomo et al., 1992; Mc Donald & Mehta, 1991), there is no evidence to 
suggest the augmentation in protein delivery when compared to conventional IHD is 
associated with improved patient outcomes. 
Removal of inflammatory mediators. 
Many critically ill patients develop ARF as a complication of sepsis (Klenzak & 
Himmelfarb, 2005). The effect of CRRT on promoting haemodynamic stability in septic 
patients leading to a reduction in the requirement for vasopressor support, not explained 
solely by improved cardiac function due to the removal of excess fluid, has been 
attributed to haemofiltration and the clearance of middle molecular weight molecules 
associated with the inflammatory process (Heering, Grabensee, & Brause, 2003). The 
improved haemodynamics observed during CRRT might also be explained by the 
extended duration blood is circulated outside of the body and the impact of mild 
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hypothermia on increasing vascular tone. The capacity of CRRT to remove cytokines 
and other inflammatory mediators has been demonstrated to occur by convective 
clearance and in the adsorptive capacity of synthetic biocompatible membranes in 
several prospective studies on humans with septic shock (Bellomo, Tipping, & Boyce, 
1993; Dahaba, Elawady, Rehak, & List, 2002; de Vriese et al., 1999; Heering et al., 
1997; Klouche et al., 2002). The ability to remove molecules of a larger molecular 
weight by convection is reduced when low-flux non-biocompatible membranes most 
associated with conventional IHD are used which have a lower sieving coefficient not 
conducive to hydraulic permeability and a limited capacity to achieve solute clearance 
by adsorption (J. B. Ponikvar, et al., 2001). Although the use of standard CRRT has 
been shown to remove septic mediators the capacity to achieve a sustained reduction of 
inflammatory molecules has not been demonstrated in patients with sepsis (Cole et al., 
2002). Since the generation of septic mediators occurs more rapidly than increases of 
urea a different approach using CRRT is suggested for sepsis compared with the method 
normally used for the management of ARF. Investigation of high-volume 
haemofiltration (HVHF) with an ultrafiltrate of 6L per hour was able to achieve a 
substantial reduction in the concentration of cytokines and other septic mediators 
incorporating a fluid exchange which otherwise would not normally be prescribed using 
standard CRRT (Cole et al., 2001). A different approach to improve the clearance of 
inflammatory mediators known as high-cutoff haemofiltration incorporates a membrane 
of increased permeability shown as being superior in the removal of specific cytokines 
(Morgera et al., 2006). The ability to moderate the inflammatory response as a result of 
severe infection is further improved when the capacity for membrane adsorption is 
increased by frequent circuit changes. The use of standard CRRT does not alone offer a 
strategy which has been shown to improve patient outcomes for the treatment of sepsis 
beyond that required in support of renal function. Only after changes are made to the 
approach normally used for ARF can the potential benefit of haemofiltration and 
adsorption when compared with conventional IHD in reducing the inflammatory 
response be adequately realised in patients with sepsis. More investigation is required to 
determine whether HVHF, the effects of high cutoff haemofiltration, and increased 
membrane adsorption lower the levels of inflammatory mediators in sufficient quantities 
to reduce the incidence of MOD and make a positive difference in patient survival.  
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Cost. 
An important aspect of CRRT to be considered when choosing to employ this 
technique as opposed to conventional IHD is the cost associated with the initial 
purchase and use of specialist equipment (van Biesen, Vanholder, & Lameire, 2003). 
The purpose-built CRRT machines now available can only be used in the ICU and is a 
treatment option which increases the workload and responsibilities of the critical care 
nurse assigned to look after the patient. The requirement to purchase sterile bags of 
dialysate solutions and/or replacement fluid increase the operational expenditure 
associated with CRRT. The cost of CRRT was shown to be significantly higher when 
comparisons were made with conventional IHD (B. Manns, et al., 2003). A summary of 
this study is provided in Table 2.4. Other authors have reported only a marginal increase 
in expenditure between the two treatment modalities when the costs of replacing 
dialysis machines, water treatment systems and the requirement for a dialysis nurse 
associated with conventional IHD are taken into account (Bellomo & Ronco, 2000). The 
cost differential between the two treatment modes has now possibly changed in favour 
of conventional IHD following the recent introduction of more sophisticated CRRT 
machinery and expense associated with specialist dialysate and replacement fluid. Using 
the most expensive form of CRRT Farese and associates (2009) compared CVVHDf 
with the costs incurred when patients were randomised to receive conventional IHD. 
The initial outlay on equipment and maintenance costs estimated by the authors 
indicated CVVHDf was more expansive to operate than conventional IHD, plus the 
total cost of consumables including the price of sterile fluid bags versus treated drinking 
water was significantly higher when patients received CVVHDf compared to those 
patients managed by conventional IHD (P-value < 0.001). The approach  used by Farese 
and associates (2009) provide for the present the most realistic cost comparison between 
CVVHDf and conventional IHD.   
Complications using each approach 
The incidence of complications associated with CRRT and conventional IHD in 
terms of haemodynamic stability, bleeding, and immobilisation are important factors to 
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A major complication of conventional IHD in the critically ill patient is the 
development of hypotension. Intravascular hypovolaemia can arise when there is a rapid 
removal of fluid to remove excess volume within the time allowed for the procedure 
(Abuclo, Shemin, & Chazan, 1993). Acetate in dialysis fluid as a buffering agent has 
now been replaced with bicarbonate-based solutions for acutely ill patients in 
recognition of the hypotensive effect which was associated with its use in conventional 
IHD (Leunissen & van Hooff, 1988). The development of adverse biological effects due 
to blood-membrane interactions can also produce episodes of hypotension during IHD 
when non-biocompatible haemodialysers are used (Hakim, 1993).  
The incidence of hypotension due to haemodynamic instability can be 
detrimental in patients with ARF causing tubular ischaemia and a temporary loss of 
pressure-flow autoregulation (Bellomo & Ronco, 1999). If subsequent reductions in 
blood pressure take place the loss of regulatory control in glomerular capillary perfusion 
can cause delay in the recovery of kidney function and in the improvement of other 
compromised organs (Bellomo & Ronco, 1999; Conger, 1990; M. Manns, Sigler, & 
Teehan, 1997). This recognition of the intolerance of some critically ill patients to 
withstand the adverse haemodynamic effects of conventional IHD was a factor which 
led to the development of CRRT (Kramer, et al., 1980). 
In a randomised cross-over study the incidence of hypotension during CAVH 
was compared with conventional IHD (Misset et al., 1996). Whilst the authors observed 
no significant difference in the highest and lowest MAP measurements between the two 
techniques (46mmHg SD+21 for CAVH versus 48mmHg SD+14 for IHD, P-value = 
0.73), a number of weaknesses in the design of the study suggest caution should be 
exercised on assessing the reliability of these results. When compared with invasive 
monitoring techniques the use of non-invasive devices throughout the study was not as 
sensitive to changes in blood pressure during episodes of hypotension, and the reporting 
of derived rather than raw data introduced imprecise comparisons of variability in MAP 
measurements. In a more recent RCT by Augustine and associates (2004) greater 
haemodynamic stability occurred with CRRT when measurements of MAP were 
recorded continuously using invasive monitoring techniques. Patients assigned to IHD 
had a significant decrease in MAP (77.6mmHg SD+12.9 baseline versus 75.0mmHg 
SD+13.8 treatment, P-value = 0.04) compared with a MAP which remained unchanged 
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in patients who received CVVHD 76.8mmHg SD+7.8 baseline versus 77.4mmHg 
SD+8.1 treatment, P-value = not significant [NS]). This correlated with a higher 
incidence of patients requiring an increase in vasoactive agents during IHD compared 
with a lower incidence in patients who received CVVHD (40% versus 12.5%, P-value = 
0.005). Although conventional IHD is associated with a fall in MAP a retrospective 
study observed the haemodynamic tolerance of critically ill patients was improved, 
when the duration of the treatment session was increased and a drop in the rate of fluid 
removal reduced the incidence of hypotension caused by the sudden loss of circulatory 
volume (Schortgen et al., 2000). Studies which have compared haemodynamic stability 
between the two techniques are summarised in Table 2.5. 
Bleeding. 
The critically ill patient who has a recent history of trauma or coagulation 
disorders is at risk of bleeding when anticoagulants are used to perform extracorporeal 
RRT (P. Y. Martin, Chevrolet, Suter, & Favre, 1994; van de Wetering et al., 1996; 
Ward & Mehta, 1993). In order to reduce premature clotting and extend circuit life the 
performance of CRRT more so than IHD requires some form of circuit anticoagulation. 
Since conventional IHD is only required to operate over several hours when 
anticoagulants are used with CRRT, the risk of bleeding is increased due to the effects 
of systemic anticoagulation.  A decision to operate CRRT without anticoagulation due 
to severe coagulopathy or the use of regional anticoagulation following surgery are 
viable alternatives for patients who are at high risk of bleeding (Morabito et al., 2003; 
Palsson & Niles, 1999; Uchino, Fealy, Baldwin, Morimatsu, & Bellomo, 2004). 
Similarly the maintenance of circuit life using conventional IHD is not as important 
when compared with CRRT and minimal or no anticoagulation may only be required 
for completion of the treatment schedule. The contraindication of anticoagulatory agents 
was a reason given why during a RCT patients initially assigned to CRRT were 
switched and instead received IHD (Vinsonneau, et al., 2006). 
Immobilisation. 
The imposition of bed rest can expose the critically ill patient to several days or 
weeks of immobilisation. Many survivors of severe ARF and the dysfunction of other 
organs suffer complications in the ICU as a result of prolonged periods of inactivity. 
The adverse effects of enforced bed rest include muscle weakness and atrophy, systemic 
inflammation and inflammatory conditions, metabolic disturbances characterised by 
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Table 2.5:  
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 increased blood sugar levels, venous stasis and the risk of blood clots, joint contractures 
leading to reduced range of movement, and the development of pressure sores (Brower, 
2009). The ability to increase physical activity safely may not be considered feasible in 
the critically ill patient but a variety of studies have shown the benefits of early 
mobilisation (Morris et al., 2008; Schweickert et al., 2009).  
 To achieve a similar degree of solute removal and the desired level of azotemic 
control the technique of CRRT is required to operate uninterrupted for a much longer 
duration than the treatment schedules normally associated with conventional IHD. 
Using both approaches will place restrictions on patient mobility but compared with 
IHD the limitations on physical activity are imposed for a greater length of time during 
CRRT. The opportunity to assist the patient who has been receiving CRRT out of bed 
for early mobilisation may be possible before the patient is attached to the circuit. A 
number of situations require elective discontinuation of the circuit and CRRT 
temporarily suspended to allow the transportation of the patient outside the ICU for 
radiographic scanning, surgery or other procedures. On each occasion the patient is no 
longer attached to the CRRT machine, important dialysis and/or ultrafiltration time is 
lost which can reduce the effectiveness of the treatment particularly if the patient is 
absent from the ICU for a long period of time, or the preparation of a new circuit causes 
a delay in the recommencement of treatment. The ability of CVVH to stabilise urea 
plasma concentration was shown to be affected when actual delivered treatment time 
within a 24hr cycle was less than 16hr (Uchino, et al., 2003a). 
Hybrid Therapies 
A number of recently undertaken international surveys have reported the 
emergence of „hybrid therapies‟ as a form of RRT now used in some ICUs for the 
management of ARF (Overberger, et al., 2007; Ricci, Ronco, D'amico, et al., 2006). The 
use of Slow, Low-efficiency Daily Dialysis/Extended Daily Dialysis (SLEDD/EDD) or 
Slow, Low-efficiency Daily Diafiltration/Extended Daily Diafiltration (SLEDDf/EDDf) 
have evolved in an attempt to maximise the advantages in using both conventional IHD 
and CRRT, whilst recognising the disadvantages each technique has when applied to the 
critically ill patient (Marshall, Golper, Shaver, & Chatoth, 2001). The advantages which 
CRRT provides in haemodynamic stability, small to middle-sized molecular weight 
solute removal and control of excess fluid volume can be achieved using hybrid 
therapies. A longer treatment time in comparison to conventional IHD allow these 
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therapies to operate at a slower blood and dialysate flow rate to achieve greater 
haemodynamic stability and electrolyte/metabolic control. The use of high-flux 
membranes with increased sieving coefficients also enables clearance of a wider range 
of different molecular-weight sized solutes and to achieve greater fluid balance 
regulation. Hybrid therapies utilise dialysis machines without the need to purchase 
dedicated CRRT machinery. The technique is not required to operate continuously 
allowing the possibility for nocturnal scheduling of sedated critically ill patients and can 
avoid placing additional demand on existing equipment normally utilised during day 
time hours for conventional IHD. Although on-line quality control in the production of 
dialysate is necessary, there is no requirement when using hybrid therapies for the 
purchase of sterile dialysate solution and replacement fluid which may deliver cost 
savings when comparisons are made with CRRT. Experience in the use of hybrid 
therapies describe treatment schedules of six to 12hr associated with a blood flow of 
100 to 200ml per min, a dialysate flow rate of 100 to 300ml per min and a replacement 
rate of 20 to 100ml per min (Baldwin, Naka, Koch, Fealy, & Bellomo, 2007; Kumar, 
Craig, Depner, & Yeun, 2000; Marshall et al., 2004).  
Since the introduction of hybrid therapies a number of small studies have sought 
to compare the use of hybrid therapies with conventional IHD and CRRT for the 
treatment of ARF in the critically ill patient. In a RCT similar haemodynamic stability 
and control of urea and creatine serum concentrations was observed in patients treated 
with EDD compared with those patients who received CVVH (Kielstein et al., 2004). 
Anticoagulation requirements for EDD when compared with CRRT were shown to be 
significantly lower in a prospective non-randomised study and performance unaffected 
by the incidence of clotting even when no anticoagulation was used (Kumar, Yeun, 
Depner, & Don, 2004). Marshall and associates (2004) undertook a small prospective 
observational study using SLEDDf. The authors demonstrated a greater dialysis dose 
was able to be delivered when compared with conventional or daily IHD treatment 
schedules and showed SLEDDf could be delivered safely by critical care nurses 
independent of the services of a dialysis nurse. Although in this study clearance of the 
larger 12 molecule was less than the removal of the smaller urea molecule, the authors 
suggest convective clearance during SLEDDf could be increased if adjustments are 
made to the permeability of the membrane. In a randomised controlled comparison of 
EDDf with CVVH the concentration levels of urea or creatinine and in the correction of 
electrolyte abnormalities was not shown to be significantly different in patients who 
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were of similar age and severity of illness (Baldwin, et al., 2007). Whilst Kielstein and 
associates (2004) reported the correction of acidosis was accomplished more rapidly 
with EDD, Baldwin and colleagues (2007) observed acidosis was better controlled 
during CVVH. This occurred despite the use of lactate as a buffer in the replacement 
solution compared to the use of bicarbonate in the dialysate solution and replacement 
fluid for EDDf. When the operational expenditure associated with the use of hybrid 
therapies was compared with the costs associated with CRRT significant savings were 
made using SLEDD (Berbece & Richardson, 2006). 
The view that CRRT is superior to conventional IHD despite a number of 
operational advantages associated with the technique has not translated into a significant 
improvement in long-term patient survival or in the return of adequate renal function 
(Antoun & Palevsky, 2009). A reasonable approach as to the choice of RRT which can 
best support the critically ill patient with ARF is to regard conventional IHD and CRRT 
as techniques which are interchangeable. The degree to which this occurs depends upon 
the severity of the underlying condition of the patient influenced by the resources and 
clinical expertise available. To date the question of whether hybrid therapies can 
provide a better outcome in the treatment of ARF for the critically ill patient than 
conventional IHD or CRRT has not been answered in any prospective comparative 
controlled study (van Biesen, Veys, & Vanholder, 2007). The major advantages and 
disadvantages of conventional IHD, CRRT and hybrid therapies are summarised in 
Table 6. The proponents of CRRT in Europe and Australia believe the disadvantages of 
the technique are offset by the advantages the treatment can bring to patients who are 
more at risk of death by offering greater haemodynamic stability, improved biochemical 
control, and superior fluid balance regulation. Any advantage gained using CRRT over 
conventional IHD and hybrid therapies nevertheless requires the maximum benefit of 
the treatment to be achieved by sustaining a continuous approach in the delivery of renal 
support. The continuity of treatment delivered to the patient will depend on the methods 
used in the application of the technique and on interventions which can promote the 
longevity of the extracorporeal circuit.   
Application of Continuous Renal Replacement Therapy 
The approach adopted in Australia for the management of the critically ill 
patient operates within a „closed‟ ICU model of care similar to the method used in New 
Zealand (Judson & Fisher, 2006). The primary responsibility for making treatment 
decisions and writing prescription orders lies with a qualified specialist trained in 
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intensive care medicine. As a consequence of this approach the management of severe 
ARF in Australia has moved away from accessing nephrology services for the 
administration of RRT, to choosing instead the continuous techniques which are able to 
be delivered solely by the critical nurse under the supervision of the treating intensive 
care specialist. The major areas for consideration in the application of CRRT include the 
choice of treatment mode, dialysate and replacement fluid composition, adequacy of 
treatment dose and factors which affect circuit life. 
Choice of Treatment Mode  
The only nationwide survey undertaken in Australia which has sought to 
investigate ICU workforce practices in the management of renal insufficiency found the 
intensive care specialist was in charge of RRT in 96.7% of cases, and in 98% of patients 
severe ARF was managed using CRRT operated by the critical care nurse (75 out of 81 
ICUs completed the survey) (Silvester, et al., 2001). The authors reported patient 
outcome was unaffected when in 57.8% of cases no nephrological consult was sought 
compared with the outcome of patients who were seen by the nephrology team. 
Analysis of the CRRT mode selected by those units surveyed showed 23.5% used 
convective therapy in the form of CVVH as opposed to 76.4% who preferred the 
combined convective and diffusive therapy of CVVHDf. Other aspects regarding the 
management practices of CRRT investigated by the authors included the use of agents 
to anticoagulate the extracorporeal circuit. The approach most often used to sustain 
circuit life was achieved by systemic anticoagulation of the patient using unfractionated 
heparin (36.8%), or a combination of either regional heparinisation or low-dose heparin 
given pre-filter (33.4%). A management practice not scrutinised during the survey was 
in regards to the „dose‟ of CRRT prescribed by the intensive care specialist. 
Another opportunity to prospectively survey the management practices 
regarding the delivery of RRT arose again when preparations were made to conduct a 
large-scale study to determine the optimal dose for CRRT in the management of ARF. 
Investigators of the randomised evaluation of normal versus augmented level (RENAL) 
study (2008) recruited 34 ICUs in Australia and New Zealand. All the ICUs who agreed 
to participate in the study used CRRT as the first choice of therapy for patients with 
severe ARF, and CVVHDf was once more found to be the most popular therapy 
selected. The technique of CVVHDf was used in 21 of the 34 ICUs surveyed (62%) 
followed by 12 (35%) who relied on CVVH and one (3%) choosing instead the option 
of CVVHD. Out of 34 units surveyed the treatment mode selected was applied in 23 of 
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cases until either the patient no longer required RRT, or was discharged from ICU, or 
the patient had died. Of the remaining 11 who responded to the survey, treatment was 
switched to IHD or SLEDD when patients were close to transfer out of the unit. In 
addition to these findings the main focus of the survey reported the approach to CRRT 
prescription was on a fixed-dose regimen and not according to patient weight. The 
average effluent generated was 2280ml per hour using pre-dilutional CVVHDf, with a 
dialysate to replacement fluid ratio of 1:1 operating at a blood flow speed of 200ml per 
minute. 
 Dialysate and Replacement Fluid Composition 
The different attributes of diffusion-based versus convection-based techniques 
are influenced by the composition of the dialysate and replacement fluid used during 
CRRT to achieve electrolyte and acid-base homeostasis (Aucella, Paolo, & Gesualdo, 
2007). Over the duration of treatment solutes are diffused or ultrafiltered across the 
semi-permeable membrane using solutions which facilitate the restoration of plasma to 
near normal values. According to the technique selected the choice of solutions to 
deliver CRRT can play an important role in how quickly biochemical abnormalities are 
resolved. 
 The delivery of solutions containing buffer is essential during CRRT to achieve 
acid-base balance in the critically ill patient (Aucella, et al., 2007). A constant supply of 
alkali is required to counter the endogenous production of acid, but is also necessary to 
compensate for the bicarbonate lost through the haemodialyser or haemofilter. The 
buffer balance during CVVH occurs by convective transport depending on the losses 
which are incurred with ultrafiltration and the amount returned in the replacement fluid. 
Alternatively, the concentration gradient between blood and dialysate provide a 
feedback mechanism during CVVHD which maintains the buffer balance by diffusive 
transport (Aucella, et al., 2007). The metabolic conversion of acetate, lactate, or citrate 
into bicarbonate have all been used as buffers in the formulation of dialysate solutions 
and in replacement fluids, as well as the direct administration of bicarbonate-based 
solutions (Aucella, et al., 2007).  
The earlier use of acetate as a buffer is now no longer recommended with 
evidence of reduced acid-base balance control and the reported higher incidence of 
cardiovascular instability when compared with lactate-based solutions (Heering et al., 
1999). The use of lactate-based solutions is usually well tolerated in the critically ill 
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patient when rapidly metabolised by the liver into bicarbonate. A normal functioning 
liver can metabolise lactate up to a rate of 100 mmols per hour and supply sufficient 
bicarbonate to match the hourly fluid exchanges required during CRRT (Macias & 
Clark, 1996). Commercially available solutions have lactate concentration levels of 
between 35mmol per L and 45mmol per L which are sufficient for the correction of a 
metabolic acidosis and in the maintenance of acid-base balance. The incidence of 
hyperlactataemia using solutions containing even low levels of lactate have nevertheless 
been reported when exogenous conversion of lactate into bicarbonate is reduced in 
patients who have liver dysfunction whilst simultaneously exposed to increased 
production of lactate due to poor circulation (Ho, 2006). The metabolic conversion of 
citrate into bicarbonate offers an alternative to lactate-based solutions as a buffering 
agent. A solution containing citrate is used to achieve regional anticoagulation of the 
circuit in patients at high-risk of bleeding (Davenport & Tolwani, 2009). Simpler 
protocols in the delivery of citrate along with increased availability of commercially 
suitable solutions can reduce the potential for acid-base disturbances when there is 
inadequate or excess citrate metabolism.  
In situations where attempts at the supplementation of bicarbonate by metabolic 
conversion have proved problematic, bicarbonate-based solutions can be directly 
administered to the patient. An improvement in acid-base control and reduced incidence 
of cardiovascular instability was observed using bicarbonate-buffered replacement fluid 
during CVVH when compared with the use of lactate-based replacement fluid 
(Barenbrock, Hausberg, Matzkies, de la Motte, & Schaefer, 2000). The use of 
bicarbonate was initially complicated by exposing the patient to the possibility of errors 
during administration when solutions were manually prepared, and the difficulty 
experienced in the manufacture and storage of commercially produced bags due to the 
problem of precipitation in solutions containing magnesium and calcium (Naka & 
Bellomo, 2004).. A breakable valve between a double chamber bag has resolved the 
problem of chemical instability by allowing the storage of bicarbonate-based solutions 
to be mixed only when immediately required at the bedside. The innovation has 
coincided with the cost of solutions increasing to almost triple the expense of standard 
single chamber bags and is a disadvantage in the routine use of commercially produced 
solutions containing bicarbonate.  
Apart from influencing acid-base balance the composition of replacement fluid 
and dialysate will assist with the regulation of electrolytes and other important 
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substances. Severe electrolyte derangements can occur during CRRT in the absence of 
careful monitoring and without attention given to the prescription of solutions. The risk 
of contamination in the preparation of customised solutions (Kanagasundaram, Larive, 
& Paganini, 2003), or errors in the prescription and injection of additives (Johnston, 
Boiteau, Charlebois, Long, & David, 2004) make the use of commercially available 
fluids the safest option. Although some additives may need to be injected at the bedside 
the composition of fluid is ready for use and comprises of electrolytes and glucose at 
physiologic concentration levels which can be administered safely. A typical bag 
manufactured for CRRT will contain sodium 140mmol per L, chloride 108 to 112mmol 
per L, potassium 0 to 4mmol per L, calcium 1.5 to 1.75mmol per L and glucose 0.15mg 
per L (Aucella, et al., 2007). The control of serum potassium levels is a major concern 
during CRRT and, without the addition of potassium in the dialysate solution and 
replacement fluid, the patient can become hypokalaemic. Sustained episodes of low 
serum potassium levels places the patient at risk of developing arrhythmias and the 
possibility of cardiac arrest (Ahern-Gould & Stark, 1998). Although hyperkalaemia can 
be a feature of AKI due to the effects of rhabdomyolysis (Bosch, Poch, & Grau, 2009),  
the regular supplementation of potassium to prevent hypokalemia is usually necessary. 
The addition of potassium in potassium-free solutions requires careful monitoring to 
ensure the desired serum potassium level is maintained. Algorithms designed to assist 
with potassium supplementation during CRRT can make the control of serum potassium 
levels easier to regulate (Brooks, 2006). The alternative electrolyte, sodium also 
requires monitoring with the control of serum levels influenced by the mode of 
treatment selected. The movement of sodium can be controlled using convective and 
diffusive transport mechanisms without concern regarding the rapid clearance of the 
ion, provided concentration levels of sodium are sufficient in the dialysate solution and 
replacement fluid. The ability to achieve normal serum sodium levels was nevertheless 
demonstrated to be superior using CVVHDf after the treatment mode was 
retrospectively compared with the alternative treatment mode of CVVH (Morimatsu, 
Uchino, Bellomo, & Ronco, 2003). The inclusion of dialysate solutions containing 
sodium at sufficient concentrations to offset movement by diffusion was reported by the 
authors more likely to avoid hyponatremia when, despite adequate concentration of 
sodium in the replacement fluid, comparisons were made with the movement of sodium 
by convection. Disturbances in the balance of other electrolytes can also occur during 
CRRT. The exchange of large volumes of fluid containing calcium place the patient at 
risk of hypercalcemia with the same cautions required to maintain an appropriate serum 
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magnesium level (Aucella, et al., 2007). The prolonged use of CRRT may induce 
hypophosphatemia requiring correction by intravenous bolus administration, but the ion 
has been added successfully to solutions containing calcium without causing 
precipitation (Troyanov, Geadah, Ghannoum, Cardinal, & Leblanc, 2004).  
The large volume of fluid which is exchanged during CRRT requires careful 
attention to the maintenance of fluid sterility and in the correct adjustment of fluid 
prescriptions when solutions are administered by the critical care nurse. Stabilisation of 
acid-base balance and correction of electrolyte disturbances is not only dependent on 
differences in the technique selected, but is also influenced by the composition of fluids 
delivered with each treatment. The physical properties of fluids chosen are now 
increasingly being recognised as important to the overall determination of outcomes 
when CRRT is required in the management of the critically ill patient (Schetz, Leblanc, 
& Murray, 2002), 
Adequacy of Treatment Dose 
The term „urea kinetic modelling‟ (UKM) is used to describe a technique 
commonly applied in clinical practice to quantify the dialysis dose required for patients 
with ESRD (Kemp, Parnham, & Tomson, 2001). The dose of dialysis therapy is 
expressed in terms of urea clearance through the dialysis membrane (K), duration of 
dialysis (t), over the volume of urea distributed in the patient. The Kt/V formula is an 
established measurement of adequacy based on the clearance of urea to achieve a 
recommended dose which is associated with improved survival of patients who have 
ESRD (Ricci & Ronco, 2005). A Kt/V of at least 1.2 UREA is considered in the 
management of ESRD an adequate treatment dose.  
In determining an adequate treatment dose for the management of ARF a 
number of problems are encountered when the Kt/V formula is applied to the critically 
ill patient. The unsteady state of the patient may create uncertainty about urea levels due 
to high catabolism and fluctuations in blood volume complicating the estimation of 
solute clearance. The ability to deliver the prescribed dose can be affected by inadequate 
blood flow using temporary vascular access devices, frequency of clotting in the 
extracorporeal circuit, and technical problems in the operation of machinery (Ricci & 
Ronco, 2005). As a consequence of the difficulties experienced using the Kt/V approach 
the measurement of clearance according to the ultrafiltration rate (ml per kg per hr) has 
now been adopted for CRRT (Ronco, et al., 2000). In applying the Kt/V formula 
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normally associated with IHD a treatment dose of 35ml per kg per hr in a 70kg patient 
using pure haemofiltration would achieve a Kt/V of 1.4UREA. This is a calculation based 
on the assumption treatment was able to be sustained for 24hr and a recognition of 
uncertainty regarding the fluctuations in the distribution of urea in the critically ill 
patient. The application of CRRT can make it difficult to achieve the predicted intensity 
of dose in ml per kg per hr or equivalent Kt/V due to problems associated with its 
capacity to operate continuously. A problem in the calculation of treatment dose can 
also arise when the ultrafiltration rate is combined with the addition of dialysis such as 
in CVVHDf and how to determine clearance in the effluent produced using both 
approaches.  
An international survey investigating the practices of nephrologists and intensive 
care specialists in the management of critically ill patients found 67% of those who 
responded to the survey did not measure the dose of RRT delivered, and in 60% of 
cases intensive care specialists as opposed to 40% nephrologists provided no 
prescription on the dose required in the management of ARF (Ricci, Ronco, D'amico, et 
al., 2006). A reduction in the ability to reach the desired treatment dose was reported to 
be associated with patients who were overweight when using IHD (Evanson et al., 
1998). The authors observed patient weight was a contributing factor which resulted in 
70% of dialysis delivered being under a Kt/V of 1.2UREA. In a recent US survey 
investigating dose intensity of renal support for the critically ill patient, only 17.9% of 
those surveyed reported dosing CRRT according to patient body weight when the 
practices of institutions were reviewed (Overberger, et al., 2007). The same lack of 
scrutiny towards a relationship between treatment dose and body weight was also 
reported by the RENAL study investigators after a survey was conducted on 
predominately CRRT practice in Australia and New Zealand ICUs (RENAL 
Replacement Therapy Study Investigators, 2008). None of the participating study sites 
prior to commencement of the investigation surveyed had previously adjusted RRT 
according to patient weight. The survey revealed a preference in 62% of ICUs for a 
fixed-dose RRT regimen of 2L per hour in the volume of effluent generated.     
The importance of determining an adequate dialysis and ultrafiltration dose has 
seen an upsurge of interest following reports of improved patient outcomes when the 
intensity of RRT delivered is increased. In a single centre randomised study the 
application of CRRT using pure haemofiltration was carried out in 425 critically ill 
patients (Ronco, et al., 2000). The authors reported patients who were prescribed an 
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ultrafiltration rate of 35ml per kg per hr or 45ml per kg per hr had significantly better 
outcomes at 15 days from the last day of treatment when compared with patients who 
were prescribed a lower ultrafiltration rate of 20mL per kg per hr (35ml per kg per hr 
group P-value = 0.0007, 45ml per kg per hr group P-value = 0.0013). A shortcoming of 
this study possibly lies in the design which did not control for differences in other 
supportive management practices, with the trial taking five years to complete and 
changes in how patients were managed being a confounding factor that may have 
influenced survival in some patients. The benefit of increasing the intensity of renal 
support has also been observed in critically ill patients receiving IHD. During a 
randomised study undertaken by Schiffl and colleagues (2002) patients were assigned to 
either the scheduling of daily IHD or conventional IHD delivered on alternate days. The 
authors observed a significant difference in the survival of patients who were exposed to 
the daily scheduling of IHD when the dose prescribed for both treatment groups 
targeted a Kt/V of 1.2UREA. Out of the 146 patients who completed the study in the 74 
patients who were treated with daily IHD, death at 14 days after last treatment dose had 
occurred in 19 patients (26%) compared with 31 patients (43%) included in the 72 
patients who had instead received conventional IHD (P-value = 0.04). The results are 
possibly difficult to generalise to the wider critically ill population since the study 
excluded patients who were haemodynamically unstable and is perhaps reflected by the 
lower mortality rate observed during the trial (34%) compared with those reported in 
other studies.  
An increase in the intensity of renal support has not always produced similar 
results of a positive effect on patient outcomes. The delivery of higher ultrafiltrate 
volumes was not shown by Bouman and associates (2002) to improve survival when 
measurement of patient recovery following discontinuation of treatment was extended 
from short-term analysis which had occurred with the other studies previously 
discussed. As part of investigations into early versus late initiation of RRT the authors 
also observed the effects of high volume haemofiltration (3 to 4L/hr) versus low volume 
haemofiltration (1 to 1.5L/hr) in 106 critically ill patients, and reported no difference in 
survival when patient follow-up was extended out to 28-days (high volume 
haemofiltration 74.3% versus low volume haemofiltration 68.8%, P-value = 0.80). A 
confounding factor which may have influenced the outcome observed by Bouman and 
associates (2002) between the different treatment groups arose as a result of not 
standardising treatment dose according to patient weight. This had the potential to 
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increase the variability of RRT delivered when the allocated prescribed dose was given 
regardless of extremes in body weight. 
The contradictory evidence observed regarding the intensity of renal support on 
improving the outcomes of critically ill patients demonstrate the shortcomings of 
making decisions to change practice based on the findings of single-centre studies. The 
uncertainty over dose intensity in the delivery of RRT has been the subject of two multi-
centre randomised, controlled trials recently undertaken in the US and as a collaborative 
project between Australia and New Zealand. The sample size and design of both the 
ATN and RENAL studies are examples of attempts made by investigators to provide 
adequate statistical power and robustness when making recommendations on the 
optimal dose of RRT required for improving survival in the management of patients 
with severe ARF. 
The members of the ATN study investigation team have recently published the 
results of the US trial which did not demonstrate a significant difference in patient 
mortality or an improvement in the recovery of kidney function when the intensity of 
renal support was increased (Acute Renal Failure Trial Network, 2008). Using a 
prospective, randomised, parallel-group study design 1124 patients were assigned to 
receive either a treatment strategy of IHD six times per week or CVVHDf at 35ml per 
kg per hr, compared with the other category of patients who received instead a treatment 
strategy of IHD three times per week or CVVHDf at 20ml per kg per hr. In the event of 
haemodynamic instability the study allowed patients assigned to IHD to switch over and 
receive the same dose-intensity using CVVHDf or SLEDD. Out of the 563 patients who 
received the intensive treatment strategy 302 patients (53.6%) died within 60 days 
following randomisation as opposed to 289 (51.5%) out of 561 patients who had 
undergone the less intensive treatment strategy (P-value = 0.47). Also, no significant 
difference was observed in the recovery of kidney function with complete return by day 
28 occurring in 85 patients (15.4%) and partially present in 49 patients (8.9%) out of the 
553 survivors who had previously received increased renal support. This contrasted with 
the other 555 patients at day 28 who had been treated using decreased renal support 
with complete return of kidney function reported in 102 patients (18.4%) and partial 
recovery observed in 50 patients (9.0%) (P-value = 0.24).  A similar result occurred 
when patients were followed-up at 60 days with no significant difference in the 
requirement for on-going dialysis reported when patients were discharged out of 
hospital (15.7% of intensive treatment strategy patients versus 16.4% of less intensive 
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treatment strategy patients, P-value = 0.75). The findings of the ATN study suggest 
there was no benefit of improved patient survival or recovery of kidney function when 
the intensity of treatment was increased above a Kt/V dialysis dose of 1.2UREA or an 
ultrafiltration rate greater than 20ml per kg per hr.  
The ATN study was a rigorous attempt to control the supportive management of 
patients throughout the duration of the study, allow for generalisation of the findings to 
the typical critically ill patient, enforce standardisation of dialysis/ultrafiltration dosages 
according to randomised allocation, and achieve the statistical power required to detect 
a 10% difference in long-term survival (60 days) between the two treatment groups. The 
approach taken was not entirely successful in achieving an equal comparison between 
„low‟ and „high‟ dose RRT for a reliable relationship between dose and response to be 
established. The switching between IHD and CVVHDf/SLEDD may have led to a 
crossover effect and inadvertly delivered an equivalent dose of low-intensity 
CVVHDf/SLEDD when the swap occurred despite the patient being assigned to receive 
high-intensity IHD.  
The investigators of the RENAL study have also recently published observations 
on the other multi-centre randomised, controlled trial established to address the issue of 
dose intensity of RRT as a factor influencing patient outcomes. In the RENAL study 
comparisons of intensity were made using only post-dilution CVVHDf  with the 
„standard‟ dose of 25ml per kg per hr versus the augmented dose of 40ml per kg per hr 
(RENAL Replacement Therapy Study Investigators, 2009). A difference in the RENAL 
study when compared with the approach taken by the ATN study group was the 
investigation of renal support resembled clinical practice in Australian and New 
Zealand ICUs. The RENAL study was designed for the randomisation of 1,500 patients 
with a statistical power to detect an 8.5% reduction in patient survival at 90 days. On 
completion of the study the authors reported 1,508 patients with similar baseline 
characteristics had been randomly assigned to receive either the augmented (747), or the 
standard (761) treatment dose. After 90 days following hospital admission 322 deaths 
(43.1%) occurred in the group of patients who had received renal support of a higher-
intensity compared with 332 deaths (43.6%) observed when patients were instead 
allocated renal support of a lower-intensity (odds ratio, 1.00; 95% CI, 0.81 to 1.23; P-
value = 0.99). Survivors of the lower-intensity group who continued to require RRT at 
90 days (18 out of 411) was not significantly different to patients in the higher-intensity 
group (27 out of 399, P-value = 0.14). 
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The findings of the ATN and RENAL studies suggest renal support beyond an 
adequate level of intensity provides no additional benefit to the critically ill patient. 
Survival of the patient and recovery of renal function does not appear to be improved 
when the Kt/VUREA exceeds 1.2, or is greater than 35ml per kg per hr (Acute Renal 
Failure Trial Network, 2008; RENAL Replacement Therapy Study Investigators, 2009). 
On reaching the same conclusion as reported by authors of the ATN and RENAL 
studies, the investigators who established the Dose Response Multi-centre International 
(DO-RE-MI) collaborative initiative observed the ability to deliver an „individualised‟ 
renal dose in patients was more difficult when associated with a higher body weight 
(DO-RE-MI Study Group, 2009). A dose below 20ml per kg per hr was suggested by 
authors of the European prospective observational study as being suboptimal in the 
management of severe ARF and the threshold reached when body weight prescription 
was constrained by the availability of technology to deliver the required intensity of 
renal support. The importance of ensuring the prescribed intensity of renal support is 
delivered to the patient make quality assurance activities towards assessment of actual 
dose received essential to avoid the risk of under dosing the patient (Palevsky, 2009). In 
order to achieve the required intensity of renal support consideration needs to be given 
to how the continuity of CRRT can be maintained in the management of the critically ill 
patient with severe ARF. 
    Factors Which Affect Circuit Life 
The ability to deliver the correct intensity of renal support using CRRT is 
influenced by the longevity in the functionality of the extracorporeal circuit. A 
physiological factor which can cause premature clotting of the circuit occurs following 
exposure of blood to non-biological materials. The use of anticoagulants can modify the 
response of the coagulation pathway and delay the development of blood clots, whilst 
the location of replacement fluid can dilute the concentration of procoagulatory 
substances (Joannidis & Oudemans-Van Straaten, 2007). Other factors of a mechanical 
nature can also impact on circuit life and cause unexpected circuit failure to occur (Kim, 
Fealy, Baldwin, & Bellomo, 2010). An understanding of the theoretical principles 
behind the technique and operational training in the use of equipment and the 
monitoring of circuit pressures is important. Consideration should be given to the design 
features of the extracorporeal circuit which incorporates the roller-pump, the 
haemofilter and venous bubble or air- trap. The influences of the venous access catheter 
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and the vascular insertion site on blood flow are other mechanical factors regarded as 
important in determining the longevity of the circuit.    
Blood Coagulation and Extracorporeal Circulation 
The sequence of events which cause the coagulation of blood is traditionally 
described as initially involving the intrinsic and extrinsic coagulation pathways. 
Activation of the intrinsic (contact) pathway is caused by blood vessel injury as opposed 
to the stimulation of the extrinsic (tissue factor) pathway due to exposure of substances 
at the site of vessel wall damage (Moran & Viele, 2005). Both of the initiating pathways 
activate coagulation factors in a sequence of events which join together to form a 
common coagulation pathway. The intrinsic pathway is initiated when coagulation 
Factor XII is activated by elements within the lumen of blood vessels. Mobilisation of 
coagulation Factor XII initiates activation of coagulation Factors XI and IX. In the 
presence of activated Factor IX, coagulation Factor VIII, calcium and phospholipids 
activate coagulation Factor X. Platelets play an important role at this point by releasing 
calcium and phospholipids. Initiation of the extrinsic pathway occurs when tissue factor, 
not normally circulating in blood plasma, is released as a result of endothelial damage to 
the blood vessel wall. Released tissue factor combines with coagulation Factor VII and 
activates both coagulation Factors IX and X. Once initiating pathways activate Factor X 
a common coagulation pathway is established and coagulation Factor V converts 
prothrombin into thrombin. Fibrinogen is converted by thrombin into fibrin and creates 
a network of threads which forms a blood clot when stabilised by the aggregation and 
adhesion of platelets (Moran & Viele, 2005). 
The circulation of blood through an extracorporeal circuit will eventually cause 
blood to clot and is a normal physiological response once blood is circulated outside of 
the body (Davenport, 1997). The mobilisation of the intrinsic coagulation pathway is 
thought to be activated when on commencement of treatment there is a rapid adsorption 
of plasma proteins onto the membrane surface area within the haemofilter and along the 
entire extracorporeal circuit. As a result of fibrinogen adsorption and exposure to 
thrombin the mechanism of interaction which occurs when blood comes into contact 
with non-biological materials is accompanied by the activation of platelets and the 
development of blood clots. In a prospective study on platelet function a reduction in 
platelet aggregation was observed during CVVH associated with activation of platelets 
caused by adherence to the filter membrane and blood lines (Boldt, Menges, Wollbruck, 
Sonnerborn, & Hempelmann, 1994). A decrease of 62% in platelet aggregation was 
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recorded after samples of arterial blood were exposed to adenosine diphosphate and 
compared with a group of patients who served as the control not undergoing CVVH. 
The dysfunction of platelets was reported by the authors to be most pronounced when 
the duration of CVVH occurred over several days and the extended duration of 
treatment coincided with an increase in patient mortality.  
The development of blood clots in the extracorporeal circuit has also been 
associated with the extrinsic coagulation pathway. The release of tissue factor along 
with other substances, normally only discharged into the circulation when damage has 
occurred to the blood vessel, can also be present in the bloodstream when cytokine and 
endotoxin levels are elevated. A study undertaken by Cardigan and associates (1999) 
found in the six out of 12 critically ill patients recruited there was an increase during 
CVVH in monocyte tissue factor levels above baseline measurements. The change in 
tissue factor levels was significantly correlated to a change in thrombin-antithrombin 
complexes over the lifespan of the circuit (r = 0.49, P-value = 0.02) and inversely 
correlated with circuit longevity (r = -0.72, P-value = 0.03). 
A number of factors predispose the CRRT circuit to the early development of 
blood clots (Schetz, 2001). The concentration of coagulation markers was observed by 
Stefanidis and associates (1996) to be elevated in critically ill patients with ARF prior to 
commencement of CVVH. The authors found in 14 patients whose causes of ARF 
varied there was significant elevation above normal in the coagulation marker levels of 
fibrinopeptide A (33 nanograms (ng) per ml SD+20, normal range <3.0) and thrombin-
antithrombin III complex (11ng/ml SD+5, normal range 1.0-4.0). Stimulus for 
coagulation may occur secondary to the disease process as in the case of sepsis where 
levels of naturally occurring anticoagulants are reported to be lower in some critically 
patients with severe infection (Hesselvik, Malm, Dahlback, & Blomback, 1991). 
Premature clotting in polyacrylonitrile haemofilters was observed to occur more 
frequently during CVVH when levels of antithrombin III and heparin co-factor II were 
reduced (Salmon et al., 1997). Out of the 12 critically ill patients recruited to participate 
in the study nine had baseline measurements which were below the normal reference 
range. On commencement of treatment the lowest level of antithrombin III and heparin 
co-factor II observed in four patients was reported by the authors to be associated with 
reduced circuit life. Based on the studies reviewed the critically ill patient is vulnerable 
to early activation of the coagulation pathway making the challenge of sustaining the 
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extracorporeal circuit more difficult to achieve in efforts to maximise the delivery of 
CRRT.     
Anticoagulation Strategies 
To sustain the extracorporeal CRRT circuit and delay the onset of blood clotting 
anticoagulant drugs are usually necessary. The goal of anticoagulation in CRRT is to 
maximise the anticoagulant affect inside the haemofilter and along the circuit, whilst 
minimising the potential harmful effects of systemic anticoagulation (Bellomo & 
Ronco, 2002a). Selection of the anticoagulant agent is determined by the patient‟s 
underlying illness, availability of the anticoagulant and clinical experience (Mehta, 
1996). Numerous anticoagulants and modes of administration have been advocated 
(Oudemans-van Straaten, Wester, de Pont, & Schetz, 2006). The most common 
available anticoagulants and strategies used for CRRT in Australia include 
unfractionated heparin, regional heparinisation, low-molecular heparins and 
heparinoids, regional citrate, platelet-inhibiting agents and thrombin antagonists. The 
following sections will focus on each anticoagulant with a brief description of the 
method, the efficacy of outcomes from published reports and issues related to its use, 
side-effects and contraindications. The efficacy of CRRT without anticoagulation in 
patients at high-risk of bleeding will also be discussed.  
Unfractionated Heparin. 
Unfractionated or standard heparin is the anticoagulant agent most commonly 
used in CRRT to prolong the life of the extracorporeal circuit in Australia (Silvester, et 
al., 2001) and in other countries such as the United Kingdom (Wright, et al., 2003). It is 
widely available and relatively inexpensive. Clinicians are also familiar with its mode of 
action, dosing and monitoring considerations (Shulman, Singer, & Rock, 2002). 
Standard heparin is made up of long-chain glycosaminoglycans which have a diverse 
molecular weight ranging between 5,000 and 30,000Da (Shulman, et al., 2002), and in 
one study were not shown to cross the membrane during haemofiltration and enter the 
ultrafiltrate in sufficient quantities to be measured (Singer et al., 1994). The 
anticoagulant effect of heparin is primarily exerted on antithrombin III to block the 
action of thrombin and factor Xa (Abramson & Niles, 1999). The pharmacokinectics of 
heparin, whilst time and dose-dependent, can be unpredictable and considerable 
variability in affect can occur from patient to patient (Schetz, 2001). Anti-factor Xa 
assays specifically relate to levels of factor Xa and the affect this has on coagulation 
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(Webb, Mythen, Jacobson, & Mackie, 1995). The anticoagulant effect of heparin is 
monitored in CRRT by measuring the activated partial thromboplastin time (aPTT) 
(Schetz, 2001). The normal aPTT varies between different laboratories and can range 
from 25 to 38 seconds (Hillman & Ault, 2002).      
Circuit priming with heparin added to 0.9% saline is used in many centres 
(Davenport, 2004a). It is theorised the negatively charged heparin molecule adheres to 
the plastic of the circuit tubing. The priming solution has been reported to vary from 
5,000 to 20,000 International Units (IU) of heparin added into 1 to 2L of 0.9% saline 
(Abramson & Niles, 1999). In one randomised cross-over study no reduction was 
observed in the thrombogenicity of the extracorporeal circuit when primed with a 
solution of 0.9% saline containing heparin at a concentration of 2,000IU per L or 
10,000IU per L compared to circuits which had no heparin added to the saline solution 
(Opatrny et al., 2002). A systemic loading dose of 5,000IU is administered by some 
centres before the initiation of CRRT to optimise the anticoagulatory effect of heparin 
when blood is first exposed to the extracorporeal circuit (Schetz, 2001). This is followed 
by a continuous infusion of heparin delivered either through the circuit or directly into 
the body. The presence or absence of coagulation abnormalities in the critically ill 
patient will influence what dose is delivered. Bellomo and Ronco (2002a) suggest a 
dose of 8 to 10IU per kg per hr, administered into the blood line before the haemofilter, 
will result in a slight systemic prolongation of the aPTT suitable for patients who are 
considered at low-risk of bleeding (42 to 46 seconds [s]). In one randomised cross-over 
study differences in the concentration of heparin and in the delivery site before the 
haemofilter was not shown to affect circuit life (Leslie, Jacobs, & Clarke, 1996). 
Van de Wetering and associates (1996) investigated the relationship of heparin 
on haemofilter survival. Survival of the haemofilter was reported to be proportional to 
the aPTT and not to the heparin dose. Clotting of the haemofilter occurred less 
frequently when the aPTT was increased by 10s, but coincided with a 50% increase in 
the incidence of intracranial or retroperitoneal haemorrhage which required a blood 
transfusion or resulted in the death of the patient. Whilst not necessarily a predictor that 
bleeding will not occur, systemic aPTT measurements do provide a method of 
monitoring the risks associated with heparin administration. A patient arterial blood 
aPTT measurement of between 35 and 45s is practiced in many centres to prevent 
circuit clotting and minimise the risk of systemic haemorrhage (Abramson & Niles, 
1999). Whilst coagulation indices such as aPTT are useful in determining the safety of a 
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given heparin regimen, the benefit of coagulation tests in monitoring the effect of 
heparin on circuit clotting has not been proven (Baldwin, Tan, Bridge, & Bellomo, 
2000; Holt, Bierer, Glover, Plummer, & Bersten, 2002).  
Haemorrhage in up to 47% of patients has been reported when unfractionated 
heparin is used to anticoagulate the blood during CRRT even when minimal amounts 
are employed (A. A. Kaplan, Longnecker, & Folkert, 1984; van de Wetering, et al., 
1996; Ward & Mehta, 1993). However, in a retrospective study by P. Y. Martin and 
associates (1994) not all bleeding episodes reported were found to be solely attributed to 
heparin administration but caused by the patient‟s underlying condition.  
Heparin-induced thrombocytopaenia (HIT) type II is a complication which can 
also be potentially life-threatening. The syndrome occurs when exposure to heparin 
causes an immune response and the development of antibodies against the multi-
molecular complex of heparin and platelet factor 4 (PF4) (Chong, 2003). The HIT 
antibody causes excessive platelet activation and agglutination resulting in the 
formation of thrombi. The depletion of platelets also occurs simultaneously due to the 
clearance of activated and antibody-coated platelets by the reticulo-endothelial system. 
The incidence of HIT type II antibodies is reported to be higher in critically ill patients 
whose exposure to heparin is greater during CRRT than the exposure experienced by 
patients receiving long-term intermittent haemodialysis (Davenport, 2004b). 
Heparin is considered a safe anticoagulant for use during CRRT provided 
administration is protocol driven to ensure the anticoagulant effects of the agent are 
monitored to achieve a low level of systemic anticoagulation in patients who are not 
regarded as being at risk of major bleeding (Oudemans-van Straaten, et al., 2006). 
Should haemorrhage occur in patients treated with CRRT, the half-life of heparin is 
relatively short and if necessary, the effects can be quickly reversed easily by the 
administration of protamine (Davenport, 2004a). A decrease in circuit life due to 
premature clotting or evidence of excessive bleeding may be an early sign of HIT with 
the manifestation of platelet antibodies adversely affecting the critically ill patient 
(Bellomo & Ronco, 2002a). In the event of a positive antibodies result, heparin 
administration should cease and an alternative agent or strategy selected. 
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Regional Heparinisation. 
A „regional‟ heparin effect localised to the CRRT circuit can be achieved when 
protamine is administered on the return line of the extracorporeal circuit. Unfractionated 
heparin delivered pre-filter maximises the anticoagulant effect inside the haemofilter 
and along the circuit. Protamine is then administered to reverse the anticoagulant effects 
of heparin before the blood is returned to the patient (Mehta, Dobos, & Ward, 1992). To 
avoid anticoagulation of the patient‟s systemic circulation monitoring of the circuit and 
the patient‟s aPTT is essential. The approach requires a circuit aPTT which is prolonged 
and a patient aPTT which is normal (Bellomo & Ronco, 2002a). 
The use of protamine to neutralise the effect of heparin has been shown to be a 
safe procedure provided adequate monitoring is undertaken (A. A. Kaplan & Petrillo, 
1987; Morabito, et al., 2003). In a prospective cross-over study regional heparin-
protamine anticoagulation was shown to extend circuit life in comparison to the use of 
low-dose heparin but variations in circuit life were not shown to be statistically 
significant. Whilst no complications in the administration of protamine were observed, 
the study was not designed to detect differences in the incidence of bleeding (Bellomo, 
Teede, & Boyce, 1993). 
Regional heparinisation may be useful in patients at high-risk of bleeding in 
situations where early clotting over the duration of a few hours produces unsatisfactory 
circuit life when no anticoagulant is used (Morabito, et al., 2003). A rebound effect can 
occur as a result of protamine activity having a shorter half-life than heparin after the 
heparin-protamine complex is broken down by the reticuloendothelial system and 
heparin is released back into the circulation. Blood samples are required to be taken 
regularly and the delivery of protamine and heparin adjusted accordingly. The 
administration of protamine can be associated with hypotension, anaphylaxis, cardiac 
depression, leukopenia and thrombocytopenia (Carr & Silverman, 1999; Horrow, 1985). 
In view of the adverse consequences of hypotension as a side effect and the difficulty 
associated with monitoring the interaction between heparin and protaimine the use of 
regional heparinisation is considered clinically difficult to perform. 
Low-Molecular-Weight Heparins. 
Low-molecular weight heparins (LMWHs) were introduced as a possible 
replacement for unfractionated heparin in antithrombotic therapy. Compared with 
unfractionated heparin, LMWH is pharmacokinetically more predictable and 
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anticoagulant response less unreliable (Schetz, 2001). Platelet function is not affected as 
much in comparison to unfractionated heparin with the incidence of HIT type II less 
likely to occur with LMWH (Warkentin et al., 1995). Under the trade names of 
Dalteparin, Enoxaparin, Nadroparin and Fragmin, LMWHs are glycosaminoglycans 
which have a reduced chain length (Davenport, 2004a). They are extracted from the 
depolymerisation of unfractionated heparin and have molecular weight close to 5,000 
Da (Abramson & Niles, 1999). Whilst the influence of factor Xa remains unchanged, 
the reduction in the molecular weight of heparin reduces its effect on antithrombin III 
activity and the risk of systemic haemorrhage (Mehta, et al., 1992). This explains why 
when using LMWHs, reversal with protamine is only partial (Schetz, 2001).  
To anticoagulate the extracorporeal circuit the dose required in CRRT is 
different according to the type of LMWH used. The half-life of different LMWHs also 
vary but all have a half-life which is approximately twice that of standard heparin 
(Davenport, 2004a). Since raised antithrombin activity is not affected by the inhibition 
of factor Xa, the measurement of aPTT values to determine the degree of 
anticoagulation activity is not as useful a test as it is when standard heparin is used. In 
order to regulate the degree of factor Xa inhibition, assays to monitor factor Xa activity 
not normally requested as part of routine coagulation blood tests should be included in 
the coagulation profile. An anti-factor Xa level of 0.25U per ml adequately 
anticoagulants the circuit whilst levels of anti-factor Xa between 0.45 and 0.8U per ml 
have been associated with bleeding complications (Jeffrey, Khan, Douglas, Will, & 
Davison, 1993). 
Low-molecular-weight heparins have been shown to be just as effective but not 
superior to standard heparin in prolonging circuit life (Shulman, et al., 2002). Biological 
activity is different and effects not necessarily interchangeable with different types of 
LMWHs. In a double-blind, randomised, cross-over study, Nadroparin and Dalteparin 
were shown to be bioequivalent with respect to anti-factor Xa activity. No difference 
was recorded in circuit longevity during CVVH with no relationship shown between 
anti-Xa activity and circuit survival time (de Pont, Oudemans-vanStraaten, Roozendaal, 
& Zandstra, 2000). No difference in circuit life and bleeding complications were 
reported when fixed-dose Dalteparin was compared with adjusted dose unfractionated 
heparin. However, anticoagulation of the circuit with Dalteparin proved to be more 
expensive than circuit anticoagulation with standard heparin (Reeves, Cumming, 
Gallagher, O'Brien, & Santamaria, 1999). In a small randomised control study the use of 
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Enoxaparin extended circuit life and correlated with anti-factor Xa activity making 
comparisons in treatment costs comparable with standard heparin which had a shorter 
circuit life and a higher incidence of bleeding (Joannidis et al., 2004). Unless superior 
circuit life without major bleeding is able to be achieved to reduce cost associated with 
LMWHs and the requirement for anti-Xa assays there is no significant advantage to 
support its use. 
Heparinoids. 
Low-molecular weight heparinoids such as Danaparoid are a group of synthetic 
glycosaminoglycurons which have a low-grade sulfation when compared with 
molecular modified heparin that reduces the incidence of platelet cross-reactivity with 
heparin-induced antibodies (Vun, Evans, & Chong, 1996). It is recommended a bolus 
dose of between 750 and 2,500U of Danaparoid is administered at the start of CRRT. 
This is followed by a maintenance dose of 2 to 4U per kg per hr which is adjusted to 
achieve an anti-factor Xa level of between 0.4 and 0.6U per ml (Wester, 2004). In a 
small observational study Danaparoid was successfully used to anticoagulate the CRRT 
circuit in patients suspected of, or had developed HIT (Lindhoff-Last, Betz, & 
Bauersachs, 2001). The anticoagulant agent has a comparatively long-half-life which is 
lengthened even further in renal failure. This can potentially cause problems of over 
anticoagulation when large infusion doses are used and there is not careful monitoring 
of both anti-factor Xa and aPTT (Davenport, 1998). There is no simple antidote to 
Danaparoid should bleeding occur other than supportive measures such as the 
administration of fresh frozen plasma (Davenport, 2004a). 
Regional Citrate. 
Citrate prevents coagulation by the chelation in whole blood of ionised calcium 
(Schetz, 2001). An ionic bond is formed between citrate and calcium which reduces the 
amount of ionised calcium available for blood to clot normally. The depletion of ionised 
calcium interrupts activation of the clotting cascade and prevention of platelet 
aggregation (Davenport & Tolwani, 2009). It is routinely used to prevent coagulation in 
blood sample specimen tubes and in blood transfusion bags. Experience in the use of 
trisodium citrate to anticoagulate the CRRT circuit was reported to be limited 10 years 
ago following a practice survey of Australian ICUs (Silvester, et al., 2001). The 
development of protocols to address concerns regarding its application and the 
availability of suitable „ready-made‟ replacement fluid and dialysate solution has more 
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recently seen an upsurge of interest in the use of citrate (Davies, Morgan, & Leslie, 
2008; Fealy, Baldwin, Johnstone, Egi, & Bellomo, 2007). 
Regional citrate anticoagulation involves the infusion of citrate ions into the 
extracorporeal circuit. On entry into the circuit ionised calcium within normal blood 
combines with citrate to form calcium-citrate complexes of non-ionised calcium. As 
blood travels along the circuit, the level of ionised calcium is reduced as the level of 
non-ionised calcium is elevated and prevents the coagulation of blood (Abramson & 
Niles, 1999). Systemic anticoagulation is avoided in three ways by limiting the effects 
of citrate to the extracorporeal circuit but allowing the restoration of normal serum 
ionised calcium levels. Firstly, the citrate molecule is small and able to pass through the 
membrane easily by diffusion or convection before blood is returned to the patient 
(Morgera et al., 2004). Secondly, the effect of citrate is able to be neutralised by the 
administration of calcium as a separate infusion to ensure a normal serum ionised 
calcium level is maintained (Davenport, 1998). Thirdly, citrate present in the return line 
is diluted by the total blood volume when it re-enters the body and is rapidly 
metabolised by the liver. Calcium released from the calcium-citrate complexes is no 
longer non-ionised and therefore contributes to the normalisation of systemic ionised 
calcium levels (Abramson & Niles, 1999).  
A variety of methods are described in the literature which use different 
approaches in the way regional citrate is administered and how the effects on 
metabolism are monitored with many of these techniques attempting to simplify the 
procedure and reduce metabolic derangements (Bagshaw, Laupland, Boiteau, & 
Godinez-Luna, 2005; Cointault et al., 2004; Hofmann, Maloney, Ward, & Becker, 2002; 
Kutsogiannis, Gibney, Stollery, & Gao, 2005; Kutsogiannis, Mayers, Chin, & Gibney, 
2000; Mehta, Mc Donald, Aguilar, & Ward, 1990; Mitchell et al., 2003; Monchi et al., 
2004; Naka et al., 2005; Palsson & Niles, 1999; Tolwani, Campbell, Schenk, Allon, & 
Warnock, 2001). Tolwani and associates (2006) have reported on a simple technique 
applied to CVVHDf. As shown in Figure 2.10 this method uses a replacement fluid 
which contains citrate and a „calcium-free‟ bicarbonate-buffered dialysate solution. The 
replacement fluid containing the citrate is delivered pre-filter with a solution of calcium 
gluconate attached to the patient through a separate central line. As blood travels along 
and mixes with citrate in the circuit, blood taken from the post-filter sample port allows 
the anticoagulant effect to be monitored. An arterial blood sample taken from the patient 
enables the effect of citrate on serum ionised calcium levels to be monitored when blood 
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is returned to the patient. According to the results from post-filter and patient arterial 
blood samples adjustments can be made to the delivery rate of the replacement fluid 
containing the citrate and in the calcium-free bicarbonate-buffered dialysate solution. 
The blood pump speed and the delivery rate of calcium gluconate infusion can also be 
adjusted in order to maintain a normal serum ionised calcium level of 0.9-1.3mmol per 
L and avoid metabolic alterations in the patient‟s blood pH. 
 
 
Figure 2.10. Regional citrate anticoagulation for continuous veno-venous 
haemodiafiltration. 
 
The use of regional citrate to anticoagulate the CRRT circuit has been reported 
to be associated with a reduced incidence of bleeding and a safer option to heparin in 
patients at high risk of bleeding or as a suitable alternative in patients with, or a history 
of, HIT (Mehta, et al., 1990; Palsson & Niles, 1999). Superior circuit life has also been 
observed by Monchi and associates (2004) in a RCT when regional citrate was used to 
anticoagulate the circuit and a comparison of circuit life made with circuits 
anticoagulated with heparin. The authors recorded circuit life of between 44hr and 
140hr with a median circuit life of 70hr for circuits‟ anticoagulated with citrate, 
compared to circuit life of between 17 hr and 48 hr with a median circuit life of 40hr 
when heparin was used to anticoagulate the circuit. A comparison of regional citrate 
versus regional heparinisation found no statistical difference in circuit life when the 
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effect of these agents was assessed using a randomised controlled crossover design, but 
the small sample size may have restricted the ability of the study to detect significant 
variations in circuit life between the two anticoagulation strategies (Fealy, et al., 2007).  
A number of metabolic complications can occur when using regional citrate to 
anticoagulate the CRRT circuit (Kutsogiannis, et al., 2005; Mehta, et al., 1990; 
Morgera, et al., 2004). Whilst these disturbances required intervention to correct the 
derangement none were reported to be of a life-threatening nature. The citrate ion is 
usually administered in the form of a hypertonic trisodium citrate solution. This 
compound as well as delivering citrate may also elevate serum sodium levels when in a 
concentrated form and, if remained unchecked, can result in hypernatremia (Davenport, 
2004a). Each citrate ion produces three bicarbonate ions which, when metabolised by 
the liver may act as a buffer against metabolic acidosis or replace bicarbonate lost in the 
ultrafiltrate, but can cause a transient metabolic alkalosis to develop (Abramson & 
Niles, 1999). If metabolism by the liver is slow and clearance through the haemofilter is 
insufficient, citrate can accumulate in the systemic circulation leading to the 
development of a metabolic acidosis. As a consequence of citrate accumulation total 
calcium serum levels may become elevated and mask a drop in ionised calcium levels 
(Abramson & Niles, 1999). If levels are not supplemented hypocalcemia may occur and 
normal systemic coagulation is affected. The presence of significant liver impairment 
will limit the metabolism of citrate and makes citrate unsuitable in patients with acute 
liver failure (Davenport & Tolwani, 2009). 
The use of citrate restricted to the CRRT circuit is an effective anticoagulant to 
sustain circuit life whilst the adverse consequences of patient anticoagulation are 
avoided. In choosing the option of citrate the complexity of CRRT is increased and 
requires extra training and vigilance in its application (Davenport & Tolwani, 2009). If 
solutions suitable for citrate administration are not commercially available the 
preparation of specific dialysate solutions and replacement fluids is a labour intensive 
procedure.  To enable citrate to be used safely the monitoring of blood pH and the 
detection of electrolyte imbalances is also required.  
Apprehension over increased treatment complexity and the risks of metabolic 
complications has not seen the widespread use of citrate in Australia. Studies which 
have reported longer circuit life (Kutsogiannis, et al., 2005; Monchi, et al., 2004) and 
reduced incidence of bleeding (Betjes, Oosterom, & Wetering, 2007) demonstrate 
 107 
citrate has several clinical advantages over heparin. A cost-benefit analysis between the 
use of heparin and the more expensive option of citrate has not been evaluated in any 
comparative study, but the extra cost incurred using specific dialysate solutions and 
replacement fluids might be offset by a decrease in the quantity of circuits used and the 
number of blood transfusions required. The use of simpler protocols and increased 
availability of suitable commercial solutions may see the use of citrate achieve a wider 
acceptance and challenge heparin as the preferred anticoagulant for CRRT in patients at 
low-risk of bleeding. 
Platelet-Inhibiting Agents. 
Prostacyclin (PGI2) and its synthetic derivative Epoprostenol prevent platelet 
aggregation and adhesion by inhibiting the formation of fibrin, leukocyte and platelet-
based microaggregates (Shulman, et al., 2002). The anticoagulant properties of PGI2 do 
not affect the intrinsic clotting pathway and can be used to augment the effects of 
heparin (Scheeren & Radermacher, 1997). Prostacyclin is initially administered 
systemically through a central line starting at 0.5ng per kg per min. The dose is 
gradually increased to a maximum rate of 5ng per kg per min (Davenport, 1998). On 
commencement of CRRT the PGI2 infusion is then administered through the 
extracorporeal circuit. Prostacyclin is added to the CRRT circuit just as the blood exits 
the outflow lumen of the venous catheter. This is to maximise the time PGI2 mixes with 
the blood for platelet deactivation to occur along the extracorporeal circuit (Shulman, et 
al., 2002). 
Prostacyclin as an alternative or in combination with heparin has been shown to 
be an effective anticoagulation strategy for maintaining the life of the circuit in CRRT 
(Canaud et al., 1988; Davenport, Will, & Davison, 1994; Fiaccadori et al., 2002; 
Langenecker et al., 1994; R. Ponikvar, Kandus, Buturovic, & Kveder, 1991). 
Langenecker and associates (1994) compared the efficacy and safety of PGI2 against 
heparin and the effect when both were used together in a prospective, randomised, 
controlled trial. No major bleeding complications were reported in either group but 
differences in haemodynamic instability, circuit longevity and solute removal were 
observed. As the sole antithrombotic agent, the authors observed PGI2 was associated 
with increased haemodynamic instability when compared to heparin or heparin 
combined with PGI2. After comparisons were made with the use of PGI2 on its own or 
in combination with heparin, circuit life was extended when compared with circuits‟ 
anticoagulated with only heparin. A reduction in the incidence of bleeding as well as an 
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extended circuit life was also observed during a comparative study of PGI2 versus 
heparin in patients with acute renal and hepatic failure (Davenport, et al., 1994). 
A test dose of PGI2 is usually given directly to the patient during the preparation 
for CRRT as a precautionary measure before a maintenance dose is delivered through 
the circuit. The response to PGI2 can vary among patients with reports of vasodilatory 
effects causing hypotension and pulmonary shunting leading to hypoxaemia 
(Davenport, Will, & Davison, 1990a). Prostacyclin has a short half-life of only minutes 
with the unwanted vasodilatory effect rapidly reversed when the infusion is stopped, but 
the inhibition of platelet activation can remain for several hours (Tolwani & Wille, 
2009). Should major bleeding occur unexpectedly the antiaggregating effect of PGI2 
may need to be reversed with the administration of fresh platelets. The cost of a PGI2 
infusion over 24 hours is more expensive than standard heparin (Davenport, 2004a) and 
the cost of a circuit change (Bellomo & Ronco, 2002a; Schetz, 2001). In view of 
possible hypotension increasing vassopressor requirements and the extra cost incurred 
when compared with other anticoagulants the use of PGI2 has been reserved for specific 
clinical situations. The addition of PGI2 combined with heparin may be useful in 
extending circuit life when continuity of treatment has been affected by premature 
clotting (Kozek-Langenecker et al., 1998; Langenecker, et al., 1994). It should also be 
considered instead of heparin for patients at risk of bleeding (Davenport, et al., 1994; R. 
Ponikvar, et al., 1991). 
Thrombin Antagonists. 
Recombinant (r) hirudin is a thrombin inhibitor independent of cofactors and not 
inactivated by PF4 which acts on bound and unbound thrombin of specific clinical value 
in patients diagnosed with HIT type II (Greinacher et al., 1999). Administration of r-
hirudin in CRRT can either be by continuous infusion or delivered in the form of 
regular bolus doses (Fischer, van de Loo, & Bohler, 1999; Kern, Ziemer, & Kox, 1999). 
The effect on coagulation is able to be measured by recording the patient‟s aPTT. 
However, a linear relationship between r-hirudin and its anticoagulant effect is only 
sensitive when the plasma concentration of r-hirudin is low (Nurmohamed et al., 1994). 
A more sensitive measurement is the Ecarin Clotting Time (ECT) which uses the 
prothrombin-activating enzyme ecarin to monitor the concentration of r-hirudin plasma 
levels (Potzsch et al., 1997). 
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Several authors have reported using r-hirudin successfully in critically ill 
patients diagnosed with or suspected of having developed HIT type II as an alternative 
agent to anticoagulate the circuit during CRRT (Fischer, et al., 1999; Hein et al., 2001; 
Kern, et al., 1999). Fischer and associates (1999) studied the use of r-hirudin to maintain 
circuit patency during CRRT on a number of medical patients suspected of having HIT 
type II. The authors reported a continuous infusion of r-hirudin 0.006 to 0.025mg per kg 
per hr, or regular bolus doses of 0.007 and 0.04mg per kg, was not associated with 
obvious bleeding or an increase in blood transfusion requirements. Kern and associates 
(1999) reported several episodes of major bleeding which were life-threatening in 
patients diagnosed with HIT type II, who required CRRT following cardiac surgery, 
having received r-hirudin at 0.01mg per kg per hr as a continuous infusion. The 
increased risk of haemorrhage being greater in surgical patients than in medical patients 
may explain why bleeding occurred in this study when r-hirudin was administered 
continuously. Hein and associates (2001) compared the use of continuous r-hirudin with 
continuous heparin administration using ECT assays to monitor the anticoagulatory 
effect of r-hirudin targeting an ECT of between 80s and 100s. The authors demonstrated 
the use of r-hirudin in CRRT to be just as effective as heparin in anticoagulating the 
circuit with no statistical significant difference in circuit life reported. Although 
bleeding complications causing a drop in the patient‟s haemoglobin was associated with 
r-hirudin administration compared with no bleeding in patients who received heparin, 
severe coagulation disorders was suggested as the cause of bleeding rather than r-
hirudin accumulation. In a similar study no bleeding complications were observed when 
r-hirudin was administered intermittently as a 0.002mg per kg bolus dose and a target 
ECT of less than 80s maintained. A decrease in circuit life was observed when 
compared to circuits anticoagulated with continuous heparin but was not shown to be 
statistically significant (Hein et al., 2004). 
Specific ECT assays are required which may not be generally available to 
monitor the anticoagulatory effect of r-hirudin accurately for exact dose adjustment 
(Nowak & Bucha, 1996). The effect of r-hirudin has also the potential to accumulate in 
the presence of renal failure as it is almost exclusively eliminated by the kidney. The 
half-life of r-hirudin is normally one to two hours but is considerably prolonged in 
patients with renal insufficiency (Fischer, 2002). The molecular weight of r-hirudin is 
6980Da with only negligible removal of the molecule by diffusion (Schetz, 2001) and 
transfer by convection according to the sieving coefficient of the membrane (Frank, 
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Farber, Lanzmich, Floege, & Kierdorf, 2002). These factors can cause the concentration 
of r-hirudin plasma levels to become elevated and the risk of bleeding considerably 
increased. Should bleeding occur no specific antidote is available (Davenport, 2004a). 
No Anticoagulation. 
Anticoagulation may need to be withheld during CRRT for it to operate safely in 
patients at risk of bleeding due to a severe coagulopathy or recent haemorrhage. 
Bellomo and Ronco (2002a) suggest no anticoagulation should be used in patients who 
have a platelet count of < 50,000, an International Normalised Ratio (INR) > 2.0, an 
aPTT > 60s or who are actively bleeding or have had a haemorrhagic event in the 
previous 24hr. 
In a prospective observational study of patients at high-risk of bleeding CRRT 
was shown to operate without anticoagulation and achieve similar circuit life, when a 
comparison of circuit life was made of circuits anticoagulated with low-dose heparin or 
regional heparin-protamine anticoagulation (Uchino, Fealy, et al., 2004). The mean 
circuit life among patients who received CRRT without anticoagulation was 19.3 hr 
compared to a mean circuit life of 20.9 hr and 21.2 hr using low-dose heparin or 
regional heparinisation.  
The use of saline flushes to promote circuit life should be considered when 
CRRT is performed without circuit anticoagulation. Using this strategy relies on regular 
flushing with isotonic saline through the circuit to remove procoagulant substances. In a 
prospective comparative study the no anticoagulation group of patients had a baseline 
aPTT > 55s and received saline flushes (100 to 150ml) every 30 min (Nagarik, Soni, 
Adikey, & Raman, 2010). The authors observed patients who were anticoagulated 
following a normal coagulation profile reached a similar circuit life as the no 
anticoagulation group of patients who had received saline flushes through the circuit 
(anticoagulation group 26hr SD+6.4 versus no anticoagulation group 24.5hr SD+6.36, 
P-value = NS). Based on these findings saline flushes was an effective strategy for 
promoting circuit life in patients who were at risk of bleeding when the use of 
anticoagulants was contraindicated.    
Under the trade name of Xigris recombinant human activated protein C (rhAPC) 
or Drotrecogin alfa (activated), is a potent thrombin antagonist which has been shown to 
reduce patient mortality in severe sepsis (Bernard, et al., 2001). The development of 
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septic shock is often associated with AKI and the requirement for renal support included 
as part of the recovery process (Uchino, et al., 2005). Activated protein C inhibits the 
generation of thrombin and modulates coagulation and inflammatory reactions which 
can serve a dual purpose for the prevention of blood clots in the extracorporeal circuit. 
As a result the use of other anticoagulants to sustain circuit life during CRRT may not 
be necessary for patients with sepsis who require rhAPC (Abbenbroek et al., 2004; de 
Pont et al., 2003). 
Anticoagulation-free CRRT is an option which should be considered in patients 
who have a co-existing coagulopathy or in patients who have had recent trauma or 
surgical wounds. The duration of circuit life without anticoagulation will be improved 
when there is good vascular access, adequate blood flow is maintained, and replacement 
of fluid is delivered before the haemofilter (Tan, Baldwin, & Bellomo, 2000).  
A summary of the agents and strategies which are used in Australia to 
anticoagulate the CRRT circuit are presented in Table 2.6. 
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Table 2.6:  
A summary of the mode of action and major advantages and disadvantages of anticoagulants used in Australia to anticoagulate the CRRT circuit 
 
Anticoagulant Mode of Action Advantages Disadvantages 
Unfractionated heparin. Effect is primary exerted on 
antithrombin III to block the action 
of thrombin and factor Xa. 
Widely available and relatively 
inexperience. Clinicians are 
familiar with dosing and monitoring 
considerations. Short-half-life. 
Effects quickly reversed with 
protamine.  
Considerable variability in dosing 
occurs between patients. Allergic 
reaction: HIT type II. Increased risk 
of systemic haemorrhage.  
Regional heparinisation 
(unfractionated heparin-protamine). 
Maximises the effect of heparin on 
blood inside the haemofilter and 
along the circuit. 
Anticoagulant effects of heparin 
restricted to the extracorporeal 
circuit, reduces the risk of systemic 
patient bleeding. 
Protamine administered 
systemically to reverse the effects 
of heparin may cause hypotension. 
Low-molecular weight heparins 
(LMWHs) and heparinoids 
(Danaparoid). 
Inhibits the action of factor Xa 
whilst the effect on antithrombin III 
is reduced. 
Anticoagulant response more 
reliable and predictable than 
heparin. Reduced risk of systemic 
haemorrhage. Incidence of HIT 
type II less likely to occur. Reversal 
with protamine is only partial. 
Special coagulation assays are 
required to monitor factor Xa 
activity. The effects and half-life of 
LMWHs vary depending on the 
type used. More expensive than 
standard heparin.  
Regional citrate (citrate-calcium). Interrupts activation of the clotting 
cascade and platelet aggregation by 
the chelating of ionised calcium. 
Avoids systemic anticoagulation. 
The risk of HIT type II is avoided. 
Labour intensive procedure. 
Hospital pharmacies can incur 
additional costs associated with the 
preparation of solutions if trisodium 
citrate and modified 
dialysate/replacement fluids are not 
commercially available. 
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Table 2.6(Cont‟d):  
 
Anticoagulant Mode of Action Advantages Disadvantages 
   Requires careful monitoring of 
blood pH and electrolyte balance. 
Potential for metabolic alkalosis, 
hypernatraemia and ionised 
hypocalcaemia due to citrate 
toxicity. Contraindicated in patients 
with liver insufficiency. 
Platelet-inhibiting agents 
(Prostacyclin). 
Prevents platelet aggregation and 
adhesion by inhibiting the 
formation of fibrin, leukocyte and 
platelet-based microaggregates. 
Can be used to augment the effects 
of heparin. 
Unwanted vasodilatory effects 
causing hypotension. Expensive. 
Thrombin antagonists (recombinant 
hirudin). 
Acts on bound and unbound 
thrombin independent of cofactors 
and PF4. 
Can be used in patients with or 
suspected of having developed HIT 
type II. 
Clinical experience limited. Half-
life is considerably prolonged in 
patients with renal insufficiency. 
No anticoagulation.  Reduces the risk of haemorrhage in 
patients who have a co-existing 
coagulopathy, liver failure, recent 
trauma or surgical wounds. 
Early clotting of the circuit may 






Replacement Fluid – administration site in the extracorporeal circuit  
The volume of plasma water lost during CRRT depends upon the treatment 
mode selected with a larger volume of fluid removed when solute clearance is 
accomplished by convection as opposed to the alternative method of diffusion (Ronco & 
Levin, 2005). To compensate for the loss of plasma water the administration of 
replacement fluid containing electrolytes is required when ultrafiltrate is produced using 
convective-based techniques. The ratio of ultrafiltrate flow (QF) to blood flow (QB) 
describes the filtration fraction arrived at during ultrafiltration and changes in the ratio 
between QB and QF will influence the extent of haemococentration which occurs as 
blood travels through the circuit (Joannidis & Oudemans-Van Straaten, 2007). Using a 
treatment dose of 35ml per kg per hr with a body weight of 80kg the amount of 
ultrafiltrate required in one hour is 2,800ml. If the flow rate is set at 200ml per min the 
volume of blood passing through the circuit will reach 15,000ml per hr (200mL x 
60min). The ratio of QF (2,800ml per hr) to QB (15,000ml per hr) achieves a filtration 
fraction of 18.6% (2800 ÷ 15000 x 100). An optimal filtration fraction which minimises 
haemoconcentration has not been defined in clinical studies, but a filtration fraction 
greater than 30% is considered to increase the likelihood of clotting within the 
haemofilter (Clark, Turk, Kraus, & Gao, 2003). Adjustment of the filtration fraction can 
also be made by monitoring the patient‟s haematocrit (HtPATIENT) (Joannidis & 
Oudemans-Van Straaten, 2007). Although several factors contribute to the viscosity of 
blood the haematocrit (Ht) value is the major determinant and many blood analysers 
will allow measurement at the bedside. The measurement obtained can be used to 
achieve a target post-haemofilter haematocrit (HtFILTER) of 0.4 and calculate the 
minimum QB required for the prescribed QF (HtFILTER = QB x HtPATIENT / [QB – QF], 
QB = QF x [HtFILTER / (HtFILTER – HtPATIENT)]). 
Pre-dilution   
   The replacement of fluid and electrolytes during CRRT can be delivered 
before the haemofilter using the pre-dilution method (Dirkes, 2000). Using the pre-
dilution method of fluid replacement ultrafiltrate volumes are not constrained by higher 
plasma water losses as the removal of plasma water is counterbalanced by the effect of 
diluting blood prior to entry into the haemofilter. The approach allows larger 
ultrafiltrate volumes to be set without increasing the filtration fraction and the extent of 
haemoconcentration inside the haemofilter (Clark, et al., 2003). Adequate volumes of 
ultrafiltrate can also be achieved in situations of reduced blood flow when the slower 
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rate would otherwise impose an excessive increase on the filtration fraction and cause 
early circuit failure from premature clotting. The dilution of blood can similarly be 
useful as a way to reduce the level of anticoagulation required to sustain circuit life, or 
the effect of anticoagulation and dilution used together by adding citrate to the 
replacement fluid (Baldwin, 2007). 
Post-dilution  
The alternative approach for the replacement of fluid and electrolytes lost during 
ultrafiltration is by the post-dilution method (Dirkes, 2000). Using the post-dilution 
method solute clearance is able to be optimised since the concentration of solute in 
plasma is not diluted when the replacement of fluid is delivered after the haemofilter. 
The advantage of reducing blood viscosity is forfeited using the post-dilution method 
and can negatively impact on circuit longevity after elevation of the filtration fraction 
occurs when the ultrafiltration rate is increased to improve solute clearance. A 
prospective observational study undertaken by Uchino and associates (2003b) recorded 
circuit life when 33 patients who required CVVH received the pre-dilution method of 
fluid replacement. After practice had changed at the study site to the post-dilution 
method a comparison of circuit life was made with 15 patients who had received the 
alternative method of fluid replacement. The authors observed the pre-dilution of blood 
before the haemofilter delayed clotting and improved the duration of circuit life 
compared with post-dilution of blood after the haemofilter (median circuit life: 18hr 
versus 13hr, P-value = 0.021). A similar observation was made by van der Voort and 
colleagues (2005) when 16 patients received CVVH using the alternative method of 
fluid replacement during a randomised crossover study (median circuit life: 45.7hr 
versus 16.1hr, P-value = 0.005). Although both of the studies demonstrated superior 
circuit life using the pre-dilution method of fluid replacement the approach was 
associated with inconclusive observations regarding whether the method caused a 
reduction in solute clearance. The median creatinine clearance achieved by van der 
Voort and associates (2005) was significantly higher using the post-dilution method 
(45ml/min) than observed with pre-dilution fluid replacement delivery (33ml/min, P-
value = 0.001). A reduction in the daily SCr value was in contrast not observed by 
Uchino and associates (2003b) to have changed significantly during the interval patients 
received replacement fluid using the post-dilution method (7.9% versus 10.2% per day, 
P-value = 0.99). As a strategy to reduce blood viscosity and promote circuit life, 
preference should be given to the replacement of fluid and electrolytes using the pre-
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dilution method. Despite the improved solute clearance associated with post-dilution, 
the ultrafiltration volumes required using the pre-dilution method can be increased as a 
compensatory measure. The possibility of increased circuit life will in turn improve the 
ability to deliver the desired treatment dose within a 24-hour period.  
Theoretical and Operational Training 
A comprehensive training programme is required to ensure nursing staff receive 
adequate instruction on the theoretical and operational aspects of CRRT (Baldwin, 
2007). The degree of effectiveness in treatment delivery and duration of circuit life can 
be influenced by staff that are not sufficiently trained or experienced in the application 
of the technique. Out of the 34 hospitals who responded to a survey undertaken in 
Canada, 31 (91%) indicated the existence of a dedicated training program for ICU 
nurses in the management of patients requiring CRRT (Langford, Slivar, Tucker, & 
Bourbonnais, 2008). In the development of a training programme several approaches 
are recommended by Baldwin (2007). Lectures presentations or self-directed learning 
packages are useful strategies to explain the basic concepts of CRRT with extra reading 
material supplied for future reference. The expertise required to operate CRRT 
successfully can be acquired by hands-on training and supervision using equipment at 
the bedside. It is also important that nurses at the bedside have access to evidence-based 
protocols and practice guidelines which are consistent with recommendations made in 
the literature. Once a training programme has been established regular assessment of 
clinical standards assist in maintaining expertise and help identify areas of practice 
where improvements can be made (Richardson, Reynolds, & Rodgers, 2006). The 
regular auditing of nursing staff to ensure competency in the use of CRRT should also 
include the recording of circuit life (Baldwin, 2007). This has been made easier 
following the introduction of CRRT machines which allow the critical care nurse to 
monitor circuit pressures continuously and to observe signs of deterioration in circuit 
function.  
Monitoring Circuit Pressures. 
The monitoring of extracorporeal circuit pressures can assist with the early 
detection of blood clots and can serve as a useful indicator of imminent circuit failure. 
The resistance to blood flow along the extracorporeal circuit increases over time when 
the veno-venous pump speed is held constant. A drop in pressure between the top and 
bottom of the haemofilter was shown by Holt and associates (1996) to be predictive in 
filter clotting when pre-filter (P-IN) and post-filter (P-Venous) circuit pressures were 
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monitored. The increasing difference in pressure as blood enters and leaves the 
haemofilter is caused by increased resistance as the result of microclotting in the hollow 
fibres of the haemofilter. New purpose-built CRRT machines have circuit pressure pods 
and computer software which allows the operator to monitor the pressure drop and other 
pressure changes that occur during the life of the extracorporeal circuit. The trans-
membrane pressure (TMP) is a derived pressure calculated from the difference in 
pressure exerted along the membrane between the blood and fluid compartments within 
the haemofilter. A gradual rise in TMP indicates the pores along the membrane are 
clogging-up with blood clots and increases in pressure required for plasma water and 
solutes to move across the membrane (P-UF). The monitoring of access pressure 
measures the degree of difficulty in establishing a negative force sufficient to achieve 
adequate blood flow from the patient access catheter and return pressure, a positive 
force which increases due to the accumulation of blood clots along the return line of the 
circuit. Observations made by Ejaz and associates (2007) showed distinct patterns in 
circuit pressure emerged and could be linked to different parts of the circuit or events 
during the life of the circuit which were susceptible to changes in blood flow or clotting. 
Circuit Design 
The design of the CRRT circuit has since its inception moved away from 
circuitry which allowed blood to pass through the haemofilter under the influence of 
arterial blood pressure, to a technique that uses a roller pump to control the flow of 
blood through a double lumen venous catheter. Differences in the design of the veno-
venous circuit to accommodate the roller pump and the requirement for a venous bubble 
trap to remove air pockets from blood lines have been associated with a reduction in 
circuit life compared to non-pumped techniques (Davenport, 1998; Schetz, 2001). 
Despite the suggestion of a reduction in circuit longevity, the pumped veno-venous 
technique provided superior solute clearance (Macias, Mueller, Scarim, Robinson, & 
Rudy, 1991; Storck, et al., 1991) and did not require arterial cannulation (Bellomo, 
1996), prompting the widespread adoption of this technique in Australia (Silvester, et 
al., 2001) and Europe (Liano, et al., 1998; Wright, et al., 2003). As shown in Figure 
2.11 the key areas of the veno-venous circuit which activate the coagulation pathway 
and lead to the development of blood clots are the roller-pump, the haemofilter and the 





Figure 2.11. Key areas of the veno-venous circuit which activate the coagulation 
pathway and lead to the development of blood clots. 
 
Roller Pump 
The CRRT machine uses a motorised roller-pump to draw blood from the 
vascular access catheter through the circuit according to the speed regulated by the 
operator (Baldwin & Bellomo, 2004). The action of the pump causes compression of the 
circuit surrounding the roller head and during rotation blood is „squeezed‟ through the 
tubing. A pattern of peristaltic blood flow occurs at this segment of the circuit and the 
turbulence which is thought to cause platelet activation, the release of clotting factors 
and damage to red blood cells (Davenport, 1997).   
Haemofilter. 
On entry into the haemofilter blood is directed through numerous hollow fibres 
which make up the blood compartment of the haemofilter. Spaces between the fibres 
make up the fluid compartment of the haemofilter which allows the movement of 
plasma water and solutes out of the blood compartment to be transported across the 
membrane of each hollow fibre. As blood travels along the hollow fibres, the surface 
area of the membrane attracts plasma proteins and causes activation of the coagulation 
pathway, leading to the formation of blood clots (Davenport, 1997). Laminar flow 
within the haemofilter is interrupted causing the passage of blood inside each hollow 
fibre to become turbulent increasing the tendency for clotting to occur.  
The physical properties of the haemofilter play an important role in reducing the 
resistance to blood flow and as a result may improve the performance of the device. 
Differences in the way fibres are configured within the haemofilter can facilitate less 
turbulent blood flow. Haemofilters consisting of hollow fibres tolerate the higher 
pressure forces generated by the speed of blood flow through the circuit when veno-
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venous CRRT systems are used (Baldwin, Bridge, & Elderkin, 1998). The resistance to 
blood flow is theoretically reduced when the design of the haemofilter allows the 
number of fibres to be increased, the length of each fibre is made short, and the inner 
diameter of the haemofilter has a large cross-sectional area (Jenkins, 1998). This 
approach for reducing the resistance to blood flow and the pressure drop as blood enters 
and leaves the haemofilter was not supported in a prospective randomised cross-over 
study. Using two polysulfone haemofilters investigators evaluated the operational 
characteristics of each device during CVVH according to differences in length and 
number of fibres (Dungen, von Heymann, Ronco, Kox, & Spies, 2001). The authors 
found the haemofilter composed of longer hollow fibres recorded lower TMP 
measurements and extended circuit life which was significantly different when the same 
measurements were taken using the shorter length haemofilter with a wider cross-
section of fibres (TMP 106mmHg versus 194mmHg, P-value = 0.02 and circuit life 
1276min versus 851min, P-value = 0.04). Although the increased number of fibres may 
have decreased the pressure drop within the haemofilter, Dungen and associates (2001) 
suggest the impact of a slower blood flow due to a wider cross-section of fibres may 
have increased blood viscosity and caused greater resistance to blood flow. The authors 
only investigated differences in length and number of fibres with the surface area for 
solute clearance remaining the same between each of the haemofilters studied. A larger 
surface area could in theory improve the performance of the haemofilter by reducing the 
rate at which pores of the membrane become clogged with trapped proteins and lessen 
the rate hollow fibres start to develop blockages due to the presence of blood clots 
(Joannidis & Oudemans-Van Straaten, 2007). In another controlled study the surface 
area of the haemofilter was allocated differently among patients who received CVVH 
after comparisons were made of circuit life according to the size of the membrane 





 was not shown by the authors to significantly hasten membrane fouling and 
clotting of the fibres which shortened the lifespan of the circuit (0.75m
2
 surface area 
mean circuit life 15.75hrs SD+14.3 versus 1.3m
2
 surface area mean circuit life 16.8hrs 
SD+13.1, P-value = 0.972).  
The haemofilter is packed with fibres constructed from materials which provide 
membrane technology among the most haemocompatible of all membranes used for 
extracorporeal RRT. Activation of the coagulation pathway is influenced by the 
interaction which occurs between the blood and membrane surface area (C. H. Jones, 
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1998). How quickly blood clots develop within the haemofilter will depend on the 
electro-negativity of the membrane, the capacity of the membrane to adsorb plasma 
proteins and the reaction of the complement system to substances present in the 
membrane. In one study polyacrylonitrile membranes were shown to have only a 
negligible effect on platelet aggregation and activation of the intrinsic coagulation 
pathway (Salmon, et al., 1997). The observations made showed no change in levels of 
contact factors when regular blood sampleling was undertaken over the lifespan of the 
circuit. Modification to existing synthetic membranes has seen the introduction of 
haemofilters where the membrane is coated with heparin designed to minimise 
activation of the coagulation pathway. Heparin-coated membranes were shown to 
require less hepain administration but achieve longer circuit life when heparin 
requirements were compared with non-heparin-coated membranes (Sieffert, Mateo, 
Deligeon, & Payen, 1997). The use of synthetic membranes can improve the overall 
haemocompatibility of the haemofilter and should always be considered as a strategy to 
promote circuit life. An extra benefit may also be gained using membranes which are 
impregnated with anticoagulation properties.   
Venous bubble or air-trap. 
The function of the venous bubble or air-trap, located after the haemofilter as 
shown in Figure 2.7, is to prevent an air-embolus from occurring should air 
inadvertently enter the extracorporeal circuit. Air is collected inside the chamber before 
blood is returned to the patient. Gretz and colleagues (1995) reported a reduction in the 
formation of blood clots when the blood-air contact in the chamber was reduced. The 
authors reduced blood-air contact by elevating the blood level inside the chamber above 
the blood inlet line so that circulating blood was not exposed to air and the appearance 
of blood sedimentation created a plasma seal. A similar affect can be achieved when a 
continuous infusion of isotonic fluid (0.9% saline) is delivered into the chamber. The 
administration of anticoagulant agents directly into the venous bubble was not shown to 
modify the effect of blood-air contact and protect the site from clotting (Baldwin, et al., 
2002). In this study the authors reported no difference in circuit life or clotting inside 
the venous chamber when the delivery of heparin was divided equally between the 
venous chamber and pre-filter infusion site, or when compared to the same dose of 
heparin after the anticoagulant was administered entirely through the pre-filter infusion 
site. 
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 Venous Access Catheter 
A common cause of circuit failure during CRRT is as a result of a lack of 
understanding on how catheter design can lead to poor blood flow and clotting 
(Bellomo & Ronco, 2002c). Vascular access for CRRT is achieved using non-cuffed, 
non-tunnelled, dual-lumen catheters to access blood flow from a central vein. During 
placement of the venous catheter, the degree of damage to the distal tip and injury to the 
surrounding tissues of the insertion site result in activation of the coagulation pathway, 
increasing the likelihood of premature clotting within the access device (Davenport, 
1997). 
The most widely used dialysis catheters for temporary vascular access are made 
from biocompatible polyurethane and silicone materials that are associated with less 
reaction and incidence of venous thrombosis when inserted into a central vein (Canaud 
et al., 1998). Whilst silicone catheters are more flexible and reduce the risk of vascular 
perforation, the added strength of semi-rigid polyurethane catheters results in easy 
insertion without cut down to the vein, a larger internal lumen that facilitates higher 
blood flows, and after exposure to body temperature softening of the catheter reduces 
tissue damage at the insertion site (Oliver, 2001).  
The internal pathway of the venous catheter should allow for laminar blood flow 
and limit turbulence. Veno-venous catheters feature a double-lumen design to direct 
blood flow through two separate parallel channels. The layout of the blood outflow and 
return lumen and configuration of the distal tip differ in several types of catheters. As 
shown during an ex-vivo laboratory study different catheters offer resistance to blood 
flow which may be variable (Tan, Bridge, Baldwin, & Bellomo, 2002). The difference 
relates to the shape of the lumen, commonly cylindrical and side by side, or in a non-
cylindrical „D‟ shape. Data extrapolated from patients receiving IHD found superior 
blood flow occurred in catheters comprising of two round cylindrical internal lumina 
when compared with catheters which had a shared common middle wall. The inferior 
blood flow was observed despite the D-shaped lumina catheters occupying a larger 
internal diameter (Atherikul, Schwab, & Conlon, 1998).  
The outflow lumen of catheters with side holes may cause the area adjacent to 
the tip to lie against the blood vessel wall, particularly when higher blood flow rates 
generate significant negative pressure at the inflow ports; this can result in a reduction 
in blood flow (Chrysochoou, Marcus, Sureshkumar, McGill, & Carlin, 2008). 
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Disconnecting the outflow and inflow blood lines from the double lumen catheter and 
switching them over may improve blood flow if resistance to aspiration on the inflow 
lumen is less compared with when blood is drawn from the outflow lumen. Similarly, 
rotating the catheter through the skin at the insertion site can realign the side holes of 
the distal tip in order to establish sufficient blood flow.  
Vascular Insertion Site 
A number of factors influence the selection of the vascular access catheter 
insertion site. The femoral vein site is selected when respiratory conditions may 
preclude intrathoracic cannulation but is also useful in patients who are nursed in the 
supine position (Canaud, Desmeules, Klouche, Leray-Moragues, & Beraud, 2004). This 
site is often used for critically ill patients who are sedated and mechanically ventilated. 
As the largest easily accessible vein, the femoral site will usually deliver better blood 
flow, provided the catheter is not kinked due to hip flexion when the patient is 
repositioned (Baldwin, et al., 1998). Should it be necessary to commence CRRT 
without delay, access to the femoral vein is technically easier during the insertion of the 
catheter and may be the preferred cannulation site (Canaud, et al., 1998). The increased 
risk of infection due to the close proximity of the femoral site to the perianal and 
genitalia region of the body is sometimes suggested as a reason why other venous 
access sites are selected instead. A multi-centre RCT involving 750 patients reported the 
colonisation of the femoral catheter was not significantly different when a comparison 
was made of catheters removed from the jugular venous site (incidence of 40.8 versus 
35.7 per 1000 catheter-days; hazard ratio [HR], 0.85; 95% CI, 0.62-1.16; P-value = 
0.31). Sub group analysis did show that patients with a high body mass index had a 
significantly higher rate of colonisation in femoral lines as opposed to jugular catheters 
(50.9 versus 24.5 per 1,000 catheter-days) (Parienti et al., 2008). The ability to keep the 
area around the femoral catheter site clean is sometimes not easy to achieve particularly 
in obese patients and the prevention of insertion site contamination made more difficult 
in situations of faecal incontinence.  
Cannulation of the subclavian or internal jugular vein is considered for patients 
who are more mobile (Uldall, 1996). Both sites allow easier access for inspection 
should interruptions to blood flow occur (Baldwin, et al., 1998). Inadequate blood flow 
can result if the subclavian vein is chosen due to the curving of the catheter under the 
clavicle and the potential for the catheter tip to lie against the superior vena cava wall. 
This is less problematic if the catheter is inserted into the jugular vein from the right 
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side as the catheter has a natural tendency to lie parallel rather than against the vein 
wall, with interruptions to blood flow less likely to occur (Bellomo & Ronco, 2002c). 
Intrathoracic catheters may experience reduced blood flow if supra cardiac central 
filling pressures are low in patients receiving positive pressure ventilation, or if the 
patient is hypovolaemic and sat in an upright position (Baldwin, et al., 1998). When 
catheters are placed in the thoracic veins, coughing can also elevate intra-thoracic 
pressure and intermittently affect blood flow.    
Various catheter lengths assist in the alignment of the distal tip into the correct 
position to secure adequate blood flow, whilst the internal diameter of the catheter 
influences the degree of resistance to blood flow. Bellomo and Ronco (2002c) 
recommend the length of the catheter should be at least 20cm when the femoral vein site 
is chosen. This is to allow the tip to be positioned in the inferior vena cava where the 
greatest blood flow is located. The authors also prefer to use catheters with large 13.5 
French Gauge internal diameters designed without side holes at the distal end of the 
catheter. The position of the catheter tip using the subclavian or internal jugular access 
site is controversial with placement at the discretion of the treating intensive care 
specialist. The desire for optimal catheter performance would indicate the location of 
the catheter in the right atrium as the preferred option. The alternative approach of the 
catheter tip situated close to the atrial junction in the superior vena cava may be unable 
to maximise blood flow but the patient is not exposed to the same risks of cardiac 
perforation and tamponade, cardiac arrhythmias and increased incidence of catheter-
induced thrombosis which can occur when the tip is placed in the right atrium (Vesely, 
2003).  
Blood Flow 
A contributory factor to variations in circuit life is the rate at which blood is 
circulated through the circuit causing an increase in the tendency for the circuit to clot 
when blood flow is reduced. Whilst lower flow rates are appropriate when smaller 
diameter circuits are used, such as in paediatric patients, likelihood of the circuit 
clotting is increased when standard adult tubing is used, if blood flow is allowed to fall 
below 100ml per minute (Kox, Rohr, & Waurer, 1996). A recommendation by Baldwin 
and associates suggest the rate of blood flow for CRRT should be maintained between 
150 and 200ml per min (1998). Observations made during one study found a blood flow 
rate set above 125ml per min did not improve circuit survival time when associated with 
the practice and frequency of flushing the circuit using 0.9% saline (Prasad et al., 2000). 
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Sufficient blood flow through the circuit may not always be possible to sustain due to 
poor vascular access or as the result of haemodynamic instability encountered when the 
patient commences treatment. A study investigating the effect of stoppages or minor 
reductions in blood flow demonstrated circuit longevity was adversely affected and, 
when interruptions were severe, correlated with circuit life more strongly than the 
measurement of blood coagulation variables (Baldwin, et al., 2004). 
In reviewing the factors which affect circuit life each one can be catorgorised 
according to whether the reasons for circuit failure was driven by a physiological or 
mechanical factor. The critically ill patient is often predisposed to physiological 
abnormalities in combination with extracorporeal circulation which cause blood to clot 
prematurely. How the body responds to these changes make the longevity of circuit life 
unpredictable, but the use of exogenous anticoagulants and the replacement of fluid 
before the haemofilter can have a beneficial affect on extending treatment delivery. The 
same improvement can be achieved when mechanical factors are considered in the 
relationship with circuit longevity. Several mechanical factors have been discussed 
which demonstrate the importance of circuit design in minimising the development of 
blood clots and the level of experience required by the operator to ensure the technique 
can be deployed successfully. A summary of the physiological and mechanical factors 
affecting the longevity of circuit life is shown in Table 2.7. 
Table 2.7  
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Importance of Circuit Life 
The success of CRRT is dependent on adequate circuit life to realise the benefits 
of the technique. Instead of the three to four hours associated with conventional IHD the 
scheduling of treatment using CRRT is prescribed over 24hr. Although intended to 
operate as a „continuous‟ therapy inadequate circuit life caused by interruptions or 
delays in the delivery of CRRT can interfere with the effectiveness of the technique. In 
situations where continuity of treatment is lost during the 24hr prescription period the 
ability of the technique to remove excess fluid and achieve biochemical control is 
reduced, and the costs associated with replacing single-use components increased along 
with the extra workload required to set-up the circuit. The adequacy of circuit life and 
the impact of circuit „down-time‟ on azotemic control was investigated during a 
prospective observational study (Uchino, et al., 2003a). When interruptions occurred in 
treatment delivery the total number of hours treatment was delayed impacted upon the 
effectiveness of CVVH to stabilise and reduce concentration levels of urea and 
creatinine. Univariate analyses showed there was a significant inverse correlation 
between treatment down-time and changes to urea and creatinine levels within a 24hr 
treatment cycle (P-value < 0.0001). Based on the percentage of change in solute 
clearance observed during the study the authors suggested an ultrafiltration of 2L per hr 
required a down-time of less than eight hours per day between treatments to ensure the 
effectiveness of the technique was maintained.    
The importance of adequate circuit life has been included as a secondary if not 
the primary outcome measure in many studies since the introduction of CRRT into 
clinical practice. Attempts at making comparisons of circuit life from the literature are 
difficult when faced with historical differences in the setup of CRRT. This inherent 
disparity between old and new technologies using „pumped‟ instead of „spontaneous‟ 
circuitry is an example of the historical differences which can occur when reviewing the 
literature. Although not previously evaluated in a prospective randomised study 
differences in circuit design may have contributed to a reported reduction in circuit life 
using veno-venous pumped circuitry when compared with the longevity of spontaneous 
arterio-venous circuits. A prospective comparative study found circuit life of patients 
who received CAVHDf was significantly longer than the duration of circuits observed 
when patients were treated with CVVHDf (75.1hr versus 42.5hr; mean difference 32.6 
hr; 99% CI 13.1 to 52.1; P-value < 0.01) (Bellomo, Parkin, Love, & Boyce, 1993). The 
decrease in circuit life observed during CVVHDf may have been the result of more 
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turbulent blood flow through the circuit leading to greater activation of the coagulation 
pathway caused by the inclusion of a roller pump and the requirement for an air trap.   
The potential for extended circuit life using arterio-venous techniques has long 
since been overshadowed by the superiority in solute clearance of veno-venous 
techniques and improvements reached following advances made in circuit design 
technology. Investigations on the use of veno-venous techniques have reported large 
variations in circuit life. The duration of circuit life using CVVHD was observed in one 
study to be as short as three hours and as long as 117hr (Holt, et al., 1996). Out of the 
five patients who required 41 circuits both measurements when incorporated in the total 
number of circuits used resulted in a mean circuit life of 30hr. Among the patients the 
authors reported upon individual mean circuit life varied between 10 to 45.5hr. Other 
investigators have used the median value rather than the mean as being less sensitive to 
outliers when reporting differences in circuit life measurements. A median circuit life of 
37.8hr using CVVHDf was reported by Reeves and associates when heparinised saline 
was used to prime the extracorporeal circuit (1997). In situations where the circuit has 
operated continuously for more than 48hr and caused a decline in membrane 
performance some authors argue that the circuit should be taken down electively 
(Macias, et al., 1991; Wendon et al., 1989).  
The variability reported in the literature demonstrates circuit life is influenced by 
a combination of physiological and mechanical factors. Underlying the longevity of 
circuit life observed is the patient‟s disease and its effect on haemostasis influenced by 
the use of anticoagulant agents, expertise in the operation of equipment and design 
features of the extracorporeal circuit. The potential also exists for differences in 
convective versus diffusive transport mechanisms to influence circuit life. Diffusive 
mechanisms in solute transport have a minimal effect on plasma water removal and 
changes in blood viscosity in contrast to the plasma water that is removed when solute 
transport is by convection. As a consequence of ultrafiltration haemoconcentration 
occurs as blood enters into the filter and increases the haematocrit, platelet count and 
coagulation factors. The passage of plasma water through the membrane increases 
blood-membrane interaction causing more haemostatic activation. The effect of 
convection during intermittent haemofiltration and haemodiafiltration was shown in a 
prospective crossover study to be associated with increased procoagulatory activity 
when compared with diffusion during intermittent haemodialysis (Klingel et al., 2004). 
Using the same anticoagulation strategy for each treatment mode the authors reported a 
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significant reduction of thrombin-antithrombin III complex and D-dimer generation 
occurred in the extracorporeal circuit, when blood sampled from the venous lumen 
during haemodialysis was compared with a similar sample taken after treatment had 
changed to haemofiltration (thrombin-antithrombin III: P-value = 0.014, D-dimer: P-
value = 0.047).  
A number of studies have compared circuit life using different CRRT modes 
(Brophy et al., 2005; Ricci, Ronco, Bachetoni, et al., 2006; van de Wetering, et al., 
1996). Observations were made using either convection-based or diffusion based 
techniques. Solute removal using convection relies on hydrostatic pressure and 
relatively high blood flows to „push‟ through solutes in order to achieve similar 
clearance as diffusion which is a more passive process where solutes „pass‟ across the 
membrane due to a concentration gradient. This increases the demand on convection to 
push through more solutes when efforts are made to achieve dose equivalence with that 
achieved using diffusion. A retrospective analysis of circuit life between CAVH and 
CAVHDf observed no difference between the two treatment modes (van de Wetering, et 
al., 1996). The study compared modes which are now no longer in common use or 
recommended when veno-venous technology is available.  A prospective survey of 
children who required CRRT did not find a correlation between mode and duration of 
circuit life (Brophy, et al., 2005). The evaluation of anticoagulation practices 
undertaken by the authors, after reviewing the management of paediatric CRRT found 
circuit life was similar for CVVH, CVVHD and CVVHDf, but a meaningful 
comparison of circuit life was difficult to extrapolate due to different anticoagulation 
strategies applied to each modality. A significantly shorter circuit life was observed 
using CVVH than measured using CVVHD in a prospective comparative crossover 
study (P-value = 0.03) (Ricci, Ronco, Bachetoni, et al., 2006). The authors 
demonstrated circuits which were exposed to higher ultrafiltrate volumes associated 
with CVVH had elevated transmembrane pressure values. When this was compared 
with measurements recorded during CVVHD the lower pressures observed indicated a 
decrease in membrane interaction. The question of whether the mode of CRRT using 
CVVH versus CVVHDf affects circuit life has not been investigated using a prospective 
randomised, controlled study.  
Summary  
The debate over which RRT is the most appropriate to treat ARF in the critically 
ill patient continues to be subject of investigation. The use of CRRT is now an 
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established treatment option when attempts using conventional IHD have failed due to 
the frequency of hypotensive episodes or in patients who are haemodynamically 
unstable. Volume overload is managed more effectively using CRRT than conventional 
IHD with greater regulation of fluid balance able to improve the function of other 
organs. The gradual removal of solutes during CRRT is important when IHD is 
contraindicated in patients who have raised intracranial pressure and at risk of cerebral 
oedema if solutes are removed too quickly. The proposition that CRRT is superior to 
conventional IHD due to a number of operational advantages which are of benefit in the 
management of the critically ill patient, has not been able to demonstrate a 
corresponding improvement in patient survival and return of renal function with 
sufficient rigor to resolve the controversy surrounding which RRT to use.  
The continuous approach to renal replacement therapy in the management of the 
critically ill patient with severe ARF was initially applied using arterial blood pressure 
to drive blood flow. The use of technology was „borrowed‟ from conventional IHD and 
experience previously gained in the area of chronic renal failure adapted to suit the 
practice requirements of the technique intended to operate continuously. A move to 
veno-venous techniques using double lumen vascular access devices and the 
incorporation of motorised roller pumps in machines designed to overcome the 
shortcomings of inadequate blood pressure improved treatment efficiency but increased 
the complexity of the original technique. The importance of circuit life was soon 
realised early on in the development of CRRT. To achieve adequate replacement of 
renal function the maintenance of circuit life is of clinical importance since treatment 
dose depends upon a measure of circuit longevity. It is also an important factor in 
reducing the time spent by nursing staff in the preparation and set-up of CRRT, in the 
containment of costs associated with the usage of single-use items and to limit blood 
loss due to circuit failure. In the application of CRRT a number of measures are used to 
improve the duration of circuit life which can reduce activation of the coagulation 
cascade when blood is circulated outside the body leading to circuit failure. In most 
instances this requires some form of continuous circuit anticoagulation with 
unfractionated heparin the most widely used anticoagulant employed in Australia.  
Despite limited evidence from RCTs in support of non-anticoagulant interventions a 
number of measures have been put forward which can assist in reducing procoagulatory 
activity.  Several design features of the extracorporeal circuit can reduce the incidence 
of premature clotting whilst the establishment of sufficient blood flow and the pre-
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dilution method of fluid replacement have been successfully employed as useful 
strategies to promote circuit life. 
An important area to consider when investigating factors which affect circuit life 
remains the issue concerning the mechanism of solute removal. Studies which have 
dealt with this issue show some relationship may exist between circuit life and the type 
of CRRT chosen either as a convective or diffusive treatment modality. Should a 
specific modality demonstrate superiority in circuit survival this would provide a 
clinically significant advantage to patients on CRRT with the potential to increase the 











The development of a conceptual framework to guide the direction of the 
research project is discussed in this chapter and was used to organise various issues and 
concepts associated with circuit life in CRRT. The grouping of information in this way 
and the establishment of a conceptual view of circuit life based on the findings of the 
literature review supported the identification and origination of factors known to 
influence the longevity of the circuit. The conceptual framework also acted as a 
reference point and provided the basis to explain possible reasons for unexpected 
findings in the data observed. 
Concept Mapping and the Development of a Conceptual Framework 
The technique of concept mapping is used to visually represent the content of a 
subject and to create a conceptual framework for the process of knowledge acquisition 
(Novak & Canas, 2006). The conceptual framework is constructed from symbols used 
in the concept map which are linked together by words arranged in a hierarchical order. 
The visualisation of important elements that relate to a specific area of enquiry (in this 
case circuit life and CRRT) is a useful method to organise information and explore 
relationships which assist the researcher to gain new knowledge on the subject under 
investigation. The development of a conceptual framework on circuit life was based on 
physiological and mechanical factors identified in the literature review as either 
contributing to clotting or unexpected failure when blood flow is circulated through an 
extracorporeal circuit (Baldwin, 2007; Davenport, 1997; Davies & Leslie, 2006; 
Joannidis & Oudemans-Van Straaten, 2007; Kim, et al., 2010). Such a framework 
provided a structure to give direction in choosing a design methodology suitable to 
answer the research question and formed the basis on which to analyse and frame 
conclusions drawn from the data collected.  
The conceptual framework shown in Figure 3.1 uses an arrow heading one-way 
to represent flow of blood and the portrayal of hollow tubing an interpretation of the 
extracorporeal circuit. On the opposite side of the tubing is an arrow pointing upwards 
symbolising increased blood clotting. At the bottom of the tubing is another one-way 
arrow representing both time and exposure to factors which affect the longevity of the 
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circuit. As a consequence of circulating blood outside of the body the development of 
blood clots occur due to the activation of the coagulation pathway and is portrayed by a 
gradual increase of tone from light to dark shading. The impact of physiological and 
mechanical factors on clotting within the circuit is represented by two rectangular boxes 
placed adjacent to one another. A one-way arrow links the rectangular boxes together 
indicating the interdependency both have with each factor and on the extent of clotting 
when blood travels through the circuit. The representation of circuit tubing is 
surrounded by square boxes which symbolise independent variables colour-coded 
according to whether they are physiological or mechanical in nature and the interaction 
that occurs with the dependent variable of circuit life.   
   Interdependency between Physiological and Mechanical Factors 
The interdependency which occurs between the physiological and mechanical 
factors as already noted influences the longevity of the CRRT circuit as blood is 
required to circulate outside of the body. The development of ARF is a common 
complication of severe infection (Uchino, et al., 2007) and the successful application of 
CRRT in septic patients dependent on maintaining adequate circuit life. The 
interdependency of physiological and mechanical factors is able to be demonstrated by 
using the example of severe infection and the experience of the nurse allocated to care 
for the patient receiving CRRT.  
Increased activation of the coagulation pathway is a physiological factor which 
occurs secondary to sepsis as part of the inflammatory response (Balk, 2000). This is 
present before the commencement of CRRT and already predisposes the circuit to the 
possibility of a shorter lifespan. A similar predisposition to early circuit failure before 
treatment has begun might also occur due to mechanical factors increasing activation of 
the coagulation pathway. The accuracy of how the circuit was assembled by the nurse 
may increase blood flow turbulence during operation when connections were previously 
not put together correctly, or the solution used to prime the circuit was incomplete and 
pockets of air remained in the circuit. The degree of interdependency between 
physiological and mechanical factors continues once treatment has commenced which 
can either increase or decrease the longevity of the circuit.  
As blood travels through the circuit the physiological effects of sepsis on 
coagulation factors interact with various components of the circuit. The coagulation 
pathway is activated on contact with non-biological materials after exposure to the 
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vascular access device, during the circulation of blood by the roller-pump through 
plastic tubing, as blood enters the haemofilter and interacts with the membrane, and 
when blood comes into contact with air in the venous air-trap chamber (Davenport, 
1997). The formation of blood clots is increased with the repeated passage of blood 
along the circuit and the effects of sepsis reducing the levels of naturally occurring 
anticoagulants normally present in blood. The administration of anticoagulatory agents 
can manipulate the physiological factor of circuit thrombogenesis in the septic patient 
and delay the onset of early clotting (du Cheyron et al., 2006). The viscosity of blood 
and the tendency to clot is increased when the ratio of ultrafiltrate to blood flow is high 
and excessive haemoconcentration occurs inside the haemofilter, with the dilution of 
procoagulatory substances a physiological factor which can promote circuit life when 
replacement fluid is delivered pre-filter (Uchino, et al., 2003b).  
As the extracorporeal circuit begins to deteriorate over time with the 
development of blood clots other mechanical factors increase the physiological factors 
associated with coagulation. The position chosen for venous access combined with the 
inner diameter and pattern of blood flow created by the design features of the catheter 
will determine the extent of turbulence and coagulation which is generated as blood 
travels through the access device. The circulation of blood is driven by the action of the 
roller-pump and laminar blood flow interrupted when the action of the roller head 
causes compression of the circuit tubing. On entry the disruption of blood flow within 
the haemofilter is repeated again when the deposits of protein, the adhesion of platelets 
and the combination of red blood cells layer the membrane and obstruct blood flow. The 
passage of blood from the haemofilter enters another turbulent phase when blood travels 
to the air-trap and passes through the chamber before being returned to the patient. The 
extent of disruption in blood flow and degree of turbulence at different locations of the 
circuit is affected by the speed of the roller-pump and the degree of circuit fouling 
which has already occurred. The delay in trouble-shooting alarms by nursing staff 
inadequately trained in the operation of equipment has the potential to interrupt blood 
flow when alarms are not resolved quickly and intensify the existing physiological 
factors causing clotting blood to clot. Under these situations a slow response by the 
operator to changes in patient positioning or other events such as patient coughing 
represents a mechanical factor which can lead to the stasis of blood and excessive 
clotting causing earlier than expected termination of the circuit.  
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Longevity of the Circuit and the Conceptual Framework 
The septic patient with ARF who requires CRRT demonstrates the value the 
conceptual framework can provide as a meaningful synthesis of information to 
accommodate the known factors which affect the longevity of circuit life. The multi-
factorial causes of premature clotting have a variable influence on circuit life and the 
example provided represents an extreme set of circumstances which is not always 
present. The physiological and mechanical factors identified in the conceptual 
framework are considered separately in the context of what is already known about the 
affect each has on circuit life. Once connections have been made in the relationships 
which occur between these factors strategies directed at the promotion of circuit life can 
be explored, and the extent of influence evaluated based on established principles 

























Figure 3.1. An illustration of the Conceptual Framework. 
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CHAPTER 4 
RESEARCH DESIGN AND METHODOLOGY  
The chapter is concerned with the research design and methodology used to 
examine the research question under investigation. A standardised approach was 
adopted in the reporting of the research project and followed guidelines based on the 
consolidated standards of reporting trials (CONSORT) statement (Begg et al., 1996). 
The CONSORT statement provides a checklist on the reporting of RCTs and, in 
describing the research design and methodology, incorporates a flowchart requiring 
information on how random assignment, data management and analysis of results were 
accomplished. Using the recommendations from the revised CONSORT statement 
(Moher, Schulz, & Altman, 2001), a flowchart shown in Figure 4.1 was devised to assist 
with compiling a report which was able to articulate the research design and 
methodology used for the project and how data analysis was organised for interpretation 
of results. This approach was adopted for the purposes of improving the ability of the 
reader to make informed judgements about the reliability and relevance of the research 
project.  
Sample 
The criteria for participation in the study required patients to be 18 years of age 
or over, admitted to the study site adult ICU and ordered CRRT as determined by the 
Intensive Care Specialist on duty. Patients who were unable to receive the standard 
heparin regimen for anticoagulation of the extracorporeal circuit, such as an existing 
coagulopathy or the development of HIT or recent trauma, were excluded from 
participating in the study. Haemostatic failure prohibiting the use of the standard 
heparin regimen was based on clinical assessment by the medical officer in charge of 





Figure 4.1. Flowchart showing how the research process was followed during the 
investigation. 
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The severity of illness within the sample of study participants was measured 
using the APACHE II scoring system. The APACHE II score is calculated from the sum 
of points assigned to the acute physiology score, age-related score and a chronic health 
evaluation score with a possible maximum APACHE II score of 71 points (Knaus, 
Draper, Wagner, & Zimmerman, 1985). The use of the APACHE II scoring system was 
developed by healthcare providers as a means to predict outcomes based on the severity 
of illness observed when patients were admitted to ICU (Marik & Varon, 1999). The 
points allocated using the APACHE II scoring system incorporate variables chosen and 
weighted according to its impact on patient survival. The 12 physiological variables 
collected during the first 24hr after admission to ICU reflect the greatest deviation from 
normal and as such predict a worse outcome for the patient (Knaus, et al., 1985). 
Included in the acute physiology score are measurements of plasma sodium, potassium 
and creatinine values to identify whether derangement and loss of urinary output has 
occurred as a consequence of renal insufficiency. The reliability of the APACHE II 
score to measure illness severity and accurately predict the survival of patients with 
AFR has been the subject of investigation following the introduction of the scoring 
system. A score of more than 40 was found in one study to be a consistent predictor of 
death when the management of ARF was associated with the use of RRT (Maher et al., 
1989).  
The APACHE II scoring system can result in errors during the interpretation and 
allocation of points when lack of agreement on the definition of renal insufficiency 
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causes inconsistent scoring to describe the physiological abnormality (Goldhill & 
Sumner, 1998). The limited number of renal parameters included in the instrument also 
reduces the usefulness of the assessment tool in its ability to estimate the prognosis of 
patients with ARF. A study by Schaefer and associates (1991) found that on admission 
to ICU patients who required RRT the median APACHE II score was similar for both 
non-survivors and survivors (non-survivors median APACHE II score 24 versus 
survivors median APACHE II score 22). Despite these shortcomings the APACHE II 
scoring system has been widely adopted by investigators to assess the severity of illness 
in critically ill patients with ARF (Bagshaw, Laupland, Doig, et al., 2005; Bellomo, et 
al., 2000; Brivet, et al., 1996; Ronco, et al., 2000).  
The sample of patients recruited to participate in the study was drawn from the 
4,326 patients admitted to the ICU at Royal Perth Hospital (RPH) between 2004 and 
2006. During this period the number of patients diagnosed with ARF was 224 (5.2%). 
Out of these patients 116 (51.8%) went on to require CRRT (RPH ICU Database). As 
part of each patient‟s APACHE II score the study incorporated the ANZICS Clinical 
Trials Group definition of ARF (Bellomo, et al., 2000): 
 A urine output averaging < 0.5ml per kg per hr over 4hr or longer 
 A serum creatinine concentration > 150µmol per L in the absence of 
premorbid renal dysfunction 
 A rise in serum creatinine concentration of > 80µmol per L in less than 
24 hr in the absence of creatine kinase > 5000 IU per L or myoglobin in 
the urine 
Setting 
The research project was undertaken in the ICU at RPH, Western Australia‟s 
largest teaching hospital. The 24 bed intensive care facility is a Level 3 adult ICU and 
complies with standards set by the Joint Faculty of Intensive Care Medicine of the 
Royal Australasian College of Physicians and the Australian and New Zealand College 
of Anaesthetists (2003). The standards define a Level 3 adult ICU as a designated area 
within the hospital which is capable of providing complex multi-organ life support and 
has access to a full range of clinical and laboratory services. In accordance with these 
standards a number of Intensive Care Specialists are employed who supervise Senior 
Registrars undertaking training in Intensive Care Medicine supported by Junior 
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Registrars and Residents of whom many are on rotation from other medical disciplines. 
The standards also require only Registered Nurses to be responsible for patient care, and 
over 50% to have a post registration qualification in intensive care nursing.  
The ICU at RPH serves as a State referral centre for the management of the 
critically ill patient with approximately 1,600 patients referred to the ICU each year 
offering sophisticated high technology medical care to treat a wide range of disease 
processes electively or as the result of a medical emergency. The „General ICU‟ admits 
a variety of medical and emergency surgical patients. The type of patients which are 
managed include patients with community acquired pneumonia who develop respiratory 
failure and require mechanical assist ventilation, or patients who are haemodynamically 
unstable due to severe infection and at risk of multi-organ failure, or patients who have 
overdosed on toxic substances which may have the potential to cause metabolic 
abnormalities and respiratory distress. The „Surgical ICU‟ is allocated for patients who 
have sustained injuries following major trauma or who have undergone cardiac surgery 
and other surgical procedures either electively or when performed urgently. The type of 
patients admitted include those who require surgery for severe closed head injuries and 
fixation of muscular skeletal fractures and/or repair of vascular damage as a result of 
major trauma, whilst cardiothoracic surgery is undertaken on patients who require 
coronary artery bypass grafting or heart valve repair or replacement. The ICU also 
accepts patients who require heart and lung transplantation, the management of patients 
who have been referred for the insertion of artificial heart technology, and patients who 
require temporary life support using Extracorporeal Membrane Oxygenation 
technology. The workload can change rapidly due to the nature and number of patients 
who are admitted to the ICU exposing the critical care nurse to a dynamic working 
environment.  
The use of CVVHDf at RPH is the preferred method of RRT by consultant 
medical staff for the management of critically ill patients who have developed severe 
ARF and not responded to supportive measures in response to a decline in renal 
function. Medical and nursing experience was first gained in the ICU using CAVHDf 
and CVVHDf. As staff became more familiar in using these techniques the importance 
of maintaining circuit life to maximise the treatment‟s effectiveness was soon realised 
and studies were subsequently undertaken in the unit to investigate aspects of both 
techniques which could impact on circuit life (Leslie, et al., 1996; Leslie & Thomas, 
1991). Although these studies used technologies which are now redundant and practices 
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no longer carried out, the information previously collected provide an historical control 




Figure 4.2. The Hygieia „Plus‟ CRRT machine (KIMAL plc, Middlesex, England). 
 
The Hygieia „Plus‟ CRRT machine (KIMAL plc, Middlesex, England) was used 
throughout the duration of the study after the appliance had been earlier introduced into 
clinical practice at the study site in 2002. Unlike the „make-shift‟ devices previously 
used, the custom-made CRRT machine shown in Figure 4.2 integrated circuit pressure 
monitoring with the regulation of fluid exchanges. A display screen allowed the 
operator to select convection-based (CVVH) and diffusion-based (CVVHDf) techniques 
with step-by-step instructions for the operator on how to setup the machine, prime and 
connect the circuit to the patient. The CRRT machine incorporated four roller pumps 
which regulated blood flow and using volumetric infra-red technology, controlled the 
rate of dialysate and fluid replacement delivered and the rate of ultrafiltrate produced. 
On commencement of treatment the operator was able to use the touch-screen controls 
to make adjustments in the rate of blood flow and on the amount of fluid to be 
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exchanged. Circuit pressures also displayed on the screen allowed the operator to 
monitor the development of flow obstruction caused for example by blood clots and if 
necessary „troubleshoot‟ problems in response to interruptions in blood flow. Negative 
outflow (arterial) and positive return (venous) pressure alarms were integrated with an 
air detector alarm on the venous blood line and a blood leak sensor in case of membrane 
rupture on the ultrafiltrate line (KIMALplc, 1999). 
The extracorporeal circuit consisted of separate outflow and inflow blood lines 
made from polyvinyl chloride (PVC) tubing and individual fluid lines of the same 
material to deliver replacement fluid and dialysate solutions (Polaschegg, 1995). Similar 
to most circuitry designed where blood is pump-driven, the arterial blood line included 
the segment required for insertion around the roller pump and the venous blood line 
incorporated the air trap chamber. The components required to perform both treatment 
modalities were the same except for minor variations associated with differences 
between the two techniques. The CVVH circuit did not require the dialysate line and the 
„heater bag‟ (as part of the Hygieia „Plus‟ CRRT machine design feature for the 
warming of fluid) was located with the fluid replacement line. In contrast the CVVHDf 
circuit used the dialysate line to incorporate the heater bag instead of the attachment 
being connected to the fluid replacement line. The differences in the layout between the 
CVVH circuit and the CVVHDf circuit are shown in Figure 4.3. The same Nephral 
300ST haemofilter (AN69 membrane) made of acrylonitrile and sodium methallyl 
sulfonate copolymer was used for both treatment modes (Hospal, Lyon, France). The 
membrane comprised of fibres which had been specially treated with heparin to improve 
biocompatibility and the length and number of fibres gave a total wet surface area of 
1.3m
2
. The operator of the CRRT machine was required to assemble and put the various 
components of the circuit together before a priming solution could be administered. A 
stockpile of circuit components were packaged and stored at the study site in marked 









Figure 4.3. An illustration of the differences in the layout between CVVH and CVVHDf circuit configurations. 
 143 
The selection of a double lumen venous catheter was based on personal 
preference and clinical judgement of the Medical Officer on the choice of catheter 
length and size of the inner diameter required. The decision was also influenced by the 
availability of the vascular device commonly used at the study site with an historical 
supply and preference for the GamCatheterTM (Joka Kathetertechnik, Hechingen, 
Germany). The device had an 11 French (Fr.) gauge inner diameter and a catheter length 
of 150mm, 200mm or 250mm according to the choice of either internal jugular, 
subclavian or femoral insertion site. The other vascular access devices used during the 
investigation included the Arrow-HowesTM (Teleflex Medical, Durham, USA) double 
lumen venous catheter which had a similar inner diameter gauge size, to the use of the 
alternative CookTM (Cook Critical Care, Bloomington, USA) double lumen catheter 
which had a larger 12 Fr. gauge inner diameter, or the NiagaraTM (Bard Access Systems, 
Salt Lake City, USA) having the largest gauge of 13.5 Fr. inner diameter catheter 
measurement. 
Design 
 The investigation of circuit life between CVVH and CVVHDf was a study 
experimental design. The term „experimental design‟ refers to a plan for assigning 
patients in a clinical study to experimental conditions followed by a plan to undertake a 
statistical analysis of the results (Kirk, 1995). The simplest form of a clinical 
experiment is the parallel groups design. Suitable patients who have consented to 
participate in the study are randomised to receive one and only one of two or more 
treatments under investigation (Fleiss, 1986). Analysis of the specific intervention 
involves the comparison of its effect on patients who received the treatment against 
those patients who were not exposed to the therapy. A potential disadvantage of the 
parallel technique lies in the design which takes no account of differences in patient 
characteristics when measuring the response to the administration of a specific 
treatment. The ability to control for differences in the severity of critical illness and the 
impact of variations in pathology amongst patients participating in the study was an 
important consideration when planning the design of a study investigating circuit life 
using different CRRT modes. 
Cross-over study design 
Similar to other interventions employed in the management of the critically ill 
patient the underlying cause of disease and illness severity can have an overwhelming 
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effect when evaluating the response to a specific treatment strategy. For example, 
differences in the coagulation profile of a patient placed on CRRT who has liver failure 
may influence the longevity of circuit life or the amount of anticoagulant required to 
maintain the circuit when compared with patients who receive CRRT but have no 
history of liver failure and are observed to have normally coagulatory activity. 
Sequential experimentation is a method of analysis which allows the response of two or 
more treatments to be compared when each treatment is administered to the same 
patient. This type of study is classified as a cross-over experimental design study with 
the objective of observing differences between each individual treatment separately. 
The sequence of treatments is not as important as the effect which is observed when the 
same patient is exposed to all of the treatments under investigation. The simplest cross-
over method is the two-period two-treatment or 2x2 study design (B. Jones & Kenward, 
1989). This method involves the delivery of two different treatments which can be 
conveniently described as the administration of treatment A followed by treatment B to 
one group of subjects as opposed to the other half who instead receive treatment B 
followed by treatment A. The main feature of the cross-over study design which 
distinguishes it from other experimental study designs is that measurements are 
therefore taken on different treatments using the same subject (B. Jones & Kenward, 
1989). This provides disadvantages as well as advantages in the way comparisons are 
made when evaluating different responses to alternative treatment options.  
The cross-over component featured in the study design offers the advantage of 
making a direct comparison of multiple treatments, whilst reducing the influence an 
underlying disease may have on the measurements observed during the assessment of 
each treatment (B. Jones & Kenward, 1989). The impact septic mediators may have on 
the coagulation profile of patients with severe sepsis compared with their absence and a 
near normal coagulation profile in patients who have undergone cardiothoracic surgery 
is an example of how the primary cause of ARF can influence circuit life when both 
patients are exposed to the same treatment mode (Schetz, 1998). The features of a 
disease process belonging to the same patient can disproportionately influence the 
responses observed in circuit life which are observed when comparisons are made 
among the other patients participating in the study. The variability observed when 
measurements are recorded from different patients in response to a specific treatment is 
often greater than the variability of treatment responses observed when repeated 
measurements are taken from the same patient (B. Jones & Kenward, 1989). 
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Another feature of the cross-over study design involves the order how each 
patient is exposed to the treatments under investigation with the potential for large 
variations to occur in repeated measurements due to the variability in severity of the 
disease process. The natural progression in the severity of disease may cause changes in 
the longevity of circuit life which are observed when over the duration of the different 
treatment modes the condition of the patient improves and adequate renal function is 
restored. As a consequence of renal insufficiency the accumulation of uremic toxins 
may contribute to a reduction in platelet activity and increase the likelihood of 
coagulation disorders (Schetz, 1998). On commencement of treatment the acquired 
platelet dysfunction is gradually resolved under the influence of CRRT and on the 
resolution of renal insufficiency.  The improvement in renal function coincides with the 
restoration of normal coagulation activity but the affect is not equally distributed and 
the influence this can have on circuit life may vary according to when each treatment 
mode was started. 
A disadvantage of using a cross-over design study is the potential for a carry-
over effect (B. Jones & Kenward, 1989). This occurs when the effects produced by one 
treatment are transferred and influence the response observed when the other treatment 
is administered. The carry-over effect is virtually overcome when three or more 
treatments are measured, but can be more of a problem when the simpler 2x2 crossover 
study design is used. On occasions where the use of a 2x2 crossover study design is 
unavoidable the chances of a carry-over effect are minimised when a „wash-out‟ period 
allows a pause to occur between each treatment. The use of a 2x2 crossover study 
design is considered appropriate when the carry-over effect is judged to be small (B. 
Jones & Kenward, 1989).     
The impact of CVVH versus CVVHDf on circuit life was investigated using a 
2x2 crossover study design which allowed for individual patient characteristics to be 
limited when evaluating the effect of treatment mode on circuit life. Each time a 
treatment was completed and the disposable circuit discarded many of the effects of the 
mode were isolated to the circuit and not carried-over to the alternative treatment. Other 
than the time normally required to take down and prepare a new circuit a specific 
„wash-out‟ period was not included in the design of the study. A limited carry-over 
effect was nevertheless possible with commencement of the alternative treatment 
influenced by differences in the progression of the disease process following the 
instigation of the previous mode and in the earlier administration of exogenous heparin. 
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The period of time required to achieve a successful crossover between CVVH 
and CVVHDf had the potential to take several days to complete. During the course of 
both treatment modes life-saving interventions including the commencement of CRRT 
would result in the likelihood of an improvement in the patient‟s condition. The 
correction of abnormalities is subsequently transferred when resolution of the disease 
process coincides with a cross-over to the alternative treatment mode. A patient with 
sepsis who develops ARF is an example of how the disease process can influence circuit 
life during CRRT when the duration taken by each mode to achieve a successful 
crossover occurs over several days. The previous treatment mode may commence when 
natural anticoagulants in the body are reduced due to the affects of sepsis on the 
coagulation system with a hypercoagulatory state prevailing in the extracorporeal blood 
(Balk, 2000). As the coagulation system returns to normal in response to the resolution 
of infection and dissipation of the inflammatory response, the alternative mode has the 
potential for extended circuit life due to decreased procoagulatory activity in the 
extracorporeal blood. The effects of sepsis on the coagulation system can also be 
diminished by the removal of septic mediators during CRRT and influence circuit life 
when commencement of the alternative treatment mode is protracted and modulation of 
the inflammatory response has occurred with the mode first assigned to the patient 
(Subramanian & Kellum, 2000). 
The use of heparin to anticoagulate blood along the circuit has the potential to 
remain active in the body after the completion of the initial allocated mode. The effects 
of the anticoagulant agent are capable of being transferred when cross-over to the 
alternative treatment occurs, and exposes the circuit to the same „heparinised‟ blood 
which was circulated through the original circuit associated with the previous mode. 
The residual influence of heparin impacting upon circuit life between treatment modes 
is influenced by the short half-life of heparin and the time required to set-up a new 
circuit. The anticoagulant effect of unfractionated heparin on antithrombin III when 
delivered intravenously has a short half-life of approximately one hour (Baglin, 
Barrowcliffe, Cohen, & Greaves, 2006). The preparation of a new circuit required 
approximately 30 minutes before the circuit was able to be connected to the patient. The 
possibility of a residual influence from the previous administration of heparin in the 
blocking of thrombin and factor Xa was subsequently minimised, since the half-life of 
the anticoagulant agent would be almost reached when the new circuit using the 
alternative treatment mode was made ready to use. 
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Allocation of patients to treatments  
The control of bias in favour of a particular treatment is important to ensure the 
integrity of the study is maintained. The process of randomisation is used in 
comparative studies to avoid conscious or unconscious bias in the allocation of 
participants to a specific treatment (Chow & Liu, 2004). This was an important 
consideration for this study when comparing circuit life since it was not possible to 
„blind‟ the investigation between the two treatment modalities. The nature of the 
intervention could not disguise the technique from the bedside nurse who was required 
to operate the CRRT machine. The set-up of the machine easily identified the technique 
in use with the inclusion of dialysate as an indicator of CVVHDf, whilst CVVH was 
recognised by the absence of dialysate. Also, the bedside nurse was required to make 
decisions in regards to solute clearance and fluid removal based on which technique was 
employed. The potential to extend circuit life using one of the techniques under 
investigation introduced the possibility for bias to occur in the sequence of treatments 
allocated to the patient. An attempt could be made by the bedside nurse to manipulate 
the mode of treatment each patient received if a more favourable circuit life was 
associated with a particular technique. Any intervention which was observed to increase 
the duration of treatment and reduce the workload associated with the set-up of a new 
circuit would be a strong motivating factor in the choice of treatment selected. 
Randomisation 
The process of randomisation can be used to avoid subjective assignment of 
treatments to patients who participate in clinical studies (Chow & Liu, 2004). Patients 
enrolled in the study represent a sample of the population under investigation and 
statistical inference is able to be drawn from the probability of distribution in the target 
patient population. The probability distribution assumption and reliability of the 
statistical analysis depend on the randomisation model used. Although treatment 
comparisons are performed by randomisation the study site and patient selection were 
not random.  
The methods used to randomise subjects to a specific treatment can be classified 
according to three randomisation techniques. They include the assignment of subjects 
either through complete randomisation, permuted-block randomisation or adaptive 
randomisation (Chow & Liu, 2004). The randomisation process chosen to investigate 
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the impact of higher volume predilution CVVH versus CVVHDf on circuit life 
employed the method of complete randomisation. 
Complete randomisation is the simplest method of selecting patients to 
randomly receive a specific treatment (Chow & Liu, 2004). The method places no 
restrictions on the sequence of randomisation provided that the number of subjects 
recruited achieves the desired statistical power and the required distribution of patient 
allocation is obtained between treatments. The application of complete randomisation in 
the design of this study created a 50% chance for patients participating in the study to 
either receive CVVH followed by CVVHDf or to receive instead CVVHDf followed by 
CVVH. The method chosen made sure all of the patients enrolled in the study were 
independently assigned to receive each treatment in a randomised order. Since complete 
randomisation placed no restrictions on the sequence of treatment allocation the study 
was exposed to unequal sample group distribution in regards to the starting treatment, 
with the potential risk of one type of mode being selected more frequently than the other 
mode under investigation. The potential for unequal sample sizes is increased among 
treatment groups when the total sample size is small (Chow & Liu, 2004).  
A set of randomised numbers can be obtained either by using a table of random 
numbers in a statistical textbook or by accessing a statistical computing software 
package (Beller, Gebski, & Keech, 2002). Study participants received both treatment 
modalities in a random order using a computer generated set of randomised numbers. 
The set of randomised numbers was generated using the „Research Randomizer‟ 
computer program retrieved from the website http://www.randomizer.org. The Research 
Randomizer uses the „Math.random‟ method within the Java.Script programming 
language to generate a set of random numbers. Similar to other computer-based 
programs the numbers are obtained by a complex algorithm originating from the 
computer‟s clock that gives the appearance of randomness. Although the computer 
cannot generate a set of „true‟ random numbers the use of a „pseudo-random number 
generator‟ is considered to be appropriate for use in the majority of clinical studies 
undertaken. 
The Research Randomizer was accessed to perform the process of complete 
randomisation using a list of parameters chosen from a menu of choices which 
determined the output produced. Only one set of random numbers was required. The set 
of numbers consisted of 150 values considered sufficient to enable each patient 
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recruited a randomised treatment allocation. The numbers „one‟ and „two‟ were used to 
represent CVVH and CVVHDf. Each number was consequently not required to remain 
unique or to be sorted in a particular order. The set of randomised numbers was 
presented using the default setting of the computer program with the layout of values 
not indicated by placement markers. The output of random numbers produced by the 
Research Randomizer is contained in the Appendix B.        
Process 
Patients admitted to ICU who required CRRT were considered as potential 
candidates for this study. A review of the patient‟s medical history determined 
eligibility in meeting selection criteria. The design of the study did not delay CRRT and 
when ordered by the intensive care specialist on duty, the normally preferred treatment 
mode of CVVHDf commenced. Patients who met the inclusion criteria as shown in 
Table 4.1 were either approached to participate in the study or the next-of-kin when the 
patient was incapable of providing consent.  
Once consent was obtained, patients were randomised and assigned to receive 
either CVVH or CVVHDf at the start of treatment or after the normally preferred 
treatment mode of CVVHDf was scheduled to be taken down. A series of sealed 
envelopes had a number written on the front of each envelope which corresponded with 
the patient‟s enrolment number. Inside each envelope was a card that gave instructions 
on which treatment the patient was assigned to receive. The envelopes were placed in a 
tray marked „un-used envelopes‟. This was stored at a central location within the ICU. 
Once the envelope had been opened and instructions given on which treatment mode the 
patient had been randomised to receive, a patient identification label was attached to the 
card and then inserted back into the envelope and placed into a second tray marked 
„used envelopes‟. The attachment of patient labels to each card when the envelope had 
been opened ensured a record of treatment allocation was able to be maintained. 
Instructions written on the card gave directions as to the location of a specially 
marked container specifically set aside for use at the study site. The container held study 
circuits, packaged and labelled according to treatment mode, which were only to be 
used for patients participating in the study rather than using circuits earmarked for 
general use. The purpose behind the creation of packaged circuits was to ensure the 
circuit correctly matched the treatment mode allocated to the patient and to avoid the 
potential for confusion during the setup of the circuit. This assisted the operator to have 
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the correct circuit components that were required for CVVH as opposed to CVVHDf 
with the supply of packaged circuits maintained throughout the study period. The use of 
packaged study circuits also allowed a record to be maintained of the total number of 
circuits used during the study according to the allocated treatment mode.  
Once the Patient had been randomly selected to receive either CVVH or 
CVVHDf thereafter, the patient alternated sequentially between these two techniques. In 
circumstances where the circuit had run its natural course on both occasions, only one 
crossover between the two treatment modalities was required. If the patient continued to 
require CRRT the normally preferred treatment modality of CVVHDf was then used.  
Determinants of a ‘Natural’ Circuit Life 
The measurement of circuit life using CVVH and CVVHDf was based on when 
the patient was first connected to the circuit until disconnection occurred following a 
decision to end treatment. A „natural‟ circuit life was defined as the spontaneous 
appearance of circuit failure caused by the accumulation of blood clots along different 
sections of the circuit. The decision to take down the circuit as a result of clotting was 
based on visual inspection and increases in circuit pressures displayed on the Hygieia 
„Plus‟ monitoring screen. Observations made by the bedside nurse showing the 
appearance of blood clots within the haemofilter and venous bubble were checked 
against evidence of higher resistance to blood flow through the circuit by a gradual 
increase of pressure across the membrane (TMP > 200mmHg) and along the return line 
(P-venous > 150mmHg). The lifespan of a circuit was not considered to have been 
reached naturally when reasons other than clotting caused the circuit to be taken down 
electively: 
 Problems with vascular access 
  Haemodynamic instability 
 Procedures to be performed outside of ICU 
 When there was a return of urinary output 
 If death of the patient had occurred. 
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Crossover Procedure 
The crossover procedure between CVVH and CVVHDf only applied when the 
circuit for both treatment modes had run its natural course and was taken down due to 
clotting. An illustration of a successful treatment crossover is shown in Figure 4.3. If on 
the other hand the CVVH or CVVHDf circuit was taken down due to causes apart from 
clotting a successful crossover was not deemed to have occurred between the two 





Figure 4.4. A successful crossover between CVVH and CVVHDF. 
  
A number of clinical scenarios were identified as possible situations which in the 
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should the patient be initially randomised to receive CVVHDf, circuit life is disqualified 
and crossover disallowed, when in the case of this scenario the patient required surgery 
and the first circuit was taken down electively in preparation for transport to the 
operating theatre. Crossover to CVVH could not take place since the natural life of the 
CVVHDf circuit had not been reached. Once the patient had returned from the operating 
theatre continuation of CVVHDf was required until a circuit using this treatment mode 
was taken down having reached its natural life. The same scenario could also be applied 
to patients who instead of surgery required radiological diagnostic procedures to be 
performed outside of the ICU. 
  
Figure 4.5. An unsuccessful crossover. 
 
The occurrence of problems with the insertion site or the catheter device is 
another example of a clinical scenario as shown in Figure 4.5 which could interrupt the 
crossover procedure. Blood flow that is failing with frequent pump stoppages due to 
inadequate vascular access would predispose to premature clotting and not represent a 
true reflection of circuit life. In response to an increasing number of blood flow 
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medical decision to replace the catheter device at the same or different insertion site and 
the judgement by the bedside nurse to prematurely terminate the circuit. The attempt to 
crossover from CVVH to CVVHDf would be invalid in this scenario since the first 
circuit was not taken down following a natural circuit life. The crossover between each 
treatment mode would also not compare circuit life with the same catheter device and 
use a potentially different insertion site. 
 
Figure 4.6. Crossover interrupted by vascular access problems. 
 
The administration of 0.9% normal saline flushes through the circuit is another 
example of a scenario which jeopardised the crossover procedure. The exposure of 
circuits to one or more bolus doses of 0.9% normal saline introduced an additional 
variable in the assessment of circuit life between the two treatment modes under 
investigation. At the time of the study there was no evidence to suggest the 
administration of 0.9% normal saline flushes would influence the lifespan of the circuit 
(Prasad, et al., 2000). Although when delivered into the circuit the infusion of 0.9% 
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normal saline can serve as a useful strategy for the visual inspection of the haemofilter 
and venous bubble trap to detect signs of clotting (Davies & Leslie, 2006). Unless the 
procedure was able to be regulated and the same intervention given to both treatment 
modalities the administration of 0.9% normal saline was not considered of sufficient 
value to be included as a variable and the practice discouraged whilst patients 
participated in the study. Only after the study was completed has evidenced been 
published to suggest in patients who are coagulopathic the use of 0.9% normal saline 
can promote circuit life when the use of anticoagulants is contraindicated (Nagarik, et 
al., 2010).     
 
Figure 4.7. Crossover interrupted by the administration of 0.9% normal saline. 
 
The scenario shown in Figure 4.6 illustrates a situation where flushing of the 
circuit with 0.9% normal saline has occurred after the patient was randomised to receive 
CVVHDf. Despite the circuit reaching a natural lifespan and taken down due to clotting 
the circuit life measured is ineligible. The administration of a 0.9% normal saline flush 
prevented a successful crossover to the alternative treatment mode of CVVH. The same 
treatment mode of CVVHDf is instead repeated and continued until the circuit using 
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this technique is taken down due to clotting without the use of 0.9% normal saline 
flushes. The recirculation of 0.9% normal saline through the circuit to allow 
disconnection from the CRRT machine and transportation of the patient outside of the 
unit for diagnostic procedures also produced a situation where the crossover process to 
the alternative technique would be interrupted. In order to achieve a satisfactory 
treatment crossover the previous mode is repeated again until it is taken down due to 
clotting without the recirculation of 0.9% normal saline having occurred during the 
lifespan of the circuit.  
The pre-dilution volume for CVVHDf was not allowed to change unless 
deterioration in the patient‟s condition required adjustments to be made to the 
haemofiltration rate of flow. In the event changes were required alterations of between 
500ml to 2L could nevertheless be made to the dialysate rate of flow which would not 
invalidate the circuit life measured. On the other hand the effect of changes in pre-
dilution volume above 600mL would introduce an extra variable in the measurement of 
circuit life. In this situation a successful crossover to CVVH was prevented. The 
scenario as shown in Figure 4.7 involves the alteration of the haemofiltrate component 
of CVVHDf. Despite a favourable crossover to CVVH following clotting of the first 
circuit the crossover was subsequently violated. During the life of the second circuit 
using CVVHDf the pre-dilution volume (normally „fixed‟ at 600mL per hr) was 
increased to 1200mL per hr. The increase in pre-dilution volume during CVVHDf 
causes the affect of haemodilution in the circuit to change. Unless the same pre-dilution 
volume is maintained comparisons of circuit life with CVVH are confounded by 








Figure 4.8. Crossover interrupted after alterations were made to pre-dilution volume 
during CVVHDf. 
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The difficulty associated with ensuring a successful crossover occurred between 
CVVH and CVVHDf is again shown in Figure 4.8 when crossover was prevented by 
the return of urinary output, or in Figure 4.9 after the patient had died before exposure 
to the alternative technique. A set of instructions on what constituted a successful 
crossover was made available at the bedside to assist the nurse to determine whether a 
successful crossover had been achieved. The ICU observation chart was also examined 
and comments as to reasons why each circuit was taken down reviewed to determine 
whether study protocols regarding crossover procedures had been followed correctly. 
 
 










 circuit taken down due 
to clotting and circuit life 
included. Crossover 
between treatment modes 
can occur.  









 circuit electively 
taken down due to 
return of urinary output 





Figure 4.10. Crossover prevented due to death of patient. 
    
Standardisation of Variables 
A number of measures were taken to standardise the approach between CVVH 
and CVVHDf so that differences in circuit life were based on the variable of interest 
(pre-dilution volume) and not confounded by other factors identified in the conceptual 
framework.  
Technique 
An ultrafiltrate dose of 35ml per kg per hr delivered pre-haemofilter was used 
for CVVH based on evidence of improved patient survival when compared with the 
post-haemofilter conventional dosage of 25ml per kg per hr (Ronco, et al., 2000). A 
record of the patient‟s body weight was made for the purposes of determining the 
volume of replacement fluid required when the patient was assigned to CVVH. In the 
majority of cases the patient‟s weight was routinely recorded within 48 hr of admission 
into ICU and often required using a hoist capable of lifting the patient and recording 









 circuit taken down due 
to imminent death of 
patient. 
Crossover to alternative 
treatment mode interrupted. 
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guidelines (at the time of the study) a fixed pre-dilution volume of 600ml per hr 
replacement fluid was used for CVVHDf with a dialysate dose of between 500ml to 2L. 
Dialysate and replacement lactate-based solutions were the same for both treatment 
modes (Haemofiltration Replacement Fluid, Baxter Health Care, Sydney, Australia). A 
lactate-free bicarbonate-buffered solution was used for severely acidotic patients 
(Hemosol BO, Gambro, Sydney, Australia). Blood flow was set and maintained at 
200ml per min. Routine blood samples were taken in the morning from arterial blood. A 
record of laboratory measurements monitoring participants‟ aPTT, INR, platelet count, 
haematocrit, urea and creatinine plasma serum levels was kept.  
Venous Access Catheter and Vascular Insertion Site  
Vascular access was achieved using non-cuffed, non-tunnelled, dual-lumen 
catheters to access blood from either the subclavian, internal jugular or femoral central 
veins. Comparisons of circuit life between CVVH and CVVHDF were made using the 
same venous access catheter and vascular insertion site. If at any stage the venous 
access catheter or vascular insertion site changed the process of treatment randomisation 
was repeated. This was undertaken to minimise the potential for variability in blood 
flow between treatment modes impacting upon circuit life due to the use of different 
venous catheters and alternative insertion sites. 
Anticoagulation 
A standard heparin based anticoagulation protocol was employed for both 
CVVH and CVVHDF. Each circuit was primed with 1L of 0.9% normal saline followed 
by a heparin rinse at a concentration of 5,000IU in 1L of 0.9% normal saline. Based on 
patient weight and pre-existing aPTT a continuous heparin infusion of 10,000IU diluted 
in 50ml of 5% dextrose using a separate syringe driver was delivered pre-haemofilter 
and adjusted between 200 and 800IU per hr to maintain a patient aPTT of 40 to 55s. A 
record was made of the amount of heparin delivered during the life of each circuit. 
Training and Supervision 
At the study site CVVHDf is routinely used in the management of critically ill 
patients with severe ARF. Whilst the majority of nursing staff were familiar with the 
set-up and operational characteristics of CVVHDf there was limited experience in using 
CVVH. It was necessary to provide training and supervision prior to the commencement 
of the study for all clinical staff, both nursing and medical, and throughout the 
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continuation of the project to account for new employees or as a refresher course to 
existing staff members. 
The structure of the education programme consisted of several different teaching 
styles designed to inform the nurse and Medical Officer about the research project. 
Specific details were given on the requirements of the study and calculation of the 
treatment dose for CVVH using 35ml per kg per hr prescription order. A variety of 
different teaching styles recommended by Baldwin (1997) to train staff in the use of 
CRRT were used. These included lecture presentations, practical demonstration of 
equipment and instruction at the bedside.  
A month before the commencement of the study two half-hour lecture 
presentations were conducted per week in the ICU seminar room. The frequency of 
lecture presentations was considered appropriate in an attempt to maximise exposure of 
the presentation to approximately 130 nursing and 40 medical personnel who were 
employed as shift-workers on a full-time or part-time basis. Several members of the 
ICU clinical staff were encouraged to attend in recognition of the important role they 
played in the department. Those targeted included medical Consultants and Senior 
Registrars responsible for the management of patients with ARF and nursing staff who 
had clinical expertise in the care of patients requiring CRRT such as Clinical Nurse 
Specialists, Staff Development Nurses and Clinical Nurses. The number who attended 
each lecture presentation was measured against a register of clinical staff likely to be 
exposed to patients receiving CRRT. In determining the commencement date of the 
study a target of 60% or more was considered as appropriate coverage for all staff in the 
department assigned to patient care.  
In addition to the lecture presentations several practical workshops were 
organised to provide „hands on‟ experience with using the technique of CVVH. 
Attention was drawn to the main difference in circuit layout being the absence of the 
dialysate fluid line and the heater bag located on the fluid replacement line. Operational 
comparisons with CVVHDf were also highlighted during the workshop using a practice 
CVVH circuit attached to the Hygieia „Plus‟TM CRRT machine. The audience was 
encouraged to adjust treatment settings and enter the correct dose for CVVH on the 
Hygieia „Plus‟TM CRRT machine using the „touch‟ display screen.  
Staff training continued once the study was underway to include supervision at 
the bedside to ensure the requirements of the study were upheld. The process of 
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treatment randomisation was observed and guidance offered to avoid procedural errors 
from occurring. Assistance was provided during the set-up of the CVVH circuit and 
agreement reached on the treatment dose to be delivered. Directions were given to 
support the nurse during the time when a crossover to the alternative treatment modality 
was imminent. Information about the study and what was required were contained in a 
manual and kept at the bedside whilst patients participated in the study. The nurse or 
medical officer could also access this manual online via the hospital‟s intranet website 
using the various computer desktops located in the department.    
Statistical Analysis 
The comparison of circuit life between CVVH and CVVHDf required statistical 
analysis on variables taken to detect a difference which was of clinical importance for 
determining the effectiveness of each treatment mode in the promotion of circuit life. 
The initial statistical work involved building a database and categorising the number of 
variables to be collected. On reaching the required number of participants the next stage 
involved comparisons between treatment groups and examination of consistency in the 
variables observed. This allowed the distribution of data to be assessed and the required 
transformation of data to compare the influence of treatment mode on circuit life. The 
inclusion of other variables and whether treatment mode alone was responsible for 
differences in circuit life completed the statistical work undertaken.  
Database Development 
A database was established using SPSS version 13 statistical analysis computer 
software (Chicago, Illinois) to enter categorical and continuous variables. The order of 
how each variable needed to be entered in the database was incorporated in the design 
and when data analysis was undertaken the structure of the database accommodated the 
specific statistical procedures required to answer the research question. Each variable 
was coded with a detailed codebook maintained for the meaning of names given and to 
provide a description of the values included in the database. The accuracy in the entry of 
data was verified using descriptive analyses and frequencies on each variable to prevent 
corruption of the database by missing data and out-of-range values. Once data had been 
entered in the database and checked for inaccuracies a number of data transformations 
were performed to allow easier interpretation of the data and increase the reliability of 
the results.  
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The data transformations undertaken included the grouping of circuits which had 
clotted according to treatment mode and the dispersal of circuit life measurements 
adjusted to accommodate normality of distribution. After data was drawn from the main 
database into a series of subsets each grouping of data was analysed by a variety of 
statistical procedures. The distribution of variables was examined using descriptive 
statistical procedures along with the measurement of relationships between different 
variables affecting circuit life. The detection of differences in circuit life between each 
treatment mode and the identification of possible causes was generalised to a wider 
population from the study sample using inferential statistical procedures.    
Intention-to-Treat Principle 
The intention-to-treat principle was adopted once consent to participate in the 
study had been granted by the patient or „next-of-kin‟. Unequal treatment distribution 
between CVVH and CVVHDf was a potential problem when compliance in mode 
allocation was threatened. The incorporation of an intention-to-treat principle allowed 
the analysis of data to be undertaken irrespective of whether the patient was given the 
sequence of treatments they were allocated to receive (Heritier, Gebski, & Keech, 
2003). During the study period the gathering of data was performed irrespective of 
protocol deviations or irregularities in the non-compliance of protocols or in the 
withdrawal of participants.  
The inclusion of all patients in the study regardless of outcome provided a 
realistic account of actual clinical practice when evaluating circuit life using CVVH and 
CVVHDf. The inventory of events contained in the analysis recorded study violations 
which led to incomplete patient participation in the study after attempts were made to 
crossover and use the alternative treatment mode. Over estimation in the efficacy of an 
intervention can occur when some participants are deliberately removed and the results 
obtained not included when data is withheld from analysis (Heritier, et al., 2003). A 
number of clinical scenarios previously discussed as part of the crossover procedure 
were identified as possible causes of incomplete patient participation, with the responses 
to both treatment modes not able to be observed whilst candidates were enrolled in the 
study. The possible causes of events which prevented a treatment crossover to occur as 
shown in Figures 4.8 and Figure 4.9 included the return of urinary output and 
restoration of renal function or a decision to end treatment due to imminent death of the 
patient. 
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Sample Size Calculation 
A number of statistical procedures are required in order to test whether a 
statement of hypothesis regarding an intervention is correct when the sample used is 
drawn from the wider population under investigation. The Central Limit Theorem states 
that for sample sizes greater than or equal to 30 drawn randomly the distribution of 
means are approximately evenly distributed (Pereira & Leslie, 2009). These remain 
constant even though the sample of data collected during the study may not resemble a 
normal distribution curve. In this study the response of CVVH and CVVHDf on circuit 
life can be tested for reliability using a random sample of patients to represent the 
general population of critically ill patients requiring CRRT. By formulating a null 
hypothesis, the response which is observed in this sample of patients can be tested on 
the basis that no difference was expected to occur (Pereira & Leslie, 2009).  
The likelihood of rejecting a null hypothesis when a real difference does not 
exist is denoted as a type I error (Altman, 1991). Usually the Greek letter alpha (α) is 
used to describe the probalility of a type I error. This is referred to as the significance 
level and 0.05 (5%) is one example of a significance level commonly used in statistical 
tests (Pereira & Leslie, 2009). A type II error on the other hand can falsely accept the 
null hypothesis when the opposite is true (Altman, 1991). Based on the statistical test 
used the study is powered to produce a calculated probability in the chances of not 
detecting a real difference. This probability is usually denoted by the Greek letter beta 
(β) and is often set at 0.2 (20%). The ability to reduce the chance of error by either 
wrongly rejecting or accepting the null hypothesis requires both α and β levels to be 
considered together. A statistical test which reduces the possibility of a type II error and 
a level of significance that minimises a type I error is usually recommended when 
undertaking hypothesis testing (Pereira & Leslie, 2009). 
The various components which determine the sample size required to test the 
hypothesis depend on the level of significance and the power set by the investigator 
(Kirkwood, 1988). These sample size calculations will also be influenced by the degree 
of treatment response required to demonstrate the effectiveness of the intervention 
under investigation. A standard equation can be used for the purposes of sample size 
calculation, n > 2k([sigma] square)/(d) square, based on the minimal n that represents 
the required number, the variance of measured variable (denoted by sigma square), the 
minimum difference of clinical significance (denoted by d) and the level of error in α 
and β values considered acceptable (denoted by k) (Columb & Stevens, 2008).  
 165 
The sample size required for the study to detect a difference in circuit life 
between CVVH and CVVHDf was based upon professional statistical advice on sample 
size calculations. A threshold of 0.05 (5%) was established at the beginning of the 
investigation before measurements of circuit life were recorded. Once the study was 
completed, in the likelihood the obtained P-value showed a number lower than the pre-
determined threshold and a postive effect was observed, the investigator is then 
prepared to accept a 5% chance that the difference in circuit life between CVVH and 
CVVHDf occurred erroneously. The study was also powered to show that the detected 
outcome between treatment mode and circuit life had an 80% chance of being correct, 
or a one in five chance (20%) of not detecting a real difference in the variable under 
investigation. 
The underlying event rate of circuit failure due to clotting was another 
component considered in sample size calculations. Observations based on other studies 
which have investigated the same topic can provide valuable information on the lifespan 
expected to be achieved using different treatment modes and the degree of variance 
reported in the longevity of circuit life measurements. A preference for pre-dilutional 
CVVHDf at the study site had earlier recorded a mean circuit life of 16.2 hours and a 
SD of 13.4 hours (Leslie, 2003). In order to evaluate the size of effect using the 
alternative technique of CVVH, a difference in circuit life of four hours was considered 
a measurement which would offer a clinically meaningful outcome when compared 
with the lifespan of circuits observed using CVVHDf. 
 
Using the aforementioned information a sample size of 30 patients exposed to 
both treatment modes was calculated as being sufficient to conduct a comparison of 
circuit life between CVVH and CVVHDf. The difference in means of each paired 
sample of circuit life was tested with a paired-sample t-test and since the difference 
could be in either direction a two-tailed test was selected. As a requirement of the 
statistical test the sample had to meet several assumptions. These assumptions included 
the SD of circuit life using CVVH would be the same as for CVVHDf and a positively 
skewed distribution curve could be normalised using logarithm transformation. 
Assessing Normality 
The initial analysis of possible differences in circuit life between CVVH and 
CVVHDf required measurements to be grouped together according to treatment mode. 
This enabled the distribution of measurements, recorded when each circuit had run its 
 166 
natural course and taken down due to clotting, to be assessed for normality. A 
Kolmogorow-Smimov goodness-of-fit statistical test was carried out to determine the 
normality in the distribution of circuit life measurements recorded in minutes. The 
sample of circuit life measurements conformed to the assumptions underlying the 
Kolmogorow-Smimov test since measurements were from a random sample and data 
collected was from a continuous variable (Daniel, 2005). Circuit life measurements 
were shown to have a positive skewed distribution curve. In a positive skewed 
distribution curve the skewness or symmetry in the distribution of data is influenced by 
the frequency of low scoring measurements distinct from a normal distribution curve 
which is bell-shaped and symmetrical about the mean. The predominance of short 
circuit life in the study skewed the distribution curve positively and the uneven 
distribution observed matched that reported in a similar study measuring circuit life 
(Uchino, et al., 2003b). 
 In choosing to use a parametric statistical test the data set is assumed to be 
normally distributed and if skewed can invalidate the statistical technique (Altman, 
1991). The advantage of parametric over non-parametric statistical techniques is the 
method used for estimation and hypothesis testing based on the central limit theorem. 
The central limit theorem is able to approximate the sample mean to the population 
mean provided the sample size is sufficiently large enough to observe the variations in 
the dependent variable (Chow & Liu, 2004). By using the central limit theorem a 
difference between groups in the case of the t-test and discovery of associations 
between variables with the Pearson‟s correlation test is more likely to occur with 
parametric than non-parametric statistical techniques.  
A decision to use parametric statistical techniques resulted in choosing an option 
for analysis which would address the problem of violations in the normal distribution of 
circuit life measurements when comparisons were made between CVVH and CVVHDf. 
Modification of the dataset was selected as one approach which would allow parametric 
statistical tests to be undertaken. In statistics working with logarithms of data instead of 
actual measurements have several mathematical properties which in some cases allow 
the distribution of data to become more symmetrical than data which has not been 
transformed (Kirkwood, 1988). The process involves the transformation of every value 
in the dataset being replaced by its logarithm with only the base chosen determining the 
logarithm and not changing the measured value when the dataset is transformed. 
Mathematicians consider logarithms to the base e (ln) a natural logarithm which can 
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simplify many formulae in the transformation of data which arises from nature when 
compared with the other commonly used logarithm to the base 10 (Evans, 1939). Using 
the process of data transformation the values obtained from circuit life measurements 
were mathematically formulated and following manipulation by the natural logarithm 
base e (ln) changed the positively skewed distribution curve to one which resembled a 
near normal dispersion of circuit life measurements. After completing the logarithm 
transformation the modified data set was subjected to parametric statistical testing using 
a paired-sample t-test.  
Paired-sample t-test 
A paired-sample t-test was selected to compare circuit life since CVVH and 
CVVHDf was administered to the same patient. The paired-sample t-test is a parametric 
statistical technique used when data is collected on the same group of individuals but 
during two different occasions or under two different conditions (Kirkwood, 1988). 
Once the assumption of normality in the distribution of circuit life measurements had 
been achieved by logarithm transformation a comparison of the mean performance in 
the lifespan of CVVHDf circuits was able to be made with that observed using the 
alternative treatment mode of CVVH. 
Wilcoxon Signed Ranks Test 
The other option for statistical testing was not to take the assumption of 
normality into consideration and instead compare circuit life measurements using a 
complementary non-parametric Wilcoxon signed ranks test. Non-parametric statistical 
techniques do not make assumptions about the underlying distribution of data when not 
shown to be normally distributed (Kirkwood, 1988). Instead of comparisons made 
between the mean scores, the Wilcoxon signed ranks test compares the median scores of 
the two groups. The scores are then converted on the continuous variable, in this case 
circuit life, to ranks and analysis undertaken of whether the ranks across the two groups, 
CVVH and CVVHDf, are significantly different. 
 Survival Analysis 
A survival analysis is used in clinical studies when the research question 
requires the investigator to measure a predetermined outcome from the point of 
initiation to a fixed time or event (Daniel, 2005). Traditionally survival data analysis has 
been concerned with time to death after treatment but has been used in other areas 
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besides mortality to observe the response of a particular intervention. One field of 
enquiry where this type of statistical test has proved popular has been in the area of 
CRRT. A number of studies investigating this topic have used survival data analysis to 
make comparisons of circuit survival times (Prasad, et al., 2000; Reeves, et al., 1997). 
The statistical technique is able to determine the cumulative effect and probability of a 
specific event, in this case the time to circuit failure, and produce survival curves when 
data on circuit life measurements are plotted onto a graph. The distinguishing feature of 
survival data analysis is in some cases the event may not have occurred during the 
observation period. When the event is not observed survival time is reported to be 
censored.  
The Kaplan-Meier method (E. L. Kaplan & Meier, 1958) was chosen to perform 
a survival analysis on the probability of circuit survival time for CVVH and CVVHDf. 
The length of time to the event of circuit failure due to clotting was recorded in minutes 
and represented a continuous time variable. This enabled the Kaplan-Meier method to 
be used for survival analysis as opposed to the alternative Cox Regression Model which 
is instead restricted to using time intervals when recording the event under 
investigation. Using the Kaplan-Meier method a survival analysis was performed on all 
circuits which had survived to clotting either as part of a treatment crossover or when 
taken down in isolation. The survival analysis on circuit life was also expressed as a 
measurement of the non- survival potential or hazard rate when comparing differences 
in circuit life using CVVH and CVVHDf. The circuit time of 960 min (16 hr) was used 
as the truncation point to determine the survival or failure rate of circuits using both 
treatment modes. This time was derived from past clinical experience using pre-
dilutional CVVHDf at the study site. The truncation point represented a measurement of 
circuit life which has been reported by others using CVVH as sufficient to ensure 
adequate renal replacement therapy is delivered (Uchino, et al., 2003a).     
Multiple Regression Analysis 
A linear multiple regression analysis was undertaken on the 93 circuits which 
had survived to clotting. Multiple linear regression techniques investigate linear 
relationships between a set of independent variables against continuous dependent 
measurements (Draper & Smith, 1998). In the case of this study it was necessary to 
determine the relationship between the continuous dependent variable of circuit life 
against the independent variables of aPTT, platelets, heparin dose, haematocrit and urea. 
An important feature of multiple regression analysis is the ability to make predictions 
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about what the affect would be on the dependent variable when the outcome is 
measured against several independent variables (Draper & Smith, 1998). In order to 
determine whether the lifespan of the circuit as the dependent variable was solely due to 
the crossover between CVVH and CVVHDf it was necessary to explore the independent 
variables of aPTT, platelets, heparin dose, haematocrit and urea as predictors of circuit 
life. A number of different statistical tests are available for predicting the strength and 
direction in the relationship of individual variables with the dependent variable of 
interest to determine the response of a specific treatment.  
Pearson’s product-moment correlation 
A Pearson product-moment correlation was used to determine whether the 
natural life of the 93 circuits which had clotted was influenced by differences in 
treatment mode alone and not by the other variables monitored which included 
measurements of aPTT, platelets, heparin dose, haematocrit and urea. This parametric 
statistical test is used for linear multiple regression analysis whereby all the independent 
variables are entered into the equation simultaneously and each variable is evaluated in 
terms of the effect each has on the other independent variables (Altman, 1991). As a 
precautionary measure in using multiple regression analysis which relies on a number of 
assumptions, the dataset was reviewed as part of the statistical test to determine 
compliance with the assumption of normality and the presence of outliers. The 
independent variables of platelets, haematocrit and urea were included in the multiple 
regression analysis, however heparin dose and aPTT values excluded since both 
variables could not be considered as independent of each other. A direct correlation 
between heparin dose and aPTT values was observed in one study when the impact of 
each variable was measured against circuit life (van de Wetering, et al., 1996). The 
presence of co-linearity amongst two variables can cause inaccuracies to occur and 
should be avoided when undertaking multiple regression analysis (Draper & Smith, 
1998). Pearson product-moment correlation coefficients (r) range from -1 to +1 
according to the linear relationship and whether it is a negative or positive correlation. 
A correlation that is either -1 or +1 indicates the relationship is perfect and the value of 
one variable is able to be determined if the other variable is known (Draper & Smith, 
1998).  
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Spearman’s Rank Order Correlation 
A Spearman‟s Rank Order Correlation was undertaken for multiple regression 
analysis as a non-parametric alternative statistical technique to determine the existence 
or absence of a correlation which was different from those previously recorded using 
the alternative parametric statistical technique. The technique was applied to the 93 
circuits which had survived to clotting and the potential for a correlation between the 
continuous dependent variable of circuit life observed against the independent variables 
of aPTT, platelets, heparin dose, haematocrit and urea.  
Design Limitations 
Although rigorous in approach this study was limited by a number of factors. It 
was a single-site analysis of circuit life in patients requiring CRRT as part of their 
clinical management in ICU. Operational variations in the application of CVVH and 
CVVHDf at the study site could be different to those carried out when the same 
treatment modes are performed in more than one ICU, and it is unknown if similar 
results would be obtained with different anticoagulation regimens or other types of 
vascular access catheters or the use of assorted CRRT machine hardware. While it was 
useful to determine if circuit life is extended by differences in treatment mode, due to 
the cross-over study design and daily blood sampling undertaken, it was not possible to 
evaluate the effectiveness on solute clearance between CVVH and CVVHDf. The 
nature of the intervention made it impossible to blind this kind of study and was open to 
bias if one treatment mode was seen by nursing staff as being more favourable in 
promoting circuit life or was viewed as easier to manage in the clinical setting. 
Ethical Issues       
The prospect of undertaking research involving the critically ill patient raises 
several important issues in regards to patient safety and the requirement for consent 
(Rischbieth & Blythe, 2005). The recruitment of patients who are critically ill comprise 
a cohort of individuals who are vulnerable and dependent on the Intensive Care 
Specialist and Critical Care Nurse for the supervision of treatment and in the delivery of 
care. Any investigator contemplating research involving the critically ill patient must 
have a sound knowledge of ethical principles governing the conduct of clinical studies 
and should be familiar with ethical guidelines followed by the institution where the 
study is planned to be undertaken. The research question under investigation and the 
conduct of this study was granted ethical approval by the Human Research Ethics 
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Committees at RPH, Edith Cowan University and Curtin University of Technology 
using guidelines consistent with those issued by the NHMRC on research involving 
humans (1999). 
Patients admitted to ICU who required CRRT and enrolled to participate in this 
study were exposed to the same risks normally associated with extracorporeal renal 
support, but were open to the possibility of extended circuit life improving the 
effectiveness of the treatment being delivered. The risks associated with extracorporeal 
renal support were no different with CVVHDf than they were for CVVH. In view of the 
preference for CVVHDf at the study site the majority of nursing staff were unfamiliar 
with differences in the operational characteristics of CVVH, and it was necessary to 
provide training and supervision prior to and during the study period. Differences in the 
set-up and fluid exchanges required between the two treatment modes could lead to 
errors in fluid management and place the patient at risk of excessive removal or 
retention of body fluids.  
The majority of patients who participated in the study were unconscious and 
unable to communicate normally due to impaired cognition as a result of sedation and 
the requirement for ventilatory assistance. In keeping with NHMRC guidelines 
involving unconscious persons highly dependent on medical care, permission to 
participate in the study was sought from individuals who had a close and continuing 
relationship with the patient (1999). The approach was made specifically to individuals 
who had been previously nominated by the patient as next-of-kin to make decisions and 
give consent on their behalf. Once the patient was no longer incapacitated the process 
followed for consent allowed the patient an opportunity to make a decision about 
whether to continue participation in the study. 
Informed written consent was obtained from patients wherever possible prior to 
enrolment in the study, otherwise consent was sought from the patient‟s next-of-kin. A 
copy of the „Information Sheet and Consent Form‟ used by the patient or next-of-kin to 
give authority for enrolment in the study is shown in Appendix C. Separate versions of 
the document were written and given to the patient and next-of-kin to reflect differences 
in wording required when providing an explanation of the study and what they were 
being asked to sign. Patients who were about to start or had already commenced CRRT 
were asked to consider whether they would agree to participate in this study. If the 
patient was incapable of speaking for themselves due to the severity of illness, the next-
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of-kin was approached to voice an opinion on their behalf. The patient or next-of-kin 
were given an opportunity to ask questions before making a decision, with information 
about the study given verbally as well as in a written statement. The information sheet 
was kept by the patient or next-of-kin after the consent form had been signed. A copy of 
the consent form was given to the patient or next-of-kin whilst the patient‟s hospital 
identification number was attached to the signed original consent form and placed in the 
patient‟s medical notes for future reference. Patients who were initially incapable of 
informed consent but had participated in the study following next-of-kin consent were 
later given the opportunity to withdraw from the study. Initial consent to participate in 
this study was able to be withdrawn at anytime and had no effect on the patient‟s 
subsequent medical treatment. 
Information collected from patients participating in the study complied with 
guidelines set out under the Privacy Act 1988 (Commonwealth) for the management 
and use of data containing personal information. Data obtained during the study was de-
identified from the patient and coded to allow analysis capable of answering the 
research question. Storage of data was on-site at RPH secured in a locked filing cabinet 
or on computer where access was password protected. Access to data was only allowed 
by research personnel associated with the study, and by representatives of the hospital 
and university ethics committee assigned to review the validity and accuracy during the 
collection and in the reporting of data.      
Summary 
The research design and methodology used for this study was an attempt to 
adopt a rigorous approach in answering the research question. In choosing a randomised 
crossover research design the potential for bias in treatment selection was minimised 
and the affect on circuit life evaluated using the same patient to minimise differences in 
the severity of illness during sequential exposure to each treatment mode. The inclusion 
of power and calculation of sample size ensured that the study contained sufficient 
number of patients to compare circuit life. This was necessary to detect a difference in 
circuit life when patients were exposed to both treatment modes and make the 
prediction that the same result would occur again should the study be repeated on a 
similar group of patients. Using the patient as the control measure the approach was 
standardised for each treatment modality. The machine hardware and haemofilter were 
common to both CVVH and CVVHDf. Circuit life was compared with the same venous 
access catheter and vascular insertion site. Each circuit was exposed to a similar rate of 
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blood flow and the method used to anticoagulate the circuit did not differ. The process 
of standardisation allowed the investigation to separate circuit life as the variable of 
interest between the two treatment modes. Only circuits which had reached a natural 
circuit life were included and crossover to the alternative treatment mode suspended 
when the circuit was taken down for other reasons besides clotting. Measurements of 
circuit life were log transformed prior to undertaking a paired t-test in order to detect a 
mean difference in circuit life as the original data was not normally distributed. The 
cumulative effect of circuit life, when plotted onto a graph using survival analysis 
techniques, was used to identify differences in the probability of circuit survival for both 
treatment modes. A multiple linear regression analysis was undertaken to rule out the 
existence of relationships which would explain differences in circuit life other than the 
choice in treatment mode. The findings of parametric analysis were strengthened to 
exclude the potential for inconsistencies using non-parametric statistical procedures. 
Standards for research involving humans were in accordance with guidelines on ethical 
conduct imposed by hospital and university authorities during the investigation of 




In this chapter data collected from patients who participated in the study 
between December 2004 and July 2006 is presented. The results contain analyses using 
descriptive statistics which included measures of central tendency and dispersion. 
Inferential statistics are also used on the sample of circuit life measurements observed 
during CVVH and CVVHDf. The linear relationship with independent variables 
associated with the two treatment modes is explored using parametric and non-
parametric statistical tests.   
Patient Characteristics 
A total of 45 patients were recruited of whom 16 were women and 29 were men. 
The mean age of participants was 57.9 years, SD+15.6 years. As shown in Table 5.1 
there was a mixed group of surgical and medical patients. Major patient diagnostic 
categories included pneumonia, septic shock and ischaemic heart disease. The mean 
worst in first 24-hour APACHE II score of the 45 patients enrolled in the study was 
25.5, SD+6.2. The mean 24-hour APACHE II score for all patients admitted to ICU 
during the recruitment period was 17 for the period starting January 2005 and finishing 
January 2006 (RPH ICU Database). This suggests the majority of patients who were 
recruited during this time period with a higher illness severity APACHE II score had an 
increased risk of death when compared with other patients who did not require CRRT. 
Although 45 patients were randomised to receive CVVH and CVVHDf, the requirement 
for both circuits to have failed due to clotting, a successful crossover to the alternative 
technique only occurred in 31 patients. Despite the number of randomised patients not 
achieving a treatment crossover, the minimum sample size target of 30 patients was 


















1a 48 Female 29 92.3 Septic Shock 
2a 40 Male 10 114 Septic Shock 
3a 46 Female 23 84.5 Septic Shock 
4a 64 Male 23 86.7 Cardiogenic Shock 
5 57 Male 30 78 Septic Shock 
6a 71 Female 21 60.5 Ischaemic Bowel 
7a 42 Female 28 88.5 Septic Shock 
8a 78 Male 31 76 Pneumonia 
9a 62 Male 29 65.1 Panceatitis 
10a 66 Male 29 78 Septic Shock 
11a 74 Male 21 109.3 Ischaemic Heart Disease 
12a 73 Male 23 105.9 Septic Shock 
13 71 Female 26 80 Septic Shock 
14a 56 Male 21 81.3 Trauma 
15a 72 Male 28 76.4 Pneumonia 
16 63 Male 24 71.8 Cardiogenic Shock 
17 59 Female 16 95.7 Pneumonia 
18a 19 Female 32 68.1 Pneumonia 
19 50 Female 17 88.5 Panceatitis 
20 53 Female 25 84.7 Pneumonia 
21 63 Female 36 63.4 Ischaemic Bowel 
22a 32 Male 36 94.4 Pneumonia 
23a 53 Male 21 124.3 Septic Shock 
24a 36 Male 23 100 Trauma 
25a 41 Male 19 105 Septic Shock 
26 57 Male 37 90 Cadiogenic Shock 
27a 68 Male 27 111.8 Abdominal Aortic Aneurysm 
28a 77 Male 24 91.9 Septic Shock 
29a 65 Male 39 88.5 Abdominal Aortic Aneurysm 
30 53 Male 23 111.7 Cardiogenic Shock 
31 71 Female 36 80.3 Cardiogenic Shock 
32a 82 Male 29 83.9 Pneumonia 
33a 35 Female 18 99.3 Pneumonia 
34a 47 Male 26 116.4 Pneumonia 
35 73 Female 15 91.8 Ischaemic Heart Disease 
36a 80 Male 22 82 Ischaemic Heart Disease 
37a 70 Male 23 81.5 Pneumonia 
38a 59 Male 22 97.4 Septic Shock 
39a 55 Male 28 89.4 Septic Shock 
40 70 Female 25 110.8 Chronic Renal Failure 
41a 75 Male 19 59.1 Ishaemic Heart Disease 
42 34 Female 34 76.4 Hepatic Failure 
43a 36 Female 28 60.2 Pneumonia 
44a 34 Male 27 63 Trauma 
45 75 Male 26 106.5 Pneumonia  
a. Successful treatment crossover 
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Randomisation 
Out of 45 patients who participated in the study 21 patients were initially 
randomised to receive CVVH and 24 patients to CVVHDf. As a result of circuits taken 
down for reasons other than clotting, out of the 45 patients enrolled, cross-over to the 
alternative mode was not possible in 14 cases. This was due to death (3 patients), 
violations in study protocols (2 patients), stabilisation of the patient‟s condition 
allowing transfer out of the unit (1 patient), or elective discontinuation (8 patients). 
Clotting of the circuit in the remaining 31 patients occurred sequentially between the 
two modalities. Of the 31 patients who achieved a successful crossover 15 were initially 
randomised to receive CVVH and 16 to CVVHDf. A diagram illustrating the 
distribution in CRRT mode following randomisation and the number of successful 
versus unsuccessful treatment crossovers is shown in Figure 5.1. 
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Figure 5.1. Mode of treatment distribution following initial randomisation and the 
number of successful versus unsuccessful treatment crossovers. 
 
‘Natural’ Circuit Life 
In the 45 patients treated 93 circuits reached a natural circuit life as previously 
defined. Of the 93 circuits, 62 were paired CVVH and CVVHDf circuits (31 of each), 
with the remaining 31 circuits reaching a natural circuit life but not able to be paired in 
 









crossovers in 14 patients 
 
Successful treatment 








a crossover. Of the 93 circuits, 43 were CVVH circuits and 50 CVVHDf circuits had 
reached a natural circuit life. The bar chart shown in Figure 5.2 illustrates the 93 circuits 
and their respective circuit life in minutes. Blue coloured bars represent circuit life when 
treatment modality was by CVVH and the red coloured bars represent circuit life when 
treatment modality was by CVVHDf. A horizontal reference line has been drawn at 960 
minutes which identifies the mean circuit life of 16.2hr which was previously recorded 
using CVVHDf as part of a quality improvement project conducted earlier at the study 
site (Leslie, 2003). Inspection of the bar chart reveals the majority of circuits (69) did 
not reach a lifespan that was greater than the 960min reference line. Out of the 24 
circuits which exceeded the reference line a greater number occurred when the 






































































































































In order to determine what statisticl approach should be taken in assessing 
circuit life differences the Kolmogorow-Smirnov goodness-of-fit statistical test was 
undertaken to evaluate the normality of data distribution. As shown in Table 5.2 the 
results from the Kolmogorov-Smirnov test (Statistic = 0.204, P-value = 0.000) indicate 
that the lifespan of the 93 circuits included in the sample does not have a normal 
distribution. Instead of a symmetrical bell-shaped distribution curve, the frequency of 
shortened circuit life caused the distribution curve to be positively skewed. The 
positively skewed distribution in circuit life measurements is demonstrated in Figure 5.3 
when displayed as a scatter plot. Inspection of the scatter plot shows the observed 
values which are distributed along a curved line plotted against the expected linear 
measurements when normally distributed.  
 
Table 5.2  
The Kolmogorov-Smirnov goodness-of-fit statistical test for all circuit life measured in 
minutes 
 
  All Circuit Life (min) 
  n = 93 
Normal Parameters Mean 781.32 
 Standard Deviation (SD) 602.016 
Kolmogorov-Smirnov Z  0.204 



























Normal Q-Q Plot of All circuit life in minutes
 
Figure 5.3. Circuit life measurements displayed as a scatter plot against expected 
measurements for a normal distribution. 
 
Given the skewed data distribution, consideration was given to manipulating the 
data on circuit life measurements to allow the option of parametric as well as non-
parametric statistical testing. Using the natural logarithm base e (ln) dataset 
transformation, measurements of circuit life were mathematically formulated and 
modified to transform a positively skewed distribution curve to one that resembled a 
normal distribution. The distribution of logarithm transformed values was again 
evaluated for normality. As shown in Table 5.3 the Kolmogorow-Smirnov statistical test 
produced a non-significant result (Statistic = 0.755, P-value = 0.618) indicating after 
natural logarithm base e (ln) dataset transformation the conditions of normality had been 
met by the mathematical manipulation of circuit life measurements. A repeat scatter plot 
of circuit life measurements after dataset transformation shown in Figure 5.4 reveals the 
distribution of values are in a reasonably straight line similar to the expected normal 





Table 5.3  
The Kolmogorov-Smirnov goodness-of-fit statistical test for all circuit life 
measurements after natural logarithm base e transformation (ln) 
 
  All Circuit Life (min) 
  n = 93 
Normal Parameters a,b Mean 6.429 
 Standard Deviation (SD) 0.662 
Most Extreme Differences Absolute 0.078 
 Positive 0.078 
 Negative -0.052 
Kolmogorov-Smirnov Z  0.755 
Asymp. Sig. (2-tailed)  0.618 
a. Test distribution is Normal 





















Normal Q-Q Plot of All Circuit Life Ln Log
Transformation
 
Figure 5.4. Circuit life measurements displayed as a scatter plot following natural 
logarithm base e (ln) dataset transformation against expected measurements for a 
normal distribution. 
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Sequential Treatment Crossovers 
Sequential treatment crossovers and paired comparisons of circuit life occurred 
in 31 patients. To illustrate the pattern of the numerical difference in circuit life between 
the two modes of treatment, a bar chart shown in Figure 5.5 expressed the difference 
between each pair according to the order patients were recruited. The bar chart depicts 
circuit life in favour of CVVH as blue coloured bars and circuit life in favour of 
CVVHDf as red coloured bars. Several examples in the bar chart illustrate that in some 
cases there appeared to be large differences in circuit life for either treatment modes. 
For example the observed difference in circuit life for patient number one was in favour 
of CVVHDf with a longer circuit life of 536 min (8hr 56min) whilst for patient number 
13 the difference in circuit life was in favour of CVVH with an extended circuit life of 
320min (5hr 20min). Out of the paired circuits CVVHDf was observed in 25 patients to 
have a greater difference in circuit life compared with only six patients where the 
difference in circuit life was in favour of CVVH. Although the bar chart shows a 
difference in the pattern of circuit life which favoured CVVHDf, the estimated 
difference in circuit life favouring CVVH occurred throughout the duration of the study 
and not as a result of increased exposure to the „new‟ treatment. This scattered result of 
circuit life shown in Figure 5.5 suggests the mode of treatment, rather than technique 
familiarity was possibly the dependent variable of differences observed in circuit life 
between CVVH and CVVHDf. 
Pre-dilution Volume and Treatment Mode 
Out of the 31 patients who achieved a successful treatment crossover the 
difference in pre-dilution volume delivered using CVVH varied considerably when 
compared with the volume of fluid delivered using the alternative technique of 
CVVHDf. As shown in Table 5.4 the difference in predilution volume delivered for 
each patient during a treatment crossover increased amongst patients who had large 
variations in body weight. The volume of replacement fluid required for CVVH was 





Figure 5.5. The pattern of paired difference in circuit life between CVVH and CVVHDf 
for 31 patients who received both techniques sequentially after each circuit had 


















Table 5.4  
Differences in pre-dilution volume of successful treatment crossovers according to body 
















92kg 3220ml/hr  600ml/hr 2620ml 
114kg 3990ml/hr  600ml/hr 3390ml 
85kg 2975ml/hr 600ml/hr 2375ml 
87kg 3045ml/hr 600ml/hr 2445ml 
61kg 2135ml/hr 600ml/hr 1535ml 
89kg 3115ml/hr 600ml/hr 2515ml 
76kg 2660ml/hr 600ml/hr 2060ml 
65kg 2275ml/hr 600ml/hr 1675ml 
78kg 2730ml/hr 600ml/hr 2130ml 
109kg 3815ml/hr 600ml/hr 3215ml 
106kg 3710ml/hr 600ml/hr 3110ml 
81kg 2835ml/hr 600ml/hr 2235ml 
76kg 2660ml/hr 600ml/hr 2060ml 
68kg 2380ml/hr 600ml/hr 1780ml 
94kg 3290ml/hr 600ml/hr 2690ml 
124kg 4340ml/hr 600ml/hr 3740ml 
100kg 3500ml/hr 600ml/hr 2900ml 
105kg 3675ml/hr 600ml/hr 3075ml 
112kg 3920ml/hr 600ml/hr 3320ml 
92kg 3220ml/hr 600ml/hr 2620ml 
89kg 3115ml/hr 600ml/hr 2515ml 
84kg 2940ml/hr 600ml/hr 2340ml 
99kg 3465ml/hr 600ml/hr 2865ml 
116kg 4060ml/hr 600ml/hr 3460ml 
82kg 2870ml/hr 600ml/hr 2270ml 
82kg 2870ml/hr 600ml/hr 2270ml 
97kg 3395ml/hr 600ml/hr 2795ml 
89kg 3115ml/hr 600ml/hr 2515ml 
59kg 2065ml/hr 600ml/hr 1465ml 
60kg 2100ml/hr 600ml/hr 1500ml 
63kg 
 













Circuit Life during CVVH and CVVHDf 
The descriptive measurement of circuit life for each treatment mode suggested 
lifespan differences shown in Table 5.4 occurred between CVVH and CVVHDf. The 
estimated mean circuit life for CVVH was eight hours 33min (SD+5hr 35 min) with an 
estimated median circuit life of six hours 35min and an estimated range of 30hr 45min. 
In comparison the mean circuit life for CVVHDf was 18hr 42min (SD+13hr 3 min), 
with a median circuit life of 16hr 5min and a range of 40hr 23min. 
Table 5.5  
Descriptive statistics of circuit life during CVVH and CVVHDf  
 
 
Treatment Modality Descriptive Statistic 
CVVH   
Mean 513.32min (8hr and 33min) 
Median 395min (6hr and 35min) 
Standard Deviation (SD) 335.21min (5hr and 35min) 
Minimum 159min (2hr and 39min) 
Maximum 2004min (33hr and 24min) 
Range 1845min (30hr and 45min) 
   
CVVHDf   
Mean 1122.13min (18hr and 42min) 
Median 965min (16hr and 5min) 
Standard Deviation (SD) 782.89 (13hr and 3min) 
Minimum 270 (4hr and 30min) 
Maximum 2693 (44hr and 53min) 
Range 2423 (40hr and 23min) 
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Comparison of Circuit Life 
Based not only on the transformed but also on the raw data distributions, the 
comparison of circuit life between CVVH and CVVHDf was made using both 
parametric and non-parametric statistical tests. The (parametric) paired-sample t test 
was applied to the normalised natural log transformed dataset and investigated the 
difference between the two sample means. The (non-parametric) alternative Wilcoxon 
signed ranks test was also carried out using the raw dataset. Application of both 
approaches was undertaken to demonstrate there was enough evidence from the datasets 
for the results to be considered statistically significant.  
Paired-sample t-test 
A paired-samples t-test was performed on the 31 paired circuit life comparisons 
for CVVH and CVVHDf using a natural logarithm base e (ln) logarithm transformation. 
This transformation was used to normalise the observed values of the paired circuit life 
so that the parametric test would be applied without violating the normality assumption. 
The transformed means and transformed standard deviations for both circuit life 
measurements are shown in Table 5.5. The t-test results for the transformed data set are 
shown in Table 5.6. Note that the mean difference was considered to be statistically 
significant and its P-value was 0.001. 
Table 5.6  
The transformed means and standard deviations (SD) for circuit life (CVVH and 
CVVHDf) 
 
 Means Standard Deviations (SD) 
CVVH  6.101 0.516 
CVVHDf  6.779 0.726 
a. Natural logarithm base e transformation (ln) 
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Table 5.7  
The parametric paired-sample t-test for 31 transformed comparisons of CVVH and 
CVVHDf circuit life 
 
Mean SD SE a 95% CI b t df P-value c           
0.679 0.665 0.119 (0.435, 0.923) 5.682 30 0.001 
a. Standard Error of the Mean (SE) 
b. 95% Confidence Interval for the Mean (Lower, Upper) 
c. P-value based on a two-tailed test 
Wilcoxon Signed Ranks Test 
The non-parametric Wilcoxon signed ranks test was applied to the raw data set 
and the Z-statistic was calculated based on the rank order for the 31 paired comparisons. 
The results are shown in Table 5.7 and there was enough evidence from the data set to 
suggest that there was a significant difference in circuit life between CVVH and 
CVVHDf (Z = -4.076, P-value < 0.001). 
Table 5.8 
The non-parametric Wilcoxon signed ranks test for 31 comparisons of CVVH and 
CVVHDf circuit life. 
 
 N Mean Rank Sum of Ranks Ties c Total Z d P-value e 
Negative Ranks 7 a 5.71 40.00 0 31 4.076 <0.001 
Positive Ranks 24 b 19.00 456.00  6   
a. CVVHDf circuit life in minutes < CVVH circuit life in minutes 
b. CVVHDf circuit life in minutes > CVVH circuit life in minutes 
c. CVVHDf circuit life in minutes = CVVH circuit life in minutes 
d. Statistic test: Z distribution 




A survival analysis was performed to appreciate the characteristics over time of 
circuit survival for both modes of CRRT studied. The survival curves for CVVH and 
CVVHDf are shown in Figure 5.6 after the probability of circuit survival time was 
estimated using Kaplan-Meier survival analysis. 
 
Figure 5.6. The Kaplan-Meier (percentage cumulative) survival curves for CVVH and 
CVVHDf treatment modes (Note the fixed truncation time line at 960 minutes was 
based on earlier data from the study site).  
  
The analysis was performed on all 93 circuits which had reached a natural 
circuit life. The blue curve represents the survival of CVVH circuits and the red curve 
the survival of CVVHDf circuits. At zero minutes, that is the commencement of 
treatment, there is 100% survival of all circuits using the method of Kaplan-Meyer for 
the survival analysis. After 500min (8hr 20min) there is a 40% chance of survival for 
CVVH circuits compared with CVVHDf circuits which at the same point in time have 
an 80% chance of survival. The mean circuit life of 960min (16hr) observed earlier at 
the study site (Leslie, 2003) was used as a predetermined truncation point for circuit life 
when comparisons of each treatment modality were made. The difference in chances of 
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survival between both treatment modalities increased to a 50% chance of CVVHDf 
circuits in operation at the predetermined truncation of 960min compared to the 
likelihood of only a 5% chance for CVVH circuits. The survival of circuits when 
expressed as a measurement of non-survival potential between the two treatment 
modalities is shown in Figure 5.7. The graph depicts the hazard or failure rate for 
CVVH circuits in blue and for CVVHDf circuits in red. At the truncation point of 
960min the cumulative risk of circuit failure is lower with CVVHDf at 0.6, whilst the 
risk of circuit failure is higher at 2.5 using CVVH.  
 
 
Figure 5.7. The hazard or failure rate of circuit survival between CVVH and CVVHDf. 
 
A Multiple Linear Regression Analysis 
A multiple linear regression analysis on the 93 circuits which had reached a 
natural circuit life and inclusive of the 31 paired comparisons formed the next and final 
stage of the statistical analysis. Exploration of linear relationships amongst variables 
was considered to determine whether circuit life was influenced by differences in 
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treatment mode alone, or influenced by exposure to other factors which could have 
impacted upon circuit life. The multiple linear regression analysis involved the 
evaluation of linear relationships or correlations between several independent variables 
against the dependent variable of circuit life.  
Before conducting a correlation analysis a scatter plot was examined to check 
for possible violations of normality assumption. The Normal Probability Plot shown in 
Figure 5.8 displays the residual differences between the obtained and predicted values 
of the natural logarithm base e (ln) circuit life measurements.  
 
Figure 5.8. The Normal Probability Plot of the natural logarithm base e (ln) circuit life 
measurements for the residual differences between the obtained and predicted values. 
 
This was generated as part of the multiple linear regression analysis which 
assumes measured differences are normally distributed. The residual differences 
appeared to be lying in a line which is reasonably straight. A Normal Probability Plot 
showing points which are approximately in a straight line indicate normality in the 
distribution of measurements (Draper & Smith, 1998). The assumption of normality in 
the transformed distribution of the circuit life measurements is also investigated by a 
second plot (a scatter plot) generated from the multiple linear regression analysis. The 
scatter plot shown in Figure 5.9 of residual measurements against predicted values of 
the dependent variable is roughly located around the zero reference line.  
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Figure 5.9. Scatter plot of residual measurements against predicted values of the 
dependent variable. 
 
Most of the values are concentrated in the centre along the zero reference line. A 
scatter plot that is centralised suggests normality in the distribution of measurements 
(Draper & Smith, 1998). Review of the scatter plot also shows the absence of significant 
outliers. Tabachnick and Fidell (2001) define outliers as standardised residual values 
which are greater than 3.3 or less than -3.3. None of the standardised residual values in 
the scatter plot are greater than 2 or less than -3. Once it had been established that the 
distribution and shape of the scatter plot indicated measurements were roughly linear 
and randomly spread, a Pearson‟s product-moment correlation was performed. 
Pearson’s product-moment correlation 
A Pearson product-moment correlation (parametric) test was chosen to evaluate 
the strength and direction of linear relationships between the dependent variable of 
circuit life and five independent variables. As shown in Table 5.8 the number of 
variables which were paired together totalled 60 and provided a sufficient quantity of 
pairs for the correlation analysis not to be influenced by the prevalence of missing data. 
A weak linear relationship with the independent variables of aPTT, platelets, heparin 
dose, haematocrit and urea was observed with the dependent variable of circuit life.  
None of the independent values had a correlation value greater than 0.4 or less than -0.4 
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indicating the strength of relationship was considerably weak. Out of the independent 
variables tested none were shown to have a correlation with each other which was 
statistically significant apart from the effect of heparin on aPTT (P-value = 0.011) and 
the impact of urea on both aPTT (P-value = 0.004) and platelets (P-value = 0.028).  
Table 5.9  
A linear multiple regression analysis demonstrating a weak correlation between the 
continuous dependent variable of circuit life against the independent variables of aPTT, 





























0.145 -0.184 0.158 0.016 -0.174 
aPTT in 
seconds 
0.145 1.000 -0.023 -0.297 -0.074 -0.344 
Platelets 
 




0.158 -0.297 0.092 1.000 0.143 0.189 
Haematocrit 
 
0.016 -0.074 0.052 0.143 1.000 0.079 
Urea -0.174 -0.344 0.247 0.189 0.079 1.000 
N 60 60 60 60 60 60 60 
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Table 5.9 (Cont‟d) 

























0.134 - 0.429 0.011 0.288 0.004 
Platelets 
 




0.114 0.011 0.243 - 0.138 0.074 
Haematocrit 
 
0.451 0.288 0.348 0.138 - 0.274 
Urea 
 
0.091 0.004 0.028 0.074 0.274 - 
N 60 60 60 60 60 60 60 
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The model summary of the multiple linear regression analysis displayed in Table 
5.9 shows the estimated determination coefficient (R Square value) to be 0.117. The R 
Square value refers to the degree of variance in the dependent variable of circuit life 
which could be attributed to the independent variables of aPTT, platelets, heparin dose, 
haematocrit and urea. When the R Square value is expressed as a percentage the 
variance in circuit life is explained as a 12% chance that the variance observed in the 
dependent variable was caused by the independent variables.  
Table 5.10  
The model summary of the multiple linear regression analysis showing the degree of 
variance in the dependent variable of circuit life which could be attributed to the 
independent variables of aPTT, platelets, heparin dose, haematocrit and urea 
 
R R Square Adjusted R Square 
0.342 0.117 0.035 
 
The analysis of variance for multiple independent variables (ANOVA) statistical 
test (Draper & Smith, 1998) shown in Table 5.10 shows an estimated P-value of 0.228 
indicating that there was no linear relationship between the studied dependent and 
independent variables. 
 
Table 5.11  
Analysis of variance (ANOVA) between the dependent variable of circuit life and the 
independent variables of aPTT, platelets, heparin dose, haematocrit and urea 
 





Regression 2.870 5 0.574 1.432 0.228 
Residual 21.641 54 0.401   
Total 24.511 59    
 
 196 
The final step of the multiple regression analysis required the evaluation of each 
independent variable to determine whether any of these variables contributed more than 
the other in the prediction of the dependent variable of circuit life. In Table 5.11 the 
estimated standardised coefficients (Standardised Beta values) are listed under the 
column labelled Standardised Coefficients, the independent variables of aPTT, platelets, 
heparin dose, haematocrit and urea have been converted to the same scale in order for a 
comparison to be made on the effect each of the independent variables had on circuit 
life. The individual contribution associated with influencing circuit life was heparin 
dose with a Beta Standardised Coefficient value of 0.246. None of the Beta 
Standardised Coefficient values of the independent variables including heparin 




Table 5.12  
Estimated standardised coefficients (Beta values) for each independent variable 
 
 Standardised Coefficients  
P-value Beta 
aPTT in seconds 0.174 0.223 
Platelets -0.174 0.195 
Heparin dose in units/kg/hr 0.246 0.076 
Haematocrit 0.012 0.925 
Urea -0.119 0.403 
 
Spearman’s Rank Order Correlation 
The strength of the linear relationship between the dependent variable of circuit 
life and the independent variables of aPTT, platelets, heparin dose, haematocrit and urea 
was calculated using the alternative non-parametric Spearman‟s Rank Order Correlation 
statistical test. None of the independent variables shown in Table 5.12 indicated to have 
a linear bivariate correlation with the dependent variable. However, among the bivariate 
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linear Spearman‟s correlation coefficients of the independent variables, there appeared 
to be a significant correlation between urea and aPTT (Spearman correlation coefficient 
= -0.409 and P-value = 0.001). 
 
Table 5.13 
The bivariate linear Spearman’s Rank Order Correlation between the continuous 
dependent variable of circuit life and the converted measurements of the independent 
variables of aPTT, platelets, heparin dose, haematocrit and urea (Note that all the 











Circuit life  1.000 0.182 -0.101 0.071 0.093 -0.193 
aPTT  0.182 1.000 0.083 -0.187 -0.012 -0.409 
Platelets -0.101 0.083 1.000 0.154 0.028 0.026 
Heparin  0.071 -0.187 0.154 1.000 0.188 0.089 
Haematocrit 0.093 -0.012 0.028 0.188 1.000 0.074 












Table 5.13 (Cont‟d) 
  Circuit 
life  




value           
(2-
tailed) 
Circuit life  - 0.132 0.425 0.503 0.462 0.123 
aPTT 0.132 - 0.523 0.124 0.926 0.001 
Platelets 0.425 0.523 - 0.226 0.827 0.841 
Heparin  0.503 0.124 0.226 - 0.136 0.483 
Haematocrit 0.462 0.926 0.827 0.136 - 0.568 
Urea 0.123 0.001 0.841 0.483 0.568 - 
 
Summary 
The results based on the statistical analyses contain several important findings. 
A broad range of conditions was represented in the sample of patients exposed to both 
treatment modalities and could be considered representative of patients‟ who require 
CRRT at the study site. Distribution in the sequence of modes between CVVH and 
CVVHDf was randomly assigned with no treatment modality being repeatedly selected 
over another. Therefore the assignment would minimise the possibility of one mode 
being influenced by timing within the exposure to patient characteristics associated with 
the course of disease progression. For instance, higher urea values associated with the 
initiation of CRRT. A significant mean difference in circuit life was observed between 
CVVH and CVVHDf in 31 paired comparisons with patients acting as their own 
controls using a sequential crossover method. Out of the 93 circuits which had reached a 
natural circuit life regardless of whether they had been paired with the alternative 
treatment modality, the strength of linear relationship between the dependent variable of 
circuit life appeared to not be significant with the measurement of other independent 
variables. The results indicate significant differences in circuit life. The differences 




The principal aim of this research was to measure and compare the lifespan of 
CRRT circuits according to differences in pre-dilution volume associated with the 
techniques of CVVH and CVVHDf. A statistically significant improvement in circuit 
life using CVVHDf was observed when compared with the circuit life achieved during 
CVVH. The difference in circuit life between the two modes of treatment was 
substantial and clinically significant with CVVHDf shown to reduce treatment „down 
time‟ associated with circuit failure and thereby better meet the continuous requirement 
of RRT delivery to the patient.  
Acute Kidney Injury leading to the development of severe ARF is a serious 
complication impacting upon the survival and recovery of critically ill patients (Thakar, 
Christianson, Freyberg, Almenoff, & Render, 2009). The option for extracorporeal RRT 
in the ICU setting has initially been limited to conventional IHD. The technique was 
associated with fluid management and haemodynamic problems when the approach was 
applied to the critically ill patient. In efforts to overcome these problems a continuous 
approach to RRT was developed (S. John & Eckardt, 2007; Kramer, et al., 1980). The 
original CRRT concept (such as CAVH and CAVHD) which relied on the patient‟s 
arterial blood pressure gave way to pumped veno-venous circuits and the techniques of 
CVVH and CVVHDf in recognition of improved ultrafiltration performance without the 
requirement for arterial cannulation (Storck, et al., 1991). Other improvements  made 
during the development of CRRT have followed further advances in extracorporeal 
membrane technology and the growth of purpose-built machines (Ricci, et al., 2004). 
Some of these technological improvements have been transferred across and are now 
used in the application of IHD where contemporary practice reduce episodes of 
hypotension and the evolution of hybrid therapies allow greater flexibility in fluid 
balance control (van Biesen, et al., 2007). 
Although the practice of CRRT has been adopted by many as the preferred 
method to support renal function in the ICU (Ronco & Bellomo, 2007), others do not 
support the abandonment of intermittent therapies unless a clear advantage in using 
CRRT can be established (Himmelfarb, 2007). Any future comparison between CRRT 
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and IHD is unlikely to show a difference in patient outcomes when the advantages and 
disadvantages of both techniques are not singled out. Attempts made to define the value 
of CRRT based solely on patient survival have proven elusive and possibly too 
simplistic given the manifestation of ICU ARF as part of MOD syndrome (Uchino, et 
al., 2005). The demonstration of a benefit may instead be influenced by the approach 
taken during the course of treatment rather than the choice of technique being superior. 
A clear advantage in choosing CRRT over IHD is demonstrated by the ability over time 
to achieve physiological stability and greater flexibility in fluid and nutritional support.  
The continuous approach has emerged following the ATN (Acute Renal Failure 
Trial Network, 2008) and RENAL (RENAL Replacement Therapy Study Investigators, 
2009) studies as the most appropriate form of RRT for vasopressor dependent patients 
when they are most vulnerable to changes in haemodynamic stability and a reduced 
capacity to maintain adequate organ perfusion pressure. In the context of MOD the 
technique of CRRT is comparable to the similar uninterrupted use of mechanical 
ventilation as a continuous support measure for the management of respiratory failure. 
Attention should now focus on the superiority of CRRT to achieve slow removal of 
excess fluid and correct biochemical abnormalities in the presence of haemodynamic 
instability which may have a beneficial effect on facilitating the return of kidney 
function and offer protection in the failure of other organs.  
The actual delivery of less than the prescribed dose to patients receiving CRRT 
has been identified as a specific problem. This occurs predominantly due to 
interruptions to the continuous nature of the technique leading to a reduction in the 
delivered dose. In two retrospective studies only 68% to 78% of patients treated with 
CRRT were found to have been delivered the prescribed dose (Uchino, et al., 2003a; 
Venkataraman, Kellum, & Palevsky, 2002). The clinical significance of delivery of less 
than the prescribed dose is uncertain. Although the ATN (Acute Renal Failure Trial 
Network, 2008 ) and RENAL (RENAL Replacement Therapy Study Investigators, 
2009) studies did not show patient outcomes were improved when the intensity of 
treatment dose was increased above standard practice (20ml per kg per hr), the 
importance of achieving a minimum treatment threshold is necessary for the patient to 
receive adequate renal replacement and clinical benefit from the intervention. At what 
level the dosing threshold is, requires further investigation. Nevertheless, when seeking 
to improve treatment delivery the ability to achieve a predetermined dose is an 
important aspect of clinical practice. Some authors have expressed the opinion the 
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intensity of renal support prescribed against the actual dose delivered to the patient 
requires greater scrutiny (Overberger, et al., 2007). It is against this background an 
investigation of possible differences in circuit life between the techniques of CVVH and 
CVVHDf was considered appropriate in order to determine whether selection of mode 
influenced continuity of treatment. Although several studies discussed in the literature 
review have investigated the question using the same or different treatment modes none 
of the studies reviewed were designed as a prospective randomised crossover 
investigation. 
Circuit Life with CVVH and CVVHDf 
The objective of this research project was to evaluate the effect on circuit life of 
a higher patient adjusted pre-dilution dose volume associated with CVVH when 
compared to CVVHDf and the delivery of a lower fixed pre-dilution and dialysate 
volume. This was accomplished using a randomised comparative crossover study design 
using a sample of patients drawn from a single centre who required CRRT as part of 
their treatment in ICU. In comparison with the mean circuit life of eight hour and 33min 
for CVVH, the use of CVVHDf extended the lifespan by almost 12hr with a mean 
circuit life of 18hr and 42 min. The shorter circuit life experienced with CVVH 
occurred despite exposing the blood to increased dilution before the haemofilter when 
compared with the limited dilution which occurred during CVVHDf. 
The lifespan of circuits observed during this study can be compared with those 
observed by other investigators. Similar to this research project Saudan and associates 
(2006) used the pre-dilution method for both CVVH and CVVHDf. No significant 
difference in circuit life between each treatment mode was reported but in this 
comparison, patients were randomised to receive only CVVH or CVVHDf and not the 
alternative technique. So unlike a crossover study design the comparison of circuit life 
was limited by not comparing exposure of both treatment modes with the same patient. 
Another example of how this finding can be compared with other investigations 
concerns the reported median circuit life of six hours and 35min for pre-dilution CVVH. 
The result was much shorter than the median lifespan observed by Uchino and 
associates (2003b) in both the pre-dilution and post-dilution methods of fluid 
replacement for CVVH (18hrs and 13hrs). Although these two examples are of studies 
that had different objectives regarding the purpose of the variable under investigation, 
they do allow a comparison to be made with observations made during this project in 
the differences in circuit life between CVVH and CVVHDf. 
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Conceptual Framework Revisited 
The possible reasons why a superior circuit life was reported using CVVHDf 
can be explained using the conceptual framework as discussed in Chapter 3. In this 
framework physiological and mechanical factors were identified as potential 
contributors to the deterioration of the filter membrane and the development of blood 
clots that result in circuit failure. As shown in Figure 3.1 connections with circuit 
longevity are possible when the conceptual framework is used to identify these factors 
as both independent and interrelated variables which impact on the longevity of circuit 
life. By using the framework connections with circuit longevity can for example be 
made when coagulation activity is identified as a physiological factor or education and 
machine use is identified as a mechanical factor. Several measures were adopted in the 
research project to „isolate‟ the variable of interest by standardising the research design 
and hardware and techniques. Differences in the treatment mode alone rather than the 
method used to perform each technique reduced the known impact of physiological and 
mechanical factors when comparisons of circuit life were made. Once these variables 
were controlled, the reason why differences occurred between CVVHDf and CVVH can 
be explored according to the dependent variable of treatment mode and differences in 
pre-dilution volume.  
Solute Transport and Plasma Water Removal   
The advantage in circuit life realised by CVVHDf over CVVH may be explained 
by the principal method each technique uses to accomplish solute transport and plasma 
water removal. The rate of solute clearance achieved using CVVHDf is primarily 
influenced by the concentration gradient in the diffusion of solutes across the semi-
permeable membrane. The technique of CVVH relies on hydrostatic pressure applied to 
the movement of plasma water for solute clearance by convection. On commencement 
of either treatment the semi- permeable membrane is unsoiled with a similar sieving 
coefficient of one for both CVVH and CVVHDf. Over the duration of treatment using 
each technique there is gradual fouling of the membrane influenced in part by the 
processes of diffusion and convection. This establishes the potential for a relationship 
between solute transport and plasma water removal with a reduction in membrane 
efficiency and the possibility of circuit failure by clotting.  
A larger volume of plasma water is required to pass through the semi-permeable 
membrane during CVVH when compared with the alternative technique of CVVHDf in 
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order to achieve a similar degree of solute clearance. The increased movement of 
plasma water which occurs during CVVH may result in greater protein adsorption and a 
reduction in the sieving coefficient of the membrane (Joannidis & Oudemans-Van 
Straaten, 2007). A theorised illustration portrayed in Figure 6.1 shows how the 
technique of CVVH facilitates the movement of plasma water and the transport of 
solutes by convection through the pores of the semi-permeable membrane. The 
movement of solutes by convection possibly leads to early saturation and occlusion of 
the membrane pores due to plasma proteins being forced by hydrostatic pressure against 
the membrane of the blood compartment. On the other hand CVVHDf uses diffusion 
much more so than convection as the primary mechanism of solute transport. Figure 6.2 
is a theorised illustration that demonstrates a reduction in the adherence of plasma 
proteins to the surface area of the membrane as a result of reduced dependence on 
hydrostatic pressure for solute transport. In turn this causes a decrease in the movement 
of plasma water and the force applied to plasma proteins against the membrane surface 
area of the blood compartment. 
 
 
Figure 6.1. An illustration of CVVH using convection to achieve solute clearance 
shows protein adherence and fouling of the membrane may be increased due to greater 





Figure 6.2. An illustration of CVVHDf using primarily diffusion to achieve solute 
clearance shows protein adherence and fouling of the membrane may be decreased due 
to less reliance on the movement of plasma water 
 
The escalation of blood-membrane interaction which occurs with the convective 
more so than the diffusive transport of solutes may not only elevate protein saturation, 
but can also cause more pronounced activation of the coagulation pathway leading to 
the premature development of blood clots (Joannidis & Oudemans-Van Straaten, 2007). 
It is theorised soon after protein adsorption has occurred platelet adhesion appears on 
the membrane surface area. The adhesion of platelets stimulate the aggregation of 
platelets and the release of clotting factors which act as triggers for both the contact and 
tissue factor coagulation pathways (Black, 2008). This theoretical explanation in the 
activation of both coagulation pathways leads to the formation of thrombin and the 
generation of fibrin threads and the establishment of a stable clot. The presence of 
trapped red blood cells along the membrane surface area portrayed in Figure 6.3 
encourages the further aggregation of platelets and the formation of larger blood clots, 
which inevitably leads to obstruction of the haemofilter blood channels and circuit 
failure. Surface reactions of blood to artificial membranes as theorised to occur during 
haemodialysis and haemofiltration in the diffusive and convective transport of solutes 
have been observed using electron microscopic imagery (von Baeyer et al., 1988). 
Observations of the inner surface area showed a continuous layer of protein molecules 
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deposited along the membrane when exposed to haemodialysis and haemofiltration. 
What differed in the study when the same polyacrylonitrile membrane was used for both 
techniques arose by the limited appearance of fibrin strands rarely visible after 
application of haemodialysis. This contrasted with a greater prevalence of fibrin strands 
observed by the authors along the membrane when blood-membrane interaction was 
associated with the application of haemofiltration.  
 
Figure 6.3. An illustration of red blood cells trapped within a fibrin mesh causing the 
formation of a stable clot and increased aggregation of platelets  
 
The convection-based technique of CVVH has been shown in one study to be 
associated with elevated transmembrane pressures and premature clotting of the circuit, 
when compared with the same pressure measurements and incidence of clotting 
observed using the diffusion only-based technique of CVVHD (Ricci, Ronco, 
Bachetoni, et al., 2006). A requirement for the higher ultrafiltration volumes associated 
with CVVH was suggested by the authors as a possible reason why increased 
transmembrane pressure values were observed, when in comparison the same pressure 
values were decreased during CVVHD since the majority of solute clearance was 
instead achieved by dialysis. The elevation of transmembrane pressure and increased 
procoagulatory activity reported by Ricci and associates (2006) might explain why a 
similar difference in circuit life was observed between CVVH and CVVHDf, favouring 
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the diffusion-based technique when the ultrafiltrate volume required for CVVH was 
substantially reduced using CVVHDf. Although the removal of small and middle-sized 
molecules was observed by Ricci and associates (2006) to be similar, the authors 
nevertheless observed a gradual deterioration in solute clearance when using both 
treatment modes. This supports the premise that the performance of the membrane is 
decreased as progressive clogging of the membrane occurs and reduces the permeability 
of the membrane.  
Strengths and Weaknesses 
The research project had several strengths and weaknesses in the way the study 
was conducted. Education and training was given special consideration during the 
conduct of the study as a potential confounding factor if the study protocol was not 
strictly followed or there was a difference in technical ability in undertaking either 
mode of CRRT. The strengths and weaknesses of the project are accounted for through 
the study design and application of each technique. 
Study Design 
The investigation was limited to a single study site using a sample of patients 
whose characteristics were nevertheless consistent with those most likely to require 
CRRT. Over half of the patients randomised to receive CVVH or CVVHDf were 
admitted to ICU for medical reasons (67%), with the remainder of patients admitted 
after surgery (33%). A similar distribution of medical and surgical patients with ARF 
requiring RRT was reported during a world-wide survey (Uchino, et al., 2005). By 
using a sample of patients which included numerous physical disorders the comparison 
of circuit life between CVVH and CVVHDf represented a response that could be 
generalised to include a broad range of critically ill patients.  
The investigation featured a study design that aimed to limit the effect of bias 
and uncontrolled variables in participant and mode selection. A randomised 
comparative crossover study design was used which successfully controlled for a 
variety of physiological and mechanical factors identified in the conceptual framework. 
The approach sought to minimise the influence each of the confounding variables 
associated with an individual patient such as severity of illness and coagulation status 
by using the patient as their own control. It also controlled for operator bias by 
predetermining the sequence of mode to be delivered to the participant at trial 
enrolment.  
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  The number of enrolled participants met the pre-determined sample size 
estimate as outlined in the Methods chapter. This calculation was based upon a 
clinically significant difference in circuit life being 4 hours, with α set at 0.05 and β at 
0.80, both of which are widely accepted statistical limits. Only circuits where a 
successful crossover had occurred in patients exposed to both CVVH and CVVHDf 
were included in the investigation and starting mode selection was randomised across 
the sample. The average mean difference observed when using CVVHDf exceeded the 
required effect of 4 hours and a 95% CI. Based on these findings there is reasonable 
evidence to suggest variations in circuit life „captured‟ during the investigation are 
plausible and reflect a „true‟ difference in circuit life between CVVH and CVVHDf. 
 The physiological factor severity of illness was also controlled for by using a 
within participant crossover design. Each patient was assigned an initial treatment mode 
through randomisation and the change in sequence of mode reduced the degree of 
influence the disease process may have impacted on circuit life. At the start of each 
crossover no treatment mode was observed to have been repeatedly selected with the 
opposite sequence of crossovers almost occurring with the same level of frequency, as 
would be expected through the randomisation process.  
In addition to reducing the possible effects of circuit sequencing and 
physiological differences among patients, the study also placed control on how CVVH 
and CVVHDf was delivered to the patient. The control placed on confounding variables 
was applied to mechanical factors identified in the conceptual framework. Using the 
same hardware (Hygieia „Plus‟
TM
 CRRT machine) blood was pumped at 200ml per min 








) and venous access site for both modes of CRRT. The decision 
to „standardise‟ both techniques strengthened as much as possible the operational 
approach of the study (no control was placed on the site chosen for the insertion of the 
vascular access catheter which was determined by clinical judgement of the attending 
medical officer). This allowed the separation of differences in pre-dilution volume (the 
variable of interest) from mechanical factors confounding the comparison of circuit life 
between CVVH and CVVHDf. 
The comparison of circuit life between CVVH and CVVHDf was aided by using 
the same haemofilter (Nephral 300ST) for both treatment modes. In this way, on 
commencement of each technique, the membrane common to both CVVH and 
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CVVHDf circuits caused a similar haemostatic reaction. It is known differences in the 
biocompatibility of the membrane can influence the degree of blood-membrane 
interaction and the extent of haemostatic activation which occurs when blood is exposed 
to non-biological surfaces (Pascual, Swinford, & Tolkoff-Rubin, 1997). By choosing 
the same material and membrane surface area to facilitate convection and diffusion the 
issue of biocompatibility identified as a physiological factor in the conceptual 
framework was controlled. The approach effectively met the diffusive requirements of 
CVVHDf and the convective requirements of CVVH, whilst standardising the exposure 
of blood to a foreign surface membrane area thereby controlling for the potential 
confounding physiological factor of biocompatibility. 
The passage of plasma water through the membrane is of particular importance 
during CVVH and requires a surface area large enough to achieve adequate clearance 
since the technique is more reliant than CVVHDf on convection for solute removal. The 
selection of membranes which provide a larger surface area to facilitate solute removal 
have the potential to reduce the resistance of blood flow through the haemofilter and 
may offer the possibility of promoting circuit life by decreasing procoagulatory activity 
(Baldwin, 2007). Using a larger surface area within the haemofilter may influence the 
rate at which the membrane is exposed to protein layering and the amount of saturation 
tolerated by the membrane. The integrity of the haemofilter is then possibly sustained 
for longer by the larger surface area. Studies which have demonstrated the successful 
application of CVVH show the surface area of the membrane selected by investigators 




 was used by Ronco and 
associates (2000) when investigating the influence of haemofiltration dose on patient 
outcomes. The use of CVVH has also been reported with the haemofilter having a larger 




 (Chung et al., 2008; Monchi, et al., 2004). Based on the 
experiences of other investigators the decision to select a surface area of 1.3m
2
 was 
considered sufficient to accommodate the convective capacity of CVVH. 
Another strength in the study design addressed the physiological factor of 
coagulation activity as shown in the conceptual framework by the application of an 
identical anticoagulation regimen for both techniques. The same concentration of 
heparin 10,000IU diluted in 50ml; of 5% Dextrose delivered at the same circuit location 
to achieve a target systemic aPTT of 40 to 55s was used. Other studies have targeted a 
similar aPTT (Nagarik, et al., 2010; van de Wetering, et al., 1996) or a higher range of 
values (Reeves, et al., 1999) when monitoring the response of heparin to achieve 
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anticoagulation of the circuit. Patients who were unsuitable for heparin anticoagulation 
were excluded from study enrolment ensuring a consistent approach to circuit 
anticoagulation throughout the project.  
A weakness of the study design was where variability in the dose of 
haemodialysis and haemofiltration delivered to the patient was allowed to occur which 
could potentially confound the comparison of circuit life between CVVH and CVVHDf. 
Using a hypothetical case of a 70kg and 100kg patient the contrast in dose delivery and 
effluent volume can be demonstrated. As shown in Table 6.1, the required effluent flow 
rate to achieve 35ml per kg per hr for CVVH equated to 2,450ml in a 70kg patient. In 
contrast, the CVVHDf dose when fixed irrespective of patient weight required an 
effluent volume of 1,600ml. This discrepancy in dose between the different treatment 
modes was further increased when the comparison was conducted on a 100kg patient as 
shown in Table 6.2. The difference in effluent volume can be explained as a result of the 
replacement fluid being routinely set at 600ml per hr and the dialysis dose for CVVHDf 
being prescribed at 1,000ml per hr despite the capacity in the study design to vary the 
volume from 500ml to 2,000ml per hr. The ultrafiltration dose for CVVH was on the 
other hand determined by the patient‟s weight and the volume of effluent required 
influenced by the body size of the patient. As a consequence of these differences the 
haemodialysis or haemofiltration dose between both techniques varied, with CVVH 
disadvantaged by the potential of increased procoagulatory activity when CVVHDf was 












Variability of dose delivery using the example of a 70kg patient in effluent volume 
required for CVVH and CVVHDf 
 





35 x 70 x 1 = 2,450ml
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(plus fluid balance 
requirements) 
 









 = 1,600ml 
(plus fluid balance 
requirements) 
 
22ml per kg per hr 
 







Variability of dose delivery using the example of a 100kg patient in effluent volume 
required for CVVH and CVVHDf 
 





35 x 100 x 1 = 3,500ml
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(plus fluid balance 
requirements) 
 









 = 1,600ml 
(plus fluid balance 
requirements) 
 
16ml per kg per hr 
 




It is unlikely that patients on this study received a dose which was under the 
treatment threshold where no beneficial effect was received and during the investigation 
the prescribed dose reflected widespread clinical practice used in support of renal 
function. When the study was conceived the dose debate was in its infancy and the 
importance of adjusting for body weight had not received much attention by clinicians. 
It was only after the study had been completed did the issue of dose become clearer and 
influence changes at the bedside. 
Another weakness of the study design allowed the variable of interest to be un-
blinded and the possibility for bias to occur when CVVHDf was seen to extend circuit 
life more than CVVH. The impact of human behaviour may have influenced the results 
observed and produced the phenomena referred to as the „Hawthorne‟ effect (Parsons, 
1974). Although guidelines on what constituted a natural circuit life were defined 
(observations showing the appearance of blood clots against TMP > 200mmHg and P-
venous > 150mmHg) the method used was open to interpretation with some circuits 
possibly being terminated earlier than would otherwise be the case had a more stringent 
criteria been applied. In operating the circuit to deliver CVVHDf the nurse performing 
the task may have had a more positive attitude to the technique and reacted differently 
to events during the lifespan of the circuit, compared with a more negative response to 
the prospect of shorter circuit life when CVVH was assigned to the patient. On 
reflection the study design may have caused a Hawthorne effect to occur but the nature 
of the investigation made attempts at blinding the study impracticable and unavoidable 
since awareness of treatment mode was necessary to perform both techniques safely.     
Education and Training 
The limited exposure of CVVH at the study site could have influenced circuit 
life when comparisons were made with measurements obtained by nurses only familiar 
with CVVHDf. A survey undertaken in Canada investigating the provision of CRRT 
training found limited exposure of staff to patients requiring CRRT increased the 
difficulty of maintaining competency in performing the technique (Langford, et al., 
2008). Ongoing evaluation of clinical practice in the application of the technique is also 
considered essential and when not addressed adequately can be an important factor 
affecting the lifespan of the circuit (Baldwin, 2007). In an effort to address this issue a 
training programme to minimise the mechanical factor of technical inexperience as a 
variable possibly impacting on circuit longevity was introduced prior to and during the 
study. All nurses allocated to patients who were participating in the study had received 
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sufficient training and recent experience to proficiently operate the Hygieia „Plus‟
TM 
CRRT machine and understood the requirements of CVVHDf. The ability to manage an 
alarm event and minimise interruptions due to stoppages in blood flow was included as 
part of the training programme and a requirement for this competency to be 
demonstrated. Variations in the operating procedures for CVVH were addressed 
separately by the provision of additional training and supervision to extend the 
knowledge of nursing staff already familiar with CVVHDf. Although circuit 
configuration and settings required were different for each mode, the semi-automated 
nature of the Hygieia „Plus‟
TM
 CRRT machine also reduced the potential for operator 
error once the machine was activated. Ultimately, if experience using CVVH had been a 
confounding mechanical factor it might be expected to see a consistent improvement in 
CVVH circuit life over the length of the study as expertise was gained. Instead the 
shortened lifespan of CVVH was observed throughout the duration of the study 
occasionally interspersed by the survival of some circuits which were comparable with 
CVVHDf. 
Summary 
The research project successfully compared circuit life using the techniques of 
CVVH and CVVHDf according to the available technology and in the protocols 
followed at the study site. No other published study has reported the use of a 
randomised crossover study design to investigate differences using the pre-dilution 
method of fluid replacement in circuit life between CVVH and CVVHDf. Organisation 
of the investigation around a conceptual framework provided one way to accommodate 
physiological and mechanical factors known to influence the longevity of circuit life. 
By making reference to these factors as possible confounding variables their potential 
impact on circuit life was controlled for during the investigation. The randomised 
crossover study design exposed the same patient to both treatment modes limiting the 
impact of physiological differences in the severity of illness affecting the comparison of 
circuit life. Attention to operator competency in using both treatment modes also 
reduced the possibility of mechanical factors confounding circuit life comparisons, 
when the same education and training was given on how to operate both techniques 
minimised the potential for operational errors to influence circuit longevity. Each 
example given demonstrates how control was achieved on several physiological and 
mechanical factors which strengthen the reliability that technique alone was responsible 
for differences in circuit life observed during the comparison between CVVH and 
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CVVHDf. At the time of the investigation the findings of this research project supported 
the continued use of CVVHDf and not CVVH given the hardware and procedures 
followed at the study site. In choosing CVVHDf the opportunity to maximise treatment 
delivery and reach the desired level of dose intensity is possibly realised more easily 






CONCLUSIONS & RECOMMENDATIONS 
This thesis reports the findings of a randomised crossover study which 
investigated the affect on circuit life of varying pre-dilution volumes associated with 
CVVH and CVVHDf. These findings suggest that for CRRT in the adult ICU patient, 
the lower pre-dilution volume and diffusive clearance required for CVVHDf will 
provide a longer functional circuit life. This was in contrast to CVVH which produced 
shorter circuit when higher pre-dilution volumes were required to achieve clearance by 
convection. The evaluation of treatment efficiency in terms of circuit life between the 
two different techniques is of clinical importance, since each treatment mode depends 
upon a measure of circuit longevity to achieve adequate replacement of renal function. 
Concluding Comments 
Taking into account the various study design factors, the findings from the study 
suggest circuit life is influenced by the choice of CRRT mode. The technique of 
prediluted CVVHDf as a diffusion-based treatment mode appears to have a protective 
effect on membrane interactivity. The transfer of solutes is predominantly a passive 
process across the semi-permeable membrane and as a result of less haemostatic 
activation the onset of clotting is delayed. The alternative technique of prediluted 
CVVH is a convection-based treatment mode which depends on plasma water removal 
in the transfer of solutes through the semi-permeable membrane. Whilst pre-dilution 
avoids haemoconcentration within the haemofilter fibres to some extent, it is theorised 
that an intensification of membrane interactivity occurs which exposes the CVVH 
circuit to greater haemostatic activation and changes in blood viscosity that is not 
compensated by the larger volumes of replacement fluid associated with the technique. 
The reduced circuit down-time observed with CVVHDf in the study may lead to more 
effective delivery of CRRT due to the increase of circuit life associated with this 
diffusion-based treatment mode.  
The study has several limitations which should be considered when evaluating 
the finding of differences in circuit life between the two treatment modes. The nature of 
the intervention made it impossible to blind this type of study and there was a potential 
for bias to occur if CVVH or CVVHDf was observed to bring about longer circuit life 
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compared with the alternative technique. As a single-centre study which tightly 
controlled technical aspects of both modes of therapy, it is unknown if similar results 
would be obtained using different anticoagulation regimens or venous access catheters 
or machine hardware. In comparing circuit life using CVVH and CVVHDf the dose 
delivered to the patient and the effluent volume required were not the same for both 
treatment modes. 
Recommendations for Future Research 
A cautious approach should be exercised when making recommendations based 
on the findings of this study. Short circuit life for many critically ill patients on CRRT is 
a problem which requires more examination. The choice of treatment mode as a strategy 
to increase the lifespan of the extracorporeal circuit and maximise the beneficial effects 
of CRRT is one example where additional research is required. Several 
recommendations based on the findings of this study are suggested for where further 
research might follow. The recommendations include proposals to substantiate the 
reported increase of circuit lifespan during CVVHDf and the investigation of other 
strategies which have the potential to maximise treatment delivery: 
 A repeat of the study using the lower dose of 25ml per kg per hr for 
CVVH would reduce the passage of plasma water required across the 
membrane when the same volume of effluent to be exchanged was used 
to compare circuit life with CVVHDf. Implementation of the lower dose 
proposed for this study would allow renal support to be above the 
minimum intensity required but provide a „buffer‟ against the possibility 
of a delay in treatment continuity caused by the time taken for a new 
circuit to be made ready.  Likewise the CVVHDf dose should be set at 
the same level and dialysate volume varied to achieve the desired dose. 
 Further attempts made at repetition of the study should include the 
analysis of TMP values following the reported correlation of shorter 
circuit life with higher pressure readings (Ricci, Ronco, Bachetoni, et al., 
2006). The decision to discontinue the circuit would continue to require 
visual inspection of the haemofilter, but evidence of clotting supported 
by TMP measurements indicating a natural circuit life had been reached 
could add further to how circuits are managed clinically and diagnosis of 
true circuit life.  
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 After the study was completed in 2006 the purchase of new CRRT 
machines at the study site offers technological improvements which 
allow the operator to adjust the volume of replacement fluid which can 
be split between the pre-dilution and post-dilution methods of fluid 
delivery. A more balanced approach may now be possible using these 
new machines during convective therapies like CVVH for reducing 
excessive haemoconcentration within the haemofilter but limiting the 
degree of dilution reducing the intensity of solute clearance. Following 
the abandonment of the 100% pre-dilution or post-dilution approach to 
replacement fluid delivery, the possibility of using an equal split between 
each method adds another area of interest which requires further 
investigation. 
 A method of recording and displaying information acquired from CRRT 
circuits is recommended to be implemented for improving assessment of 
circuit function. The use of CRRT machines like the Hygieia „Plus‟
TM
 
used in the study provide real-time digital output of parameters, alarms 
and events that occur during treatment, but currently information remains 
under utilised by the bedside nurse due to lack of appropriate data 
capture and analysis software. Circuit pressure monitoring technology 
may provide the opportunity to improve the performance of CRRT by 
the graphical display in real-time of specific events which occur during 
the lifespan of each circuit. Understanding aspects of events which cause 
circuit failure, such as patient repositioning interrupting blood flow or 
changes in procoagulatory activity leading to premature clotting, are 
worth investigating to minimise the affect each may have in the delivery 
of treatment or during the evaluation of interventional studies. The 
information obtained has the potential to be used by the bedside nurse to 
minimise unexpected circuit failure by allowing appropriate action to be 
undertaken according to physiological factors associated with the patient, 
or the result of mechanical factors such as equipment malfunction. 
Alternatively the capture of information on circuit function may be 
archived and pressure trends reviewed for teaching purposes, or used in 
the development of protocols to direct areas of practice which match 
pressure profiles associated with natural circuit life. 
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 The study should be repeated again as a multi-centre investigation with 
the enrolment of larger patient numbers using assorted hardware to 
compare differences in circuit life between CVVH and CVVHDf. The 
possibility of operational variations might arise when both techniques are 
performed by more than one ICU and will require the development of 
standardised protocols for both CVVH and CVVHDf across each of the 
study sites. 
 The decision to repeat the study again may instead involve the 
investigation based on comparisons using alternative circuit 
anticoagulation regimens. The emergence of citrate as a regional 
anticoagulant with CRRT is one example which could be applied to 
CVVH and CVVHDf. The use of citrate to anticoagulate the circuit can 
be performed using both techniques by the pre-dilution method of fluid 
replacement. 
 The degree of interaction which occurs when blood comes into contact 
with the surface area of the membrane during convective versus diffusive 
mechanisms of solute removal should be investigated using electron 
microscopic imagery. A scoring system similar to the one used by 
Hofbauer and associates (1999) to measure the effect of different 
anticoagulation regimens on blood membrane interactions can provide a 
quantitative means to describe the degree of membrane haemostatic 
activity between CVVH and CVVHDf. The clotting score includes a 
description of thrombosis formation, evidence of fibrin threads, the level 
of platelet aggregation, the accumulation of trapped red blood cells, and 
the extent of occlusion in the fibre lumen. After each treatment was 
completed on the same patient the CVVH and CVVHDf circuits would 
be taken down and the haemofilter saved for electron microscopy 
analysis. The procedure would require the dissection of each haemofilter 
to expose individual fibres and the surface of the membrane. Once 
imagery of the membrane surface area was completed the morphology of 
thrombosis formation during CVVH and CVVHDf can compare 
haemostatic activity according to the clotting scoring system.  
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OUTPUT OF RANDOM NUMBERS 
17/11/2004 
www.randomizer.org/form 
CVVH = 1 
CVVHDf = 2 
“Research Randomizer” results: 
1 set of 150 non-unique numbers per set 
Range: From 1 to 2 – unsorted 
 
1 2 17 2 33 2 49 2 65 1 81 2 
2 1 18 2 34 1 50 1 66 1 82 2 
3 1 19 2 35 2 51 2 67 1 83 2 
4 1 20 1 36 1 52 1 68 2 84 2 
5 2 21 1 37 2 53 1 69 2 85 1 
6 2 22 1 38 1 54 2 70 1 86 1 
7 1 23 1 39 2 55 1 71 2 87 2 
8 2 24 2 40 1 56 2 72 2 88 2 
9 1 25 1 41 2 57 1 73 1 89 1 
10 2 26 2 42 1 58 1 74 1 90 1 
11 1 27 1 43 2 59 2 75 1 91 2 
12 1 28 1 44 1 60 2 76 2 92 2 
13 2 29 2 45 2 61 2 77 2 93 1 
14 2 30 2 46 2 62 1 78 1 94 1 
15 2 31 2 47 2 63 1 79 1 95 2 
16 1 32 2 48 1 64 1 80 2 96 1 
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97 2 106 1 115 1 124 2 133 1 142 2 
98 1 107 2 116 2 125 2 134 1 143 1 
99 1 108 1 117 1 126 2 135 2 144 2 
100 1 109 1 118 1 127 2 136 1 145 2 
101 1 110 2 119 2 128 2 137 1 146 1 
102 1 111 2 120 1 129 2 138 1 147 2 
103 1 112 2 121 2 130 1 139 1 148 1 
104 2 113 2 122 1 131 2 140 1 149 2 











PATIENT CONSENT FORMS 
A RANDOMISED COMPARATIVE CROSSOVER STUDY TO 
ASSESS THE AFFECT ON CIRCUIT LIFE OF VARYING PRE-
DILUTION VOLUMES ASSOCIATED WITH CONTINUOUS 
VENO-VENOUS HAEMOFILTRATION (CVVH) AND 
CONTINUOUS VENO-VENOUS HAEMODIAFILTRATION 
(CVVHDF). 
Principle Investigator: Hugh Davies, RN 
Research Supervisors: 
Dr Gavin Leslie, Associate Professor Critical Care Nursing, Royal Perth Hospital 
Dr Steve Webb, Intensivist, Royal Perth Hospital 
Information Sheet and Consent Form (Patient) 
Trial Summary 
You are being asked to participate in a study comprising patients who have been 
admitted to intensive care diagnosed with kidney failure. Kidney failure is a common 
complication of severe illness. The treatment for kidney failure in the intensive care 
setting is continuous renal replacement therapy (CRRT). One way of achieving this is 
the use of a haemofilter which acts as an artificial kidney. The removal of substances 
dissolved in blood and the management of body fluid volume can be achieved by using 
two types of CRRT: continuous veno-venous haemofiltration (CVVH) and continuous 
veno-venous haemodiafiltration (CVVHDf). Both techniques provide adequate 
treatment for kidney failure but differ in the way this is achieved. Standard therapy for 
kidney failure at Royal Perth Hospital ICU has been CVVHDf. We wish to evaluate 
CVVH, a treatment used in over 25% of Australian ICUs for its effect on the life of the 
haemofilter and blood circuit. 
Although CRRT is described as a continuous treatment, stoppages in treatment 
usually occur due to circulating blood outside of the body through the artificial kidney. 
Other reasons include the need for procedures to be carried outside the ICU, such as 
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surgery or special x-rays. These stoppages can result in a delay in treatment because a 
new haemofilter and blood line has to be prepared. Should clotting of the system occur, 
the quality and quantity of renal replacement therapy that is delivered can be impaired. 
We wish to test whether one type of CRRT, either CVVH or CVVHDf, can reduce the 
down-time caused by premature clotting of the blood line. This study has been deemed 
to be a quality assurance exercise by the Ethics Committee at Royal Perth Hospital but 
has been cleared on ethical aspects by the chairman. It has also been approved by Edith 
Cowan University Ethics Committee. 
Your Role In The Study 
   Once you consent you will be randomised to have a „fifty-fifty‟ chance of 
initially receiving either CVVH or CVVHDf. You will the alternate between these two 
techniques whilst treated for kidney failure. Blood samples will be taken as part of 
normal treatment, but no additional blood samples will be required. Should your 
kidneys recover whilst in ICU then CRRT will be stopped irrespective of technique 
used. 
Risks Associated With The Study 
The risks associated with blood lines, such as loss of blood through inadvertent 
disconnection of the circuit. Are no different with CVVH than they are with CVVHDf. 
While the two techniques differ in terms of fluid delivery there has been no 
demonstrated difference in the occurrence of problems or complications associated with 
the administration of CVVH or CVVHDf. Both treatments are delivered by a fully 
automated kidney replacement machine (the Kimal
TM
 CRRT machine). Monitoring of 
the machine‟s performance and the patient‟s progress is the same for both treatments. It 
is not proposed that there will be any difference in the drugs routinely used to stop 
blood clotting for either CVVH or CVVHDf. While nursing staff are experienced in the 
running of CVVHDf using the Kimal
TM
, training and ongoing supervision will be given 
to highlight the differences for CVVH. 
Voluntary Participation 
Regardless of the differences in techniques used (CVVH or CVVHDf), other 
treatments prescribed for kidney failure are not affected by the study and individuals 
participating in the study will not be disadvantaged in anyway. Your participation in this 
study is entirely voluntary. You are free to refuse to give consent or can withdraw 
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consent at any time should you change your mind. Refusal to take part in, or subsequent 
withdrawal from the study, will have no adverse effects on your medical treatment. You 
will continue to receive appropriate intensive care treatment whether or not you give 
consent for participation in this study. 
Further Information 
If you require further information or have any questions about this study, please 
contact: 
For enquiries in regards to the specifics or design of the study: 
Hugh Davies PhD Student 
RN, B.Nurs, Grad Dip Nurs (Intensive Care), MHM 
Clinical Nurse, Intensive Care Unit, Royal Perth Hospital, Wellington Street,   
PERTH WA 600 
Phone 08 9224 2727 
For enquiries in regards to ethical concerns of the study: 
Clinical Professor J. A. Miller 
Chairman of the Ethics Committee 
Phone 08 9224 2244 
If after reading this sheet you are interested in participating, you will be asked to 










CONSENT TO PARTICIPATION IN A STUDY TO INVESTIGATE 
THE AFFECT ON CIRCUIT LIFE OF VARYING PRE-DILUTION 
VOLUMES ASSOCIATED WITH CONTINUOUS VENO-VENOUS 
HAEMOFILTRATION (CVVH) AND CONTINUOUS VENO-
VENOUS HAEMODIAFILTRATION (CVVHDF). 
 
I,……………………………………….agree to participate in the above study 
and allow the researcher access to my medical records to collect data relevant to this 
project. I have read and understood the attached information sheet and I have retained a 
copy of the signed document. I have been given the opportunity to ask questions about 
the study by the investigator. I understand that I may withdraw from the study at any 
time without affecting any future medical treatment, or the treatment of the condition 











  A RANDOMISED COMPARATIVE CROSSOVER STUDY TO 
ASSESS THE AFFECT ON CIRCUIT LIFE OF VARYING PRE-
DILUTION VOLUMES ASSOCIATED WITH CONTINUOUS 
VENO-VENOUS HAEMOFILTRATION (CVVH) AND 
CONTINUOUS VENO-VENOUS HAEMODIAFILTRATION 
(CVVHDF). 
Principle Investigator: Hugh Davies, RN 
Research Supervisors: 
Dr Gavin Leslie, Associate Professor Critical Care Nursing, Royal Perth Hospital 
Dr Steve Webb, Intensivist, Royal Perth Hospital 
Information Sheet and Consent Form (Next-of-Kin) 
Trial Summary 
You are being asked to agree to your relative‟s participation in a study 
comprising patients who have been admitted to intensive care diagnosed with kidney 
failure. Kidney failure is a common complication of severe illness. The treatment for 
kidney failure in the intensive care setting is continuous renal replacement therapy 
(CRRT). One way of achieving this is the use of a haemofilter which acts as an artificial 
kidney. The removal of substances dissolved in blood and the management of body 
fluid volume can be achieved by using two types of CRRT: continuous veno-venous 
haemofiltration (CVVH) and continuous veno-venous haemodiafiltration (CVVHDf). 
Both techniques provide adequate treatment for kidney failure but differ in the way this 
is achieved. Standard therapy for kidney failure at Royal Perth Hospital ICU has been 
CVVHDf. We wish to evaluate CVVH, a treatment used in over 25% of Australian 
ICUs for its effect on the life of the haemofilter and blood circuit. 
Although CRRT is described as a continuous treatment, stoppages in treatment 
usually occur due to circulating blood outside of the body through the artificial kidney. 
Other reasons include the need for procedures to be carried outside the ICU, such as 
surgery or special x-rays. These stoppages can result in a delay in treatment because a 
new haemofilter and blood line has to be prepared. Should clotting of the system occur, 
the quality and quantity of renal replacement therapy that is delivered can be impaired. 
We wish to test whether one type of CRRT, either CVVH or CVVHDf, can reduce the 
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down-time caused by premature clotting of the blood line. This study has been deemed 
to be a quality assurance exercise by the Ethics Committee at Royal Perth Hospital but 
has been cleared on ethical aspects by the chairman. It has also been approved by Edith 
Cowan University Ethics Committee. 
Your Relative’s Role In The Study 
   Once consent for your relative‟s participation has been given, your relative 
will be randomised to have a „fifty-fifty‟ chance of initially receiving either CVVH or 
CVVHDf. Your relative will then alternate between these two techniques whilst treated 
for kidney failure. Blood samples will be taken as part of normal treatment, but no 
additional blood samples will be required. Should your relative‟s kidneys recover whilst 
in ICU then CRRT will be stopped irrespective of technique used. 
Risks Associated With The Study 
The risks associated with blood lines, such as loss of blood through inadvertent 
disconnection of the circuit, are no different with CVVH than they are with CVVHDf. 
While the two techniques differ in terms of fluid delivery there has been no 
demonstrated difference in the occurrence of problems or complications associated with 
the administration of CVVH or CVVHDf. Both treatments are delivered by a fully 
automated kidney replacement machine (the Kimal
TM
 CRRT machine). Monitoring of 
the machine‟s performance and the patient‟s progress is the same for both treatments. It 
is not proposed that there will be any difference in the drugs routinely used to stop 
blood clotting for either CVVH or CVVHDf. While nursing staff are experienced in the 
running of CVVHDf using the Kimal
TM
, training and ongoing supervision will be given 
to highlight the differences for CVVH. 
Voluntary Participation 
Regardless of the differences in techniques used (CVVH or CVVHDf), other 
treatments prescribed for kidney failure are not affected by the study and individuals 
participating in the study will not be disadvantaged in anyway. Your relative‟s 
participation in this study is entirely voluntary. You are free to refuse to give consent or 
can withdraw consent at any time should you change your mind. Refusal to take part in, 
or subsequent withdrawal from the study, will have no adverse effects on your relative‟s 
medical treatment. Your relative will continue to receive appropriate intensive care 
treatment whether or not you give consent for participation in this study. 
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Further Information 
If you require further information or have any questions about this study, please 
contact: 
For enquiries in regards to the specifics or design of the study: 
Hugh Davies PhD Student 
RN, B.Nurs, Grad Dip Nurs (Intensive Care), MHM 
Clinical Nurse, Intensive Care Unit, Royal Perth Hospital, Wellington Street,   
PERTH WA 600 
Phone 08 9224 2727 
For enquiries in regards to ethical concerns of the study: 
Clinical Professor J. A. Miller 
Chairman of the Ethics Committee 
Phone 08 9224 2244 
If after reading this sheet you permit your relative to participate, you will be 















CONSENT TO PARTICIPATION IN A STUDY TO INVESTIGATE 
THE AFFECT ON CIRCUIT LIFE OF VARYING PRE-DILUTION 
VOLUMES ASSOCIATED WITH CONTINUOUS VENO-VENOUS 
HAEMOFILTRATION (CVVH) AND CONTINUOUS VENO-
VENOUS HAEMODIAFILTRATION (CVVHDF). 
 
 
I, ……………………………………………. agree for my relative to participate in the 
above study. I have read and understood the attached information sheet and I have 
retained a copy of the signed document. I have been given the opportunity to ask 
questions about the study by the investigator. I understand that I may withdraw my 
relative from the study at any time without affecting any future medical treatment, or 
the treatment of the condition which is the subject of the study. 
 
 
Signed………………………………………………………..            Date……………. 
 
Relationship to patient……………………………………... 
 
Signature of Investigator……………………………………            Date……………. 
 
 
 
 
 
